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Chlamydia pneumoniae have been found to have a strong association with human 
atherosclerosis in the presence of low density lipoproteins and macrophages. Many recent 
studies, point towards a possible etiological relationship with Chlamydia pneumoniae. 
This respiratory pathogen is mainly found in the lung and then will have to be transported 
to cardiac tissue.  The method which it is carried depends on the bronchoalveolar 
macrophages, as they will phagocytotize the elementary bodies of Chlamydia 
pneumoniae, thus gaining entry to the bloodstream and will be transported to sites of 
vascular injury in coronary vessels.  
 
The aim of this thesis is to investigate the genetic expression patterns of the 
interaction between Chlamydia pneumoniae and macrophages namely U937 cells in the 
presence of low density lipoprotein. Five models of studies were designed and they are;  
macrophages alone to act as control at times 24 hours, 72 hours and 96 hours, secondly 
macrophages and low density lipoprotein only for 24 hours, thirdly, macrophages and 
Chlamydia pneumoniae only for 72 hours and the fourth and fifth models in which 
Chlamydia pneumoniae, low density lipoprotein and macrophages were added together 
but in different order.  
 
Differential display was used to analyze the intracellular interactions between 
Chlamydia pneumoniae and macrophages. From the series of differential display 
experiments, a repertoire of possible genes that could be closely associated with the 




then subjected to analysis using various bioinformatics tools. Searches of the databases 
yielded potentially interesting genes worth further analysis. Differential display RT-PCR 
was employed to analyze mRNAs from U937 human macrophage cells following 
infection with Chlamydia pneumoniae (TWAR39) and/or with low density lipoproteins in 
order to understand better the cellular gene responses to Chlamydia pneumoniae infection 
at the transcriptional level. The results obtained will provide insights into atherosclerosis; 
as the five models of study has been designed to mimick the events in plaque formation. 
From 190 differentially expressed sequence tags (ESTs), all were of human origin; of 
those 32 were novel. The expression pattern was noted and the models were compared to 
the various control models at the three stipulated timings of 24, 72 and 96 hours.  
 
Some of the interesting hits with the database are as follows : Homo sapiens, 
Similar to IK cytokine, down-regulator of HLA II ; nuc2 homolog; Homo sapiens 
genomic DNA, chromosome 8p11.2, senescence gene region ; Homo sapiens BCL2-
related protein A1 (BCL2A1); Homo sapiens cyclic AMP phosphoprotein, 19 kD (ARPP-
19), mRNA ; Homo sapiens ribosomal protein L27a (RPL27A), mRNA ; Homo sapiens 
cell division cycle 2, G1 to S and G2 to M (CDC2) gene.  
 
In relation to the atherosclerosis, the results of the selected bands generally seem 
to exhibit two main modes of action. One is involved in cell proliferation mechanisms, 
and the other is involved in the regulation of the immune response. Genes which are 
involved in the cell proliferation pathway includes cell cycle genes NUC2, CDC2, CDC 




and membrane integrity. The other set of genes are those that invoke or prevent an 
immune response which equals to an inflammatory response which is the latest version of 
the mode of onset of atherosclerosis, such modules involves those signal trafficking 
modules; similar to IK cytokine, GDBR1, CAMP, IRS2, HSPC150, BLAME and GPR6 
which links the infection to the immune response system of the host, This is due to the 
fact that these signal trafficking modules have to link the onset of the infection to the 
immune system. The altered expression patterns were further authenticated via semi-
quantitative RT-PCR and real-time RT-PCR have been done for further authentication.  
The results obtained had demonstrated the feasibility of mRNA differential display for 
elucidating the expression profiles of human genes in response to Chlamydia pneumoniae 
infection in the presence of low density lipoprotein.  
 
The results obtained from the study conducted have further shown the linkage of 
the presence of Chlamydia pneumoniae and atherosclerosis and it will allow an 
alternative approach for managing atherosclerosis which is one of the main initiators of 
the number one killer, heart attack that occurs predominantly in developing and 
developed countries. By adopting a genomic approach in my research, it will be 
beneficial to start from the fundamental basis, furthermore coupled with the various new 
technologies that are available for assaying gene expression studies. This will then 
provide an in depth understanding, and possible preventive approaches may stem from 














In this 21st century, despite the elucidation of the Human Genome Project, 
and the advances of the modern technology; scientists all over the world are still 
being puzzled and intrigued by the mechanisms of which major diseases which are 
prevalent in most developed countries in the world. One area of major concern is 
cardiovascular disease, which remains to be at the top of leading causes of deaths in 
most developed countries. Cardiovascular disease is an expanding problem found in 
the elderly age group, causing nearly 70% of all deaths beyond the age of 75. 
Coronary heart disease often emerges without warning and one in five coronary 
attacks presents as a sudden death. Therefore, awaiting overt signs and symptoms of 
coronary disease before treatment of this is no longer justified. Examination of the 
incidence, prevalence, mortality, and natural history of coronary heart disease suggest 
the need for a preventive approach.  
 
A preventive approach involving detection and correction of predisposing 
conditions before the advent of overt clinical disease is necessary for the control of 
the disease. In the last decade the number of publications on genetic contributions to 
heart disease has risen exponentially. It is believed that genetics, along with 
traditional risk factors will provide an insight into the understanding of cardiovascular 
disease. Recent studies have shown that atherosclerosis is the main underlying 
pathological process of cardiovascular diseases. Chlamydia pneumoniae has been 
touted to be the bacterial cause of atherosclerosis; judging from the evidence for its 




Firstly, there has been a correlation of the coronary heart disease and other 
atherosclerotic disease with antibodies against Chlamydia pneumoniae. Secondly, 
Chlamydia pneumoniae could be detected with different techniques in a high 
percentage of atheromas from different sites. Thirdly, the target cells of 
atherosclerosis (endothelial, macrophages and cardiac muscle cells) can be infected 
by Chlamydia pneumoniae in vitro. Lastly, experimental animal studies conducted 
have also proven that Chlamydia pneumoniae is the main cause of the condition, 
atherosclerosis. Furthermore, following the technological advances in the present era, 
new fields of study and approaches such as transcriptomics and functional genomics 
are being new tools that are used in the ongoing battle against those diseases that have 
plagued mankind for centuries. 
 
1.1       Atherosclerosis 
Atherosclerosis is a major cause of stroke, coronary heart disease, peripheral 
vascular disease, and aortic aneurysm. Atherosclerosis is the process of lipid 
deposition in localized plaques in arterial walls, mediated by an inflammatory 
reaction. The inflammatory reaction is characterized by the presence of monocyte-
macrophages, activated T cells and fibrosis; whereby both antibody and cellular 
immune responses can modulate inflammation and atherosclerosis. The heart is an 
important part of the body, thus a constant supply of oxygen and nutrients must be 
delivered to it via the coronary arteries for it to function well. Atherosclerosis can 
develop in any artery in the body, namely the aorta (the largest blood vessel in the 




arteries in the legs and abdomen. The intima of the artery is the innermost layer and 
includes the endothelium, underlying connective tissue, and smooth muscle on the 
luminal side of the internal elastic lamina. This intimal layer has been referred to as 
the battleground of the atherosclerotic process. The idea for the mechanisms of 
atherosclerostic disease are considered due to inflammatory responses.  
 
 
Figure 1 Fatty Streak formation in Atherosclerosis (adapted from Glass K.C., 
Witztum L.J., 2001) 
        
Molecules associated with the migration of leukocytes across the endothelium, 
act in conjunction with chemo attractant molecules generated by the endothelium, 
smooth muscle and monocytes, especially modified low density lipoproteins which is 
one of the key factors in the study conducted, to attract monocytes and T cells into the 
artery as shown above. Chemokines may be responsible for the chemotaxis and 




Fatty streaks initially consist of lipid laden monocytes and macrophages (foam 
cells) together with T lymphocytes; in which foam cells formation is mediated by 
oxidized low density lipoprotein. This is depicted in Figure 1 as above. 
 
 
Figure 2 Formation of an Advanced and complicated lesion of Atherosclerosis 
(adapted from Glass K.C., Witztum L.J., 2001) 
 
      The fatty streaks will then become advanced lesions, which tend to form a 
fibrous cap that walls off the lesion from the lumen. The fibrous caps cover the 
necrotic core which is made of a mixture of leukocytes, lipids and debris. This is 





Figure 3 Rupture of fibrous cap in Atherosclerosis (adapted from Glass K.C., 
Witztum L.J., 2001) 
 
Rupture of the fibrous cap can rapidly lead to thrombosis and usually occurs 
at sites of thinning of the fibrous cap that covers the advanced lesion. The influx and 
activation of macrophages are the main causes of the thinning of the fibrous caps that 
cover the advanced lesions. The plaque formed can break open and lead to the 
formation of a blood clot. The clot covers the site of the rupture, also reducing blood 
flow. The clot becomes firm over time. The process of fatty buildup, plaque rupture, 
and clot formation recurs, progressively narrowing the arteries. This cycle then 
repeats itself, till when the blood supply is nearly or completely, and abruptly, cut off, 
a heart attack results. Furthermore, when this occurs, the cells in the heart muscle that 
do not receive enough oxygen will begin to die. The damaged or dead heart cells are 
irreplaceable, this results in a permanent cell loss and serious damage done to the 





















   Figure 4 Pathogenesis of Atherosclerosis  
 
Scientists also have looked at atherosclerosis, from another angle, in which 
the first stages of heart disease are lesions and cracks forming in the blood vessel 
walls normally at the points of highest pressure or stress (near the heart). The second 
stage is the body trying to repair itself by depositing fatty substances (cholesterol, 
lipoproteins) inside the blood vessels to fill the cracks. These fatty substances can 
begin to build up and clog the blood vessels causing stroke and heart attack. 
Atherosclerosis is triggered by excess amounts of unstable particles known as 
oxygen-free radicals, which bind with and alter other molecules, a process called 
oxidation (Kuo C.C., et al. 1993.). Following an elevation in plasma low density 
lipoprotein (LDL) cholesterol levels will result in the penetration of low density 
lipoprotein into the arterial wall with a consequent series of cellular events leading to 
the formation of plaque. After it builds up, the injury to the arteries signal the immune 
system to release white blood cells (particularly those called macrophages) at the site. 
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This initiates a process called the inflammatory response. White blood cells, or 
monocytes, also enter the endothelium, where they become macrophages that 
accumulate low density lipoprotein lipids and are transformed into foam cells. 
Macrophages literally "eat" the oxidized cholesterol leaving behind foamy cells that 
attach to the artery's smooth muscle cells. The foam cells will then build up within the 
artery. After the immune system senses the foam cells, it releases other factors called 
cytokines, which attract more white blood cells and perpetuate the whole cycle. This 
cycle usually repeats itself forming atherosclerotic lesions.  This is depicted in Figure 
4 as above. The growth of an atherosclerotic plaque may partially block an artery or 
slow the flow of blood, causing ischemia in the corresponding organ. Macrophage 
scavenger receptors, which mediate the uptake of lipids into macrophages, have been 
shown to bind to gram-negative bacterial LPS in the process of phagocytosis and 
clearance. The immune response to Chlamydia pneumoniae infection may also 
generate the production of reactive oxygen species which may enhance oxidized low 
density lipoprotein, further leading to foamy cell formation. The risk of coronary 
heart disease increases as blood cholesterol levels increase (Melnick, S. L., et al. 
1993.). Due to the progressive nature of the development of the atherosclerosis, 
infectious agents that are able to exist in a persistent latent state and maintain the 
ability to reactivate will be able take advantage of the situation to its own advantage. 
Chlamydia pneumoniae, an infectious agent, is able to survive and replicate 
intracellularly to penetrate or infect human endothelial and smooth muscle cells and 





The application of molecular genetic methods combined with the full mapping 
of the human genome will enable the elucidation of many more genetic variants 
contributing to atherosclerosis. The emerging possibility of the new genes that play 
important roles or influence atherosclerosis in the presence of Chlamydia pneumoniae 
has sparked off an interest of controlling this coronary heart disease at the genetic 
level.  
 
1.2       Strategy of Study: The Five models 
The interaction between the invading pathogen and host macrophages is one 
of the main factors affecting the susceptibility to infectious diseases. The influence of 
genetic background on host-pathogen interactions can be seen by assessing the 
transcriptional responses of macrophages to infection by Chlamydia pneumoniae to 
the macrophages in the presence of the low density lipoprotein. To allow the 
development of therapeutic approach and vaccines, we have to first determine the 
exact nature of the association between Chlamydia pneumoniae and atherosclerosis at 
the cell and molecular level. The main focus of my prospective studies will be on the 
interaction between the Chlamydia pneumoniae and macrophages in the presence of 
low density lipoproteins. Chlamydia pneumoniae is endowed with several attributes 
that may contribute to the development of atherosclerotic lesions or promote tissue 






Two key events that are directly involved in the atherogenic process include 
the development of foam cells from macrophages and the oxidation of lipoproteins at 
the site of lesion development. The foam cells will allow for deposition and 
accumulation of cholesterol-containing low-density lipoprotein (LDL) and the 
oxidation of lipoprotein can contribute directly to tissue damage locally. By looking 
at the differential expression profiles and the genes of interest at the genomic level, 
we are able to search for an approach for arresting this major disease. The strategy 
and approach of the study have been illustrated in figures 2 and 3 respectively. I have 
decided to study the association and interaction of Chlamydia pneumoniae and 
macrophages in the presence of low density lipoprotein based on studies done 
(Campbell L.A., 1999; Boman J. et al, 2002.).  
 
Susceptibility to infection might be due to the Chlamydia pneumoniae, the 
foam cells or a deadly combination of both, which leads us to the creation of the five 
study models. Five models of this interaction were designed simulating the various 
events and possibilities that might occur in the human body. This is depicted in 
Figure 5. 
  
The first model consists of only the human macrophage U937 cell line and 
they are untreated as these will serve as controls at the various timing of 24 hours, 72 
hours and 96 hours respectively (Apfalter P., et al., 2000). The first model shows that 
in the human body whereby there is the absence of Chlamydia pneumoniae, and low 




The second model consists of human macrophage U937 cell line and low 
density lipoprotein, after addition of low density lipoprotein. The model will be left 
only for 24 hours which is the optimum interaction timing. The second model is 
designed to allow us to determine and confirm that the formation of foam cells is not 
due solely to the low density lipoprotein, and Chlamydia pneumoniae is necessary for 




Figure 5 A schematic overview diagram of the five models of study of the 
association of Chlamydia pneumoniae and Atherosclerosis. 
 
The third model consists of human macrophage U937 cell line and Chlamydia 
pneumoniae; the human macrophage U937 cell line will be infected with the bacteria 
and will be allowed to interact only for 72 hours which is the optimum interaction 
timing for the action of Chlamydia pneumoniae. The third model is designed to allow 
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of all three main components, of which are Chlamydia pneumoniae, low density 
lipoprotein and macrophage; and not due to Chlamydia pneumoniae alone. In the 
fourth model, low density lipoprotein was added to the macrophages and allowed to 
interact with the macrophages for 24 hours; and then after which the bacteria 
Chlamydia pneumoniae, is added, and allowed to interact with both the macrophages 
and low density lipoprotein for another 72 hours which are found out to be the 
optimum time of interaction respectively. This mimics the conditions of that whether 
the order matters or not, in the real life, this could be the situation in which an obese 
person on contracting the bacterial infection. Any significant difference may provide 
an insight and a different approach towards the final treatment of the patient in the 
prevention of atherosclerosis. In the fifth model, the bacteria Chlamydia pneumoniae, 
is added to the macrophages first and allowed to interact with the macrophages for 72 
hours; and then after which low density lipoprotein is added and allowed to interact 
with both the macrophages and Chlamydia pneumoniae, for another 24 hours, which 
are found out to be the optimum time of interaction respectively. This model is 
included and part of the consideration, as we know from the various serology studies 
being conducted, the patient could have a early infection of Chlamydia pneumoniae 
and due to the bad dietary habits which cause the accumulation of fats which will 
then provide a favorable conditions for the formation of the foam cells which in turn 
be infected by the existing population of Chlamydia pneumoniae being circulated in 





Furthermore, the difference of the gene expression profiles between the last 
two models especially will help us get an better grip and understanding to the existing 
disease, atherosclerosis. The fourth and fifth models although similar in design and 
components, differ slightly from one another; and could serve as an interesting 
viewpoint depending on the nature and context of the results obtained. In both the 
models, Chlamydia pneumoniae, low density lipoprotein and macrophages were 
added together; however the difference lies in the order of the addition of the 
Chlamydia pneumoniae and low density lipoprotein.  
 
These two models were designed to allow us to determine whether those 
patients that have high cholesterol levels, especially referring to the obese patients, 
following which be infected by the bacteria, Chlamydia pneumoniae, and eventually 
lead to the onset of atherosclerosis (Fourth Model). Alternatively, these patients that 
may have been infected by the bacteria, Chlamydia pneumoniae, initially; then due to 
the progressive accumulation of low density lipoprotein (Fifth Model) which leads to 
the onset of the atherosclerosis. Theoretically, the fifth model is the ideal model of 
study due to the obligatory intracellular characteristic of the bacteria, Chlamydia 
pneumoniae. Any differences between the expression studies conducted and the 
results obtained for the fourth and fifth models will no doubt be interesting and 
provides one with another insight to the mechanism of atherosclerosis at the genomic 
level. Thus, based on the models adopted for my study, the experimental procedure 




As the study models are designed in view of the conditions happening to the 
human population, by the understanding of the whole scenario at the in vitro level. 
The information gathered will serve as an aid to study and understand the mechanism 
and interaction of Chlamydia pneumoniae and macrophages in the presence of the 
low density lipoproteins. We would be able to formulate `weapons’ in our ever 
growing arsenal in our ongoing battle against atherosclerosis. The regulation and the 
various patterns of gene expression is the key process for adaptation to changes in 
environmental conditions and thus for survival. Bioinformatical techniques allow an 
educated guess of the function of many proteins and could allow for better analysis 
and the design and development of therapeutical drugs, regardless of enhancing the 
properties of the existing range of drugs in the prevention or treatment, such 
knowledge may allow the design of more powerful and effective drugs. Integration of 
this information may permit to predict the metabolic capability and other 
physiological properties of the organism, Chlamydia pneumoniae in the presence of 




























Figure 6 Outline of the experimental strategy 
Human Monocytic Cell Line U937 Cells were cultured and passaged. 
At various timings, namely 24hrs, 72hrs, 96 hrs, the Chlamydia pneumoniae 
was added to the respective models in study.
At the various timings, 24, 72 and 96 hrs respectively, the cell cultures are 
then centrifuged, and RNA isolated, OD reading taken. 
Model 5
96hrs 
Differentiated Display Reverse Transcription Polymerase Chain reaction was 
done to the RNA samples extracted for the various timings 
Bands of interest which display differential expression were extracted and 
then reamplified and sequenced 
Analysis of the various information obtained regarding the sequenced bands
Computer analysis of sequences using bioinformatics tools  
Real Time Analysis and determination of the obtained differential expression 
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2.1 Genomics and Transcriptomics 
Genomics is the study of genes and their function. Recent advances in the world 
aided by the surge of biotechnological advances, especially in the field of genomics are 
bringing about a revolution in our understanding of the molecular mechanisms of disease, 
including the complex interplay of genetic and environmental factors. Genomics have 
fueled, in one way or another, the discovery of breakthrough healthcare products by 
revealing thousands of new biological targets for the development of drugs, and by giving 
scientists innovative ways to design new drugs, vaccines and DNA diagnostics. 
Genomics-based therapeutics includes "traditional" small chemical drugs, protein drugs, 
and potentially gene therapy. Thus, it is a logical approach to study the interaction of 
pathogenic bacteria and its association with diseases at this level. All the characteristics 
of a plant, insect or fungus are described in its genome. The relatively new scientific 
discipline of genomics provides detailed understanding of the genetic material of a target 
organism, allowing researchers to identify specific genes responsible for specific proteins 
with specific functions in an organism. Genomics also refers to the large-scale 
investigation of the structure and function of genes. Through the understanding of the 
structure and function of genomes, this no doubt will help in drug discovery and 
development; furthermore, sequencing and characterization of the genome and analysis 
of the relationship between gene activity and cell function will allow us to gain an 
important and much needed insight into the intrinsic mechanism and/or also the 
development of the disease. Genomic studies will allow us to understand the structure 
and function of the genetic information that belongs to a cell or organism. The study of 
the genome is known as the organism's 'biological blueprint of DNA, chromosomes and 
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genes. Information systems, databases and computerized research tools have joined 
forces in the Human Genome Project, which is a worldwide collaborative effort to 
identify and record the 80,000+ genes and 3 billion DNA segments that define the human 
species. Specifically, genomics refers to the study of genome composition, structure and 
function, which can be classified into classical genomics, physical genomics (DNA 
sequence-based) and genome informatics. An omics is a neologism referring to a field of 
study in biology, ending in the suffix -omics such as genomics or proteomics. The 
original use of the suffix "ome" was in the word "genome", which refers to the complete 
genetic makeup of an organism. Because of the success of large-scale quantitative 
biology projects such as genome sequencing, the suffix "ome" has been extended to a 
host of other contexts. The omes are a useful way for computational biologists to 
encapsulate a particular class of cellular processes, or information processing related 
mechanisms. The proteome is one of the more common "omes" that is well-established 
within genomics. The proteome is the totality of proteins (expressed genes) in an 
organism, tissue type or cell, and proteomics is now well-established as a term for 
studying the proteome. Less well-established "omes" have been proposed, but are not 
universally used within genomics or biology as a whole. It is far less clear (unlike in the 
case of genomics or even proteomics) that a systematic enumeration of entities like these 
is feasible, or would help in providing biological insight. One of the new and less 
established ones which are attaining more recognition is the transcriptome. The 
transcriptome is the mRNA complement of an entire organism, tissue type, or cell; the 
associated field is transcriptomics. Transcriptomics refers to the genome-wide study of 
mRNA expression levels, and will be one of the approaches used in my research study.  
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As we know, the phenotypic changes in microbes and their host during infections 
are encoded by the genomes of microbial pathogens and their hosts, and may be 
expressed in certain environmental conditions devoted to specific microbe-host 
interactions. Ultimately, this taking in the form of genome-wide approaches to 
genotyping and expression profiling will eventually lead to a better and more in depth 
understanding of microbial pathogenesis, allowing for the efficient and rapid diagnosis of 
infectious diseases, and assist in the development of novel strategies to control infections.  
 
2.2 Human Macrophage Cell Line (U937) 
 A human monocytic cell line (U937), obtained from the European Collection of 
Animal Cell Cultures (Porton Down, UK; ref. 85011440) (Whyte, J., et al., 2000). They 
are classified as tumor and have an infinite life span; furthermore, they have a 
lymphocyte-like morphology. U-937 is a neoplastic, histocytic cell line (Sundstrom C. 
and Nilsson K., 1976). U-937, an unusual human cell line, derived from a patient, with 
histolytic lymphoma which synthesizes lysozyme. The cell line lacks immunoglobulin 
and Epstein-Barr virus (EBV) genome, but bears receptors for immunoglobulin and 
complement (Ralph, P., et al, 1976). Studies have shown that Chlamydia pneumoniae is 
shown to grow in macrophages, especially in this human monocytic cell line (Gaydos, 
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2.3 Chlamydia Pneumoniae  
Chlamydia pneumoniae is a human respiratory pathogen serving as the etiologic 
agent in cases of pneumonia. Chlamydia pneumoniae can cause persistent infections of 
the respiratory tract, it has been suggested that persistent infection with Chlamydia 
pneumoniae in the coronary arteries contributes to the development of atherosclerosis. 
For such an infection to occur, the bacteria should be not only present but viable in the 
coronary arteries (Hammerschlag M.R., et al. 1992). The association of Chlamydia 
pneumoniae with atherosclerosis is corroborated by the presence of the organism in 
atherosclerotic lesions throughout the arterial tree and the near absence of the organism in 
healthy arterial tissue (Kuo C.C., Jackson L.A., et al., 1995). Chlamydial contribution to 
the development of atherosclerosis is a fascinating hypothesis that may initiate a radical 
change of clinical practice for one of the leading causes of death. Chlamydia pneumoniae 
infection has been recently accepted as an important cause of atherosclerosis. Recent 
reports suggest that Chlamydia pneumoniae is a key microbial organism that causes 
atheroma developments in the carotid artery. According to the "Chlamydia theory", once 
the artery is infected, the inner lining becomes inflamed. The inner lining will then swells 
and blisters, leaking enzymes and other chemicals into the blood stream. The body 
attempts to heal this damage by depositing cholesterol and a thin layer of congealed 
blood over the infected site. Unfortunately, once the infection has run its course, the body 
has no way to remove the cholesterol plaque that has built up. This is because the layer of 
congealed blood prevents chemical agents in the blood stream from reaching the 
cholesterol and re-dissolving it. 
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Chlamydia pneumoniae was first described as an agent causing atypical 
pneumonia in 1986 (Grayston J.T., et al. 1990). Morphologically, it resembles the gram-
negative bacteria, but is characterized by its unique obligate intracellular parasitism. It is 
a well known pathogen that causes upper and lower respiratory tract infections, thus 
commonly found in alveolar macrophages and moderately persistent resulting in re 
infections. Due to its obligate intracellular nature, it is difficult to isolate from clinical 
specimens. This organism never shows up in truly healthy tissue, unlike the other 
infectious agents sometimes shown in both healthy and unhealthy patients; hence any 
signs of detection of the presence of these bacteria signify its presence and suggest 
possible roles of it which may play in the disease. The PCR method and cell culture have 
also found the bacterial organism, Chlamydia pneumoniae in atherosclerotic coronary 
arteries (Kuo C.C., et al., 1993; Ramirez J.A., 1996). The presence of Chlamydia 
pneumoniae in these samples will be detected by means of polymerase chain reaction, 
and this may provide a better marker for an actual infection (Boman J. and Gaydos C.A., 
2000).  
 
2.3.1 Chlamydia Pneumoniae AR39 
One particular strain of Chlamydia pneumoniae (AR39) appears to be more 
frequently involved in atherosclerosis thus was the chosen strain of Chlamydia 
pneumoniae to work with (Movahed M.R., 1999). Chlamydia pneumoniae AR39 has a 
genome length of 1 229 858 base pairs. The genome sequence of Chlamydia pneumoniae 
strain AR39 (1 229 858 nt) was determined using a random shotgun strategy. This is 
depicted in figure 7. 




Figure 7 A schematic representation of the Chlamydia pneumoniae AR39 DNA 
molecule (adapted from T. D. Read, et. al., 2000) 
 
Although the chlamydial genomes were highly conserved, there were intriguing 
differences in key nucleotide salvage pathways: Chlamydia pneumoniae has a uridine 
kinase gene for dUTP production. Chromosomal comparison between members of the 
same family revealed that there had been multiple large inversion events apparently 
oriented around the axis of the origin of replication and the termination region. The 
striking synteny of the Chlamydia genomes and prevalence of tandemly duplicated genes 
are evidence of minimal chromosome rearrangement and foreign gene uptake, 
presumably owing to the ecological isolation of the obligate intracellular parasites. The 
Chlamydia pneumoniae AR39 chromosome was >99.9% identical to the previously 
sequenced Chlamydia pneumoniae CWL029 genome, however, comparative analysis 
identified an invertible DNA segment upstream of the uridine kinase gene which was in 
different orientations in the two genomes. AR39 also contained a novel 4524 nt circular 
single-stranded (ss) DNA bacteriophage, the first time a virus has been reported infecting 
Chlamydia pneumoniae.  
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2.3.2 Developmental Cycle of Chlamydia Pneumoniae 
Chlamydia are known to have a distinctive biphasic growth cycle with dimorphic 
forms that are functionally and morphologically distinct. The chlamydiae exist in nature 
in two forms: 
(a) An extra cellular, non-replicating, infectious particle called the elementary 
body (EB), 0.25 to 0.3 µm in diameter that is released from ruptured infected cells and 
can be transmitted from one individual to another. The elementary body, which is 
covered by a rigid cell wall, contains a DNA genome along with a cryptic DNA plasmid. 
It also contains an RNA polymerase responsible for the transcription of the DNA genome 
after entry into the host cell cytoplasm and the initiation of the growth cycle. Once 
endocytosed, the EB differentiates into a larger pleomorphic form called the reticulate 
body (RB), as mentioned below. Ribosomes and ribosomal subunits are present in the 
elementary bodies. This is depicted in Figure 8. 
 
(b) An intracytoplasmic form called the reticulate body (RB), 0.5 to 0.6 µm in 
diameter that engages in replication and growth. The reticulate bodies replicate by binary 
fission (Kuo C.C., Jackson L.A., et al., 1995). One thing to note is that the DNA genome, 
proteins, and ribosomes are retained in the membrane-bound prokaryotic cell (reticulate 
body) throughout the developmental cycle. This is depicted in Figure 8. 
 
The developmental cycle of Chlamydia pneumoniae has four main stages; firstly 
in the dormant phase, the elementary bodies (EBs) have little or no metabolic activity.  
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Secondly, EBs will adsorb to the host cell membrane and utilize glucose-6-
phosphate as substrate and also mitochondrial functions. EBs mass will increase because 
of macromolecule synthesis. Thirdly, the elementary bodies will be developed into 
reticulate bodies. The series of events are depicted in the diagram below, figure 8. Lastly, 
the reticulate bodies matured and EBs will be formed and the life cycle is completed. EBs 
will then be released from the ruptured cells.  
 
 
Figure 8 Developmental lifecycle of Chlamydia pneumoniae in macrophages 
(adapted from T. D. Read, et. al., 2000) 
 
A typical cell ingests an elementary body (EB) (pear-shaped cell) of Chlamydia 
pneumoniae by endocytosis into a vesicle. (1) Chlamydia pneumoniae prevents the 
vesicle, which has matured into a phagosome, from fusing with a lysosome. (2) The EB 
now will instead differentiate to form a reticulate body (RB) which then replicates by 
binary fission. (3) This will result in the formation of a mature inclusion. Persistence 
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might occur at this stage in cases of immune stress when RB cells adopt a non-replicating, 
non-infectious persistent form, shown as an orange cell depicted in the figure 8 above. (4). 
Otherwise the RBs re-differentiate into EBs. (5) Finally, these infectious EBs are released 
by lysis of the host cell, after which other cell types can be infected.  
 
 
Figure 9 Possible mode of action of Chlamydia pneumoniae leading the event of 
atherosclerosis.  (adapted from T. D. Read, et. al., 2000) 
 
A Chlamydia pneumoniae elementary body (EB) is endocytosed by an alveolar 
macrophage in the lung of the infected individual. The EB differentiates to form a 
reticulate body (RB), which replicates to produce a mature inclusion. Circulating 
monocytes become infected and are disseminated. Formation of an inclusion in 
macrophages up regulates the adhesion of ligands on the cell surface (shown in red 
depicted in the figure 9 above), which will then enable the adhesion to the arterial 
endothelium. 
 
Survey of Literature 
 
24 
2.3.3 Medical Significance of Chlamydia Pneumoniae 
Chlamydia pneumoniae, a common and ubiquitous respiratory tract agent is the 
main cause of approximately 10% of all pneumonias worldwide. Chlamydia pneumoniae 
is transmitted from person to person by micro-droplets exhaled during breathing and by 
fecal contamination. The incubation period lasts from seven to twenty one days. Primary 
infection most often occurs in childhood or adolescence and re-infection occurs 
commonly. Chlamydia pneumoniae causes pharyngitis, otitis, sinusitis, bronchitis, and 
pneumonia, and may also be involved in asthma. It causes 6 to 10% of community-
acquired pneumonia. Chlamydia pneumoniae antibodies are rarely detected in children 
under the age of five except in developing and tropical countries. Subsequently, antibody 
prevalence increases rapidly from ages 5 to 14 to reach 50% at the age of 20, and 70 to 
80% between 60 and 70 years of age. Virtually everyone is infected at some point in life 
(Saikku P., 1999). The spectrum of Chlamydia pneumoniae infection has been extended 
to atherosclerosis and its clinical manifestations. It has been postulated that infection with 
Chlamydia pneumoniae can promote the progression of coronary heart disease by 
triggering either a local vascular or a systemic inflammatory process (Ridker P.M., et al. 
1997). Chlamydia pneumoniae is the bacteria responsible for the increase of a person 
exposure to risk of developing atherosclerosis or clogged arteries. Studies suggested that 
the bacterium may damage the lining of coronary arteries, which would promote the 
build-up of plaque. The bacterium was found in macrophage foam cells which lead to the 
hypothesis of the bacterium involved in the promotion of early-onset atherosclerosis. The 
main mode of infection involves the interaction of Chlamydia pneumoniae with 
macrophages in the presence of low density lipoprotein. This will results in the 
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transformation of the macrophages into foam cells which will eventually accumulate 
around the lining of the artery which will lead to the formation of the atherosclerosis, 
which will eventually lead to heart disease.  
 
2.3.4 Difficulties of Chlamydia Pneumoniae 
The two principal difficulties that touch every aspect of chlamydial research are 
firstly chlamydiae only grow within eukaryotic host cells and secondly there are limited 
genetic approaches available to allow one to understand to allow the development and 
design of drugs and therapy to eradicate this nagging problem. The respiratory pathogen 
which is mainly found in the lungs will have to be transported to the cardiac tissue.  The 
method is which this is carried out depends mainly on the bronchoalveolar macrophages, 
as they will phagocytize the elementary bodies of Chlamydia pneumoniae resulting from 
a lytic pulmonary infection. Thus, this will result in the end result of the Chlamydia 
pneumoniae gaining entry to the bloodstream and be transported to sites of vascular 
injury in coronary vessels.  
 
2.3.5 Possible mechanisms of Chlamydia Pneumoniae involved in Atherosclerosis 
The various possible mechanisms were also proposed from the literature survey 
done. However , extensive work and experimental results have proven that the second 
mechanism listed below of that of the ox-LDL uptake mechanism is the most commonly 
seen, and is also the proposed possible mechanism of Chlamydia pneumoniae. Thus, the 
addition of low density lipoprotein is an important consideration to be taken in this 
experiment. A graphical illustration of the various ways of mode of action by the bacteria, 
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Chlamydia pneumoniae can be seen in Figure 10. In a nutshell, the infected monocyte 
adheres to the arterial endothelium and migrates between adjacent endothelial cells into 
the intima. Completion of re-differentiation of the RB in the inclusion to yield an EB 
allows infection of other cell types, including resident arterial macrophages, which 
upregulate low-density lipoprotein (LDL) uptake and oxidation to become cholesterol-
filled foam cells — an early marker of atherosclerotic lesions.  
 
 
Figure 10 Possible mechanisms by which Chlamydia pneumoniae might promote 
atherosclerosis.  (adapted from T. D. Read, et. al., 2000) 
Smooth-muscle cells are infected by the EBs, which stimulates proliferation. 
Infection of endothelial cells leads to production of tissue factor (TF), vascular-cell-
adhesion molecule 1 (VCAM-1), intracellular-adhesion molecule 1 (ICAM-1), E-selectin, 
interleukin-6 (IL-6) and IL-8. Cytokine production by infected smooth-muscle cells can 
affect atheroma biology. Infection of macrophages induces production of matrix 
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metalloproteinase (MMP) and expression of TF, which leads to plaque destabilization 
and thrombus formation. The latter can result in myocardial infarction (Danesh J., 1997). 
However, the studies have reported the mechanisms or preferred pathways taken are 
namely:-  
(i) Induction of cytokines – Chlamydia pneumoniae gains direct access to the 
vasculature following pulmonary infection via macrophages. This systemic infection 
produces elevated C-reactive protein (CRP) levels, increased leukocyte counts, and 
cytokine release. Infection prompts the release of various inflammatory cytokines, which 
cause hepatocytes, cells in the liver, to produce CRP. CRP concentrations are used as a 
systemic inflammation marker for the prediction of coronary events in patients suffering 
from angina. CRP induces expression of monocyte tissue factor, which elicits 
monocyte/macrophage activation. It has been demonstrated that Chlamydia pneumoniae 
can also elicit the production of adhesion molecules in these cells. Infection of 
endothelial cells has been shown to stimulate tissue factor activity and enhance platelet 
adhesion (Danesh J., 1997). 
(ii) ox-LDL uptake – Chlamydia pneumoniae has been shown to have definite 
effects on lipids. LPS, an endotoxin found in all gram negative bacteria, induces 
endothelial cells to produce free radicals, which oxidize Low density lipid (ox-LDL). ox-
LDL is a known risk factor in atherosclerosis. Macrophages infected with Chlamydia 
pneumoniae uptake ox-LDL and transform into highly vacuolated, lipid laden foam cells. 
These foam cells are key cells in the atherosclerotic process. Infections may have an 
effect on lipid metabolism, thereby producing an atherogenic lipid profile. Decreased 
levels of high density lipid (HDL) and increased triglyceride values may result from the 
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continuous cytokine production associated with chronic infection. However, the 
atherogenic effects of Chlamydia are dependent upon serum cholesterol levels. 
Hypercholesterolemia in conjunction with Chlamydia pneumoniae infection significantly 
increased the extent and severity of lesions, as compared to a diet high in cholesterol with 











Figure 11 The role of Chlamydia pneumoniae in the development of arterial plaque. 
The presence of oxidized low-density lipid (ox-LDL) inhibits nitric oxide (NO) 
synthesis.  Down regulation of NO production causes platelet aggregation and 
vasoconstriction.  Simultaneously, the ox-LDL and newly synthesized cytokines cause 
direct damage to the endothelial cells of the blood vessels.  Monocytes are activated by 
ox-LDL and newly synthesized cytokines, and then convert to macrophages.  Monocyte 
derived macrophages then take up oxidized LDL in vitro to become foam cells. Oxidation 
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cells, or smooth-muscle cells (DeGraba TJ, et al, 1991).  In addition to its participation in 
the formation of foam cells, oxidized LDL-cholesterol appears to contribute to 
atherogenesis in three other ways: (1) It has cytotoxic properties that may promote 
endothelial injury; (2) it acts as a chemo attractant for circulating monocytes, leading to 
their increased accumulation with plaques; and (3) oxidized LDL-cholesterol inhibits 
egress of macrophages from plaques. In the presence of Chlamydia pneumoniae, the 
macrophage on sensing the foreign particles (Chlamydia pneumoniae) phagocytizes the 
Chlamydia pneumoniae.  Engulfment of Chlamydia pneumoniae in the presence of ox-
LDL creates a foam cell (Danesh J., 1997).  Foam cells, ox-LDL, and Chlamydia 
pneumoniae are major constituents of arterial plaque; thus they are an important 
consideration in the overall planning and selection of the models (as depicted in figure 
11). (iii) Antigenic Mimicry - There is growing evidence to support the theory that there 
is an autoimmune reaction component to atherosclerosis. The physiological phenomenon 
of antigenic mimicry, an immunological cross reactivity between microorganisms and 
self antigens due to a certain degree of genetic homology, is suspected. Chlamydial heat 
shock proteins (Hsp) which will cross-react with human Hsp, which will leads to 
antibodies that recognize self antigens. HSP60 is the key heat shock protein in chronic 
Chlamydia infections. It is associated with hypersensitivity reactions and induces release 
of adhesion molecules. Hsp60 is found intracellularly on the mitochondria, as well as on 
the surface of Chlamydia pneumoniae. The a myosin heavy chain of heart muscle has 
sequence homology to outer membrane proteins of Chlamydia. Human Hsp60 and 
Chlamydial Hsp60 are both found in atherosclerotic plaques (Danesh J., 1997). 
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2.3.6 Studies of Chlamydia Pneumoniae and Atherosclerosis 
The first possible epidemiological link between Chlamydia pneumoniae and 
atherosclerosis was established in 1988. Most humans are exposed to this obligate 
intracellular bacterium at some point in their lives, as evidenced by increasing antibody 
titers with age. There is clear experimental evidence that Chlamydia pneumoniae can 
infect macrophages, endothelial cells, smooth muscle cells, and induce the formation of 
foam cells (John D., et al., 2000). Infective hypothesis as the main possible pathogenetic 
mechanism involved in atherosclerosis has received increasing attention. Researches have 
recently focused their attention on the role of Chlamydia pneumoniae, a gram-negative 
intracellular organism, as infection by this bacterium has been demonstrated frequently 
associated with atherosclerosis (Bauriedel G., et al., 1999). Several experimental studies 
have shown that the biological properties of Chlamydia pneumoniae can explain its 
potential role in initiating and/or modulating plaque formation. Recent appreciation of 
atherosclerosis as a chronic, inflammatory disease has rekindled efforts to examine the 
role that infectious agents may play in atherogenesis (Blasi F., et al., 1999). The 
possibility that a prokaryote contributes to atherogenesis has high clinical interest, as 
Chlamydia pneumoniae infection may be a treatable risk factor. Furthermore, as 
Chlamydia pneumoniae never shows up in truly healthy tissue, the presence of the 
Chlamydia pneumoniae elementary bodies in the atherosclerotic plaques and fatty streaks 
of the aorta and coronary arteries of autopsy cases strongly suggested a close association 
(Shor A., et al., 1992). 
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Atherosclerosis is apparently the result of ultrachronic persistent infection by 
Chlamydia pneumoniae and not the result of different risk factors. The Koch-Henle 
criteria for the proof of the etiology are largely fulfilled as firstly, there is a correlation of 
coronary heart disease and other atherosclerotic disease with antibodies against 
Chlamydia pneumoniae. Secondly, Chlamydia pneumoniae could be detected with 
different techniques (PCR, immuno histology, electron microscopy, culture) in a high 
percentage in atheromas from different sites (Kuo C.C., Gown A.M., et al., 1993). 
Thirdly, the target cells of atherosclerosis (endothelia, macrophages, muscle cells) can be 
infected by Chlamydia pneumoniae in vitro. Lastly, animal studies indicate that 
Chlamydia pneumoniae can accelerate the development of atherosclerosis and antibiotic 
administration of macrolides, such as roxithromycin, azithromycin, clarithromycin as 
potential antichlamydial agents can prevent it in coronary heart disease were successful. 
Chlamydia pneumoniae infection occurs in human vascular walls and may accelerate the 
foam cell formation of macrophage and smooth muscle cells, and may play a causative 
role in atherosclerosis. And when an infected macrophage travels down on a vessel wall, 
it may infect the cells lining the arterial surface.  Under these conditions, the artery would 
attract more immune cells, which will deliver more bacteria to the site and cause more 
serious inflammation. It was concluded that C. pneumoniae has the capacity to infect one 
of the most important types of cells (smooth muscle) found within atherosclerotic lesions 
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2.4 Lipids - Low Density Lipoprotein 
Lipids are important components of lipoproteins in the blood. Lipids are 
transported in the blood by packaging the lipids into particles with enough polar or 
amphipathic molecules that the entire particle can dissolve in the blood. These lipid-
containing particles are called lipoproteins. Lipoproteins are spherical particles found in 
the blood and lymph which are composed of several types of molecules, including: 
triglycerides (TG), free fatty acids (FFA), phospholipids (PL), cholesterol (C), cholesterol 
esters (CE), and proteins. Phospholipids are defined as complex lipids consisting of fatty 
acids, phosphate and nitrogenous base. Lipoproteins are composed of an amphipathic 
outer surface that consist of apolipoprotein (APO), phospholipids and cholesterol; and 
also a hydrophobic inner core consisting of the triglycerides and cholesteryl ester. The 
protein component confers solubility to the complex so that the lipids in the core of the 
complex can circulate in the blood.  
 
The most hydrophobic compounds (TG, CE, FFA) hide away in the centre while 
the more amphipathic compounds (PL, C, protein) surround them. The phospholipids in 
this surrounding layer will be arranged such that the polar head is on the outside 
interacting with the aqueous solution, while the non-polar tails face inward and interact 
with the hydrophobic stuff inside. The proteins are found non-covalently bound to the 
surface of the sphere. The major types of lipoproteins includes chylomicrons, very low 
density lipoproteins (VLDL), low density lipoproteins (LDL), lipoprotein Lp(a) and high 
density lipoproteins (HDL). Chylomicrons are the largest type of lipoproteins and are 
formed in the intestine; they carry mainly triglycerides of dietary origin, and also smaller 
amounts of cholesterol and proteins.  
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Chylomicrons decrease in diameter as they circulate in blood.  The triglycerides 
are broken down enzymatically in the circulation, releasing free fatty acids, which are 
taken up by fat cells. The resulting chylomicron remnants are taken up by liver cells 
which use the fatty acids to manufacture other lipoproteins (HDL, VLDL and LDL). The 
cholesterol is either stored as ester form or oxidized to bile acids. Very low density 
lipoproteins (VLDL) transport triglycerides from the liver to the tissue; low density 
lipoproteins (LDL) transport tissue cholesterol to the liver. Following a high fat and high 
glucose intake, the liver synthesizes triglycerides from the fatty acids carried to it by 
chylomicrons. Triglycerides and cholesterol are then incorporated into VLDL, which will 
be secreted into the blood.  The triglycerides in VLDL are hydrolyzed in the circulation 
to release fatty acids for storage in fat cells.  As a result, VLDL is converted to 
intermediate density lipoprotein (IDL) which is reduced further to LDL.  One good 
example of low density lipoprotein is cholesterol. In the process of atherosclerosis, LDL 
undergoes oxidation in the blood and is then engulfed by macrophages which become 
“foam” cells that adhere to the inner lining of arterial walls.  These contribute 
subsequently to the development of a thrombus (“clot”), which will be fatal leading to the 
heart attack when the blockage is found to be in the coronary arteries. Cholesterol is the 
fatty lipid found in the body tissues and blood plasma of vertebrates; which is also a 
natural and necessary component of your body cells and many hormones. Cholesterol is 
transported in the bloodstream as lipoproteins to their destinations. Cholesterol is 
important as it is the main component used for membrane synthesis, thus usually only 
half of the amount of cholesterol is converted to bile acids or excreted as waste. The 
weak ability of cholesterol to dissolve in water is a major factor in the development of 
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atherosclerosis, a condition associated with coronary artery disease. Cholesterol becomes 
bad when high levels are present. Lipoprotein Lp (a) is a lipoprotein with an LDL-like 
moiety and a protein, Lp (a).  It is found in atherosclerotic plaques and contributes to 
coronary artery disease by preventing the break-up of clots. HDL has been considered the 
good counterpart of the lipoprotein family, as they help to remove excess cholesterol 
from the body. HDL is “manufactured” in the liver as small particles called prebeta-1 
HDL.  As it circulates in the blood, it increases in size by receiving free cholesterol from 
the cell membranes of other tissues.  It is finally taken up by the liver cells which then 
remove cholesterol from the particles. It is also said that the presence of the amount of 
HDL versus LDL will allow one to gauge the chances of getting heart attacks. This could 
be stemmed from the understanding of the various different members of the lipoprotein 
family.  
 
Atherosclerosis can be resulted from the presence of elevated blood lipids, 
elevated cholesterol levels in particular. Atherosclerosis is the most common cause of 
heart disease. It is a hardening or thickening of the arteries due to the slow build-up of 
deposits (plaques) of fatty substances, cholesterol, calcium and fibrin (a clotting factor in 
the blood) within the inner lining of an artery known as the atheroma.  The entire artery 
may consequently be blocked, leading to a heart attack or stroke. High levels of 
cholesterol in the bloodstream are associated with hardening of the arteries, premature 
coronary heart disease and many other vascular disease problems. The first stages of 
heart disease are lesions and cracks forming in the blood vessel walls normally at the 
points of highest pressure or stress (near the heart). The second stage is the body trying to 
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repair itself by depositing fatty substances (cholesterol, lipoproteins) inside the blood 
vessels to fill the cracks. Chlamydia pneumoniae possesses a lipopolysaccharide 
molecule that is capable of reacting with LDL, thus allowing the LDL molecules to be 
more easily oxidized. Once the LDL molecules are oxidized, their uptake by 
macrophages is enhanced, thus triggering the process of atherosclerosis. Low density 
lipoprotein (LDL) is the major cholesterol carrier in the blood. If too much LDL 
cholesterol circulates in the blood, it will slowly buildup in the walls of the arteries that 
are feeding the brain and heart. Together with other substances it can form plaque, a thick 
hard deposit that can clog those arteries. This will lead to the blockage of the normal 
blood flow to part of the heart muscle and this will cause a heart attack These fatty 
substances can begin to build up and clog the blood vessels causing stroke and heart 
attack (Kuo C.C., et al., 1993). A high level of LDL cholesterol (160mg/dL and above) 
reflects an increased risk of heart disease; thus also known as “bad” cholesterol. Lower 
levels of LDL cholesterol reflect a lower risk of heart disease. Low density lipoprotein 
(LDL) is known to bind to arterial wall proteoglycans (APG), an interaction that will 
initiate cholesterol deposition in the arterial wall. This focal deposition process is an 
important step in the pathogenesis of the early, fatty streak and the advanced 
atherosclerotic plaque (Berenson G.S., et al., 1986). Lipid accumulation occurs both 
intracellularly and in association with the components of the arterial wall (Camejo G., 
1982). Lipoprotein metabolism can be carried out in three main pathways, namely 
exogenous, endogenous and reverse cholesterol transport. 
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2.4.1 Lipoprotein Metabolism - Exogenous Pathway  
The exogenous pathway describes how dietary cholesterol is absorbed from the 
gut, packaged into lipoproteins (chylomicrons), and transported to various tissues. Before 
they can be absorbed from the gut, cholesterol and other dietary lipids must be emulsified. 
Emulsification, which is aided by the bile acids and the churning action of the stomach, 
increases the surface area upon which lipases can work, thus removing fatty acids from 
triglycerides. The resultant fatty acids, mono glycerides and diglycerides are then 
incorporated with cholesterol into bile acid micelles so they can cross the unstirred layer 
and be taken up into intestinal epithelial cells. Inside the cell, triglycerides are 
reassembled and cholesterol is esterified via the enzyme acylCoA-cholesterol-
acyltransferase (ACAT). The triglycerides and cholesterol esters are then packaged with 
phospholipids, free cholesterol, and protein into chylomicrons and secreted from the 
basolateral surface of the cell. The chylomicrons move from the interstitium into 
lymphatic vessels and eventually into the circulation. Another function of these intestinal 
cells is to excrete excess cholesterol by secreting it back out into the lumen of the 
intestine. This is accomplished via a group of enzymes called ATP binding cassettes 
(ABCs) which act as cholesterol transporters. Remember that to maintain homeostasis, 
the amount of cholesterol gained each day must equal the amount excreted. Most 
cholesterol is excreted in the form of bile acids, but some gets excreted directly from the 
intestinal cells. The main structural protein in the chylomicron is apoB-48, which is an 
apoB variant that is only found in intestinal epithelial cells. The ‘normal’ apoB is apoB-
100, the major structural protein for VLDL, IDL and LDL. ApoB-48 comes from the 
same gene, but the intestinal epithelial cells contain an enzyme which ‘edits’ the mRNA 
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to produce a premature stop codon. The protein is therefore about half the normal size, 
and is missing a C-terminal LDL-receptor binding domain. The ‘nascent chylomicrons’ 
secreted from the intestinal cells have only this apoB-48 and some apoA apoproteins. 
However, once they reach the blood they pick up apoC and apoE (from HDL particles) 
and become mature chylomicrons. The mature chylomicrons circulate in the blood and 
eventually off-load their triglycerides to peripheral tissues such as muscle and adipose 
tissue. The way this works is the chylomicron binds to lipoprotein lipase (LPL), which is 
found attached to the luminal surface of capillary endothelial cells. ApoC-II helps 
activate the LPL, which hydrolyzes the triglycerides into glycerol, monoglycerides and 
free fatty acids (FFA) for use by nearby cells. As the chylomicrons get rid of their 
triglycerides, they get smaller. As part of this shrinking process, they also lose 
phospholipids, free cholesterol and apoproteins which are transferred from the 
chylomicron coat to HDLs. The other way chylomicrons get rid of triglycerides is by 
exchanging them for cholesterol from mature HDL using the enzyme cholesterol ester 
transfer protein (CETP). After the chylomicrons have lost triglycerides, gained CEs, and 
lost the apoC-II that helps them interact with LDL, they are much smaller and are called 
chylomicron remnants. Their apoproteins are mainly apoB-48 and apoE, and they are 
removed from circulation by a receptor-mediated process that occurs in the liver. ApoE 
on the remnants binds to LDL-receptors or LDL-receptor-like protein (LRP) expressed 
on the hepatocyte surfaces, and the remnants are internalized via endocytosis. For LRP, it 
is actually a two-step process where the remnant binds first to a heparin sulfate 
proteoglycan (HSPG) on the cell surface and is then transferred to the LRP for 
internalization.  
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2.4.2 Lipoprotein Metabolism - Endogenous Pathway  
The endogenous pathway describes how cholesterol is synthesized in the liver and 
intestine. This pathway for de novo synthesis uses acetyl-CoA as its starting material, and 
the rate-limiting step is mediated by an enzyme called HMG-CoA reductase. A major 
group of cholesterol-lowering drugs, statins, act by inhibiting this enzyme. The 
cholesterol synthesized in the liver is packaged up with triglycerides and PL into large 
lipoprotein particles called VLDL (very low density lipoproteins). The major structural 
protein in VLDL is apoB-100 (compare with chylomicron and apoB-48), and an enzyme 
called microsomal triglyceride transfer protein (MTP) helps the apoB acquire lipid during 
VLDL synthesis.  
 
Like chylomicrons, VLDL pick up apoC and apoE from HDL in the blood, and 
interact (via apoC) with LPL on the surface of capillary endothelial cells. The LPL 
hydrolyzes triglycerides into free fatty acids, monoglycerides, and glycerol which can be 
used by various tissues. Now depleted of some of their triglycerides, the particles are 
called IDL (intermediate density lipoproteins) and have lost the apoC which allows them 
to interact with LPL. So next they go to the liver, where they interact with hepatic lipase 
(HL). This enzyme also hydrolyzes and removes triglycerides. These particles are low 
density lipoproteins after being depleted and having lost the apoE which aids in binding 
to the LDL-R, and these low density lipoproteins can circulate in the blood for up to 3 
days. Eventually they will be taken up into cells via receptor-mediated endocytosis 
involving the LDL-receptor (LDL-R), like chylomicron remnants.  
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Once inside, the cholesterol esters and proteins are broken down and intracellular 
cholesterol synthesis is reduced. About 50% of the total LDL is metabolized in the liver, 
but adrenal and adipose tissues also use a significant amount. LDLs have apoB-100 
which can interact with the LDL-R, while the apoB-48 of the chylomicron can’t. The 
apoE of IDL facilitates binding to the LDL-R, so it actually has a higher affinity for the 
LDL-receptor than LDL does; thus, IDL can either be converted to LDL or taken up 
directly by hepatocytes. A mutation in the LDL-receptor can be a cause of familial 
hyperlipidemia. In general, the more LDL you have binding to receptors and getting 
internalized, the better. It is better to have cholesterol in the cells than floating around in 
the bloodstream, as the free floating cholesterol will be increasing the chances of the 
onset of atherosclerosis. It is believed that both insulin and thyroid hormone promote 
LDL binding and internalization, thus people with poorly controlled diabetes or 
hypothyroidism has an increased risk of atherosclerosis. The cells themselves will usually 
regulate the expression of LDL-R based on their own needs: if a cell is getting low in 
cholesterol it will increase the number of LDL receptors, and vice versa. When a statin is 
used to inhibit cholesterol synthesis, it will cause the intracellular cholesterol levels drop, 
which eventually results in increased LDL-R expression. These extra receptors help pull 
the cholesterol out of the blood and into the cells, thus reducing serum cholesterol levels. 
The endogenous pathway regulates itself based on the amount of cholesterol in the 
system. When there is a large amount of cholesterol coming into the cell, a protein called 
“sterol regulatory element binding protein” (SREBP) will become activated. The 
activated SREBP will then travel to the nucleus of the cell, and bind to specific sequences 
called “sterol regulatory elements” (SRE).  
Survey of Literature 
 
40 
This binding will result in a number of genes being up or down regulated. These 
genes have protein products that are involved in cholesterol metabolism, for example: 
LDL-R, HMG CoA reductase, ACAT, MTP, etc. So, in the example of high dietary 
cholesterol, the activated SREBP will down-regulate HMG CoA reductase (since there’s 
reduced need for de novo synthesis of cholesterol), and will up-regulate ACAT (which 
esterifies excess cholesterol for storage in the cell). It’s a good system, but other 
influences can mess it up. For example, external factors can increase TG and VLDL 
synthesis, such as: high carbohydrate diet, ethanol consumption, high insulin/low 
glucagon states. 
 
2.4.3 Lipoprotein Metabolism - Reverse Cholesterol Transport  
Reverse cholesterol transport describes the uptake of HDL by the liver, but this 
section will include a more general discussion of the action of HDL, which is synthesized 
in the liver and intestine, and has the job of picking up excess cholesterol in the periphery 
and bringing it back to the liver. During this process, it undergoes various 
transformations and interacts with other lipoproteins, particularly LDL. The major protein 
of HDL is apoA-I, but it also has apoC and apoE. The HDL secreted initially by the liver 
into the blood is called discoidal HDL and is very low in cholesterol. As it picks up 
cholesterol and cholesterol esters from the peripheral tissues, it becomes rounder. Any 
free cholesterol picked up can be converted to cholesterol esters by the enzyme lecithin-
cholesterol acyltransferase (LCAT), which is associated with HDL and activated by 
apoA-I.  This round, cholesterol-rich version of HDL is called, for reasons which remain 
rather obscure, HDL3. The next step is the transformation of HDL3 into HDL2, which 
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involves the exchange of cholesterol esters for triglycerides from LDL and chylomicron 
remnants, via cholesterol ester transfer protein (CETP). Thus the HDL gains triglycerides 
and the LDL and remnants gain cholesterol esters. Eventually the HDL2 will make its 
way to the liver, and interact with either hepatic lipase (HL) or scavenger receptor B1 
(SR-B1). If it interacts with HL (this interaction is enhanced by apoA-II), its triglycerides 
get hydrolyzed and it gets converted back to HDL3. If it interacts with SR-BI, the 
cholesterol esters will be taken up by the hepatocyte. 
 
2.5 Real Time Polymerase Chain Reaction using LightCycler (Roche 
Diagnostics, Germany) 
Gene-expression analysis is increasingly important in biological research, with 
real-time reverse transcription PCR (RT-PCR) becoming the method of choice for high-
throughput and accurate expression profiling of selected genes, given the increased 
sensitivity, reproducibility and large dynamic range of this methodology (Apfalter P., et 
al., 2001). Quantification of nucleic acids, especially of mRNA, is increasingly important 
in the field of biomedical research. The recently developed quantitative real-time 
polymerase chain reaction (PCR) – a highly sensitive technology for the rapid, accurate 
and reproducible quantification of gene expression – offers major advantages over 
conventional quantitative PCR. Transcript quantification is performed in the exponential 
phase of the PCR reaction through extrapolation of fluorescence signals from a standard 
calibration curve which represents the initial copy number for a given fluorescence 
signal. Real-time PCR assays have shown great applicability for the detection of 
Chlamydia pneumoniae in clinical samples (Tondella, M. L. C., et al., 2002).  
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The recent development of real-time PCR has offered the opportunity of sensitive 
and accurate quantification of mRNA levels that is crucial in biomedical research. Real-
time polymerase chain reaction (PCR) has become an indispensable tool for the rapid 
testing of various biological specimens and fluids for the presence of microorganisms 
(Kuoppa Y., et al., 2002).  
 
The LightCycler is a rapid air-heated thermal cycler which incorporates a 
fluorimeter for the detection and quantification of Polymerase Chain Reaction (PCR) 
amplified products. It provides real-time cycle-by-cycle analysis of product generation 
and the amplification are carried out in glass capillary tubes. The LightCycler DNA 
Master SYBR Green I is a ready to-use reaction mix for PCR, containing the SYBR 
Green I dye as detection format. This product is specifically adapted for PCR in glass 
capillaries using the LightCycler Instrument. SYBR Green I is a DNA double-strand 
specific dye, and its fluorescence is greatly enhanced by its binding to dsDNA. During 
each phase of DNA synthesis, the SYBR Green I dye that is already included in the 
reaction mix, binds to the amplified PCR products, and the amplicon can be detected by 
its fluorescence. Specificity and sensitivity of amplification reactions detected with the 
SYBR Green I dye can be greatly enhanced by combining amplification with a melting 
curve analysis. The LightCycler DNA Master SYBR Green I provides convenience, high 
performance,  reproducibility, and minimal contamination risk. Only template DNA, 
primers, and if necessary, additional MgCl2, have to be added. The products are detected 
using a fluorescent double stranded DNA binding dye or fluorescent probes.  
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Real-time PCR-based fluorescence assays have advantages over nested or single-
step gel-based assays (Tompkins L.S., et al., 2000). First, fluorescent probes make the 
assays more specific than a non-probe-based PCR. Second, they require less 
manipulation, reducing the potential for amplification product carryover. Finally, relative 
copy number values can be determined for any unknown sample by the use of a standard 
curve for the target of interest. Quantitative assays may be useful for determining the 
chlamydial load in Chlamydia pneumoniae carriers, especially for epidemiologic studies 
or for monitoring the effect of therapy in treatment trials. Fluorescent monitoring of DNA 
amplication is the basis of real-time PCR, from which target DNA concentration can be 
determined from the fractional cycle at which a threshold amount of amplicon DNA is 
produced. Absolute quantitation can be achieved using a standard curve constructed by 
amplifying known amounts of target DNA. The real time PCR results were analyzed by 
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3.1 Overview of the experimental techniques employed 
Culture, immunofluorescence, enzyme immunoassay and polymerase chain 
reaction (PCR) have been described as the laboratory gold standards for the testing and 
detection of Chlamydia pneumoniae (Gaydos C.A., et al., 1996). In our studies, the 
detection methods are based primarily on the laboratory gold standardsas decribed above. 
Molecular methods and differential display techniques (Liang, P., et al., 1995; Zhu, H., et 
al, 1997; Leong, W.F., et al, 2002; Liew, J.L. and Chow T.K., 2004) will be used to allow 
us to observe, and latest techniques such as real time polymerase chain reaction will also 
be used (Campbell L.A., et al., 1992). The various detection techniques and studies 
regarding Chlamydia pneumoniae were obtained from the existing protocols that were 
performed by others in the lab (Bobryshev Y.V., et al., 2004; Koh W.P., et al., 2003; Koh 
W.P., et al., 2002; Chow V.T.K., et al., 2001). The results obtained were subjected to 
bioinformatical analysis so as to interpret the data obtained and also gain an insight to the 
transcriptomics of the disease atherosclerosis that is closely associated with Chlamydia 
pneumoniae. 
 
3.2 Human macrophage U937 Cell Line Propagation and Maintenance 
The human macrophage cell line U937 (ATCC ) was selected as the main host for 
the infection with Chlamydia pneumoniae. This is to complement and stimulate the actual 
happenings in the human state, especially in the arteries near the heart whereby the 
bacteria are known to reside in these host cells. Low-passage stock cultures which had 
undergone <15 passages were adopted. 
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 The macrophages (U937 cells) were grown in antibiotic free medium for one 
week before infection was to be carried out as shown in the next section. Confluent U937 
cells were checked using the microscope and then the media along with the cells were 
transferred to 15ml falcon tubes and the supernatant were separated from the cell mass by 
centrifugation at 1,500g for 5 min (Biofuge 15R, Heraeus, Hanau, Germany). The 
centrifuged cell mass was then resuspended in phosphate-buffered saline (PBS) pH7.4 
(NUMI, NUS, Singapore); and then the supernatant were again separated from the cell 
mass by centrifugation at 1,500g for 5 min (Biofuge 15R, Heraeus, Hanau, Germany). 
This time the supernatant was discarded and fresh medium of RPMI growth medium for 
the U937 cells were added and were seeded into new 25cm3 Nunc cell culture flasks 
(Nalge Nunc International, NY, USA) at an appropriate split ratio for this cell type.  The 
respective growth media (Appendix 1) were added and the flasks kept in a humidified 
incubator at 37oC in 5% CO2 for 3 to 4 days. The U937 cells which were revived from 
the storage in liquid nitrogen tanks were grown for a short period of time (approximately 
one week) before it was used for the research. A small portion of cells were extracted and 
the cell concentration was checked to be 1.0 x 106 cell/ml or more with a 
haemocytometer (Iwaki, Tokyo, Japan). U937 (ATCC CRL 1998) was used as a host for 
infection of the bacteria Chlamydia pneumoniae. Furthermore, HEp2 cell line (ATCC 
CCL-10) was used initially for Chlamydia pneumoniae propagation, maintenance and 
initial trial runs. The HEp2 cell line was later dropped and human macrophages, U937 
cells, were used throughout the duration of the project. Confluent U937 cell suspension 
were centrifuged, removed of supernatant, then rinsed with phosphate-buffered saline 
(PBS) pH7.4 (NUMI, NUS, Singapore) and the process repeated and then followed by 
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passage with the new media. The cell suspensions were seeded into new Nunc cell 
culture flasks (Nalge Nunc International, NY, USA) at an appropriate split ratio for each 
cell type.  The human macrophage cell line is found to have a optimum growth rate of 4 
days towards confluency. The respective growth media (Appendix 1) were added and the 
flasks kept in a humidified incubator at 37oC in 5% CO2 for 3 to 4 days. 
 
3.3 Infection of human macrophage U937 cell line 
The human macrophage U937 cells were infected with Chlamydia pneumoniae 
AR39 .The same size inocula (105 inclusion-forming units [IFU]/ml) were used in the 
study conducted for each of the five different proposed models and an infection ratio of 
1:1, in which one Chlamydia pneumoniae will be present for every U937 cell, is being 
selected as the basis for our study. This is to allow sufficient chances of infection and it is 
the recommended infection ratio obtained from the literature cited. Furthermore, the 
amount of low density lipoprotein added is calculated to be at a concentration of 100µg 
per ml of media used in each of the NUNC 25 cm2 flasks. The growth media of the 
confluent cells were removed and the cells washed in PBS (NUMI, NUS, Singapore) and 
the appropriate amount of bacteria was added.  The flasks were incubated in a humidified 
incubator at 37oC in 5% CO2 for the designated optimum duration for each of the 
proposed model of study as illustrated in the figure 12. The study model 1, which have 
uninfected Chlamydia pneumoniae cells, served as a control while other models served as 
the various referencing and study approaches for a particular situation which will be 
further elaborated at each time point.   
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The five models were then harvested at day 1 (24 hours), 3 (72 hours) and 4 (96 
hours) respectively after infection and treatment with LDL as depicted in figure 12. The 
harvested cells were then subjected to differential display RT-PCR experiments and the 
results obtained were verified by the Real Time PCR experiments. This is depicted in the 
figures 12 to 15 as shown.  
 
3.4 Viable Cell Count 
Cell viability was performed by the Trypan blue dye exclusion test that stains 
dead or dying cells that are unable to repel the dye. A stock of 0.4% of Trypan blue 
(Sigma-Aldridge, St. Louis, USA) in PBS (NUMI, NUS, Singapore)was diluted 10-fold 
in PBS and 500µl of U937 cell suspension, taken directly from the flask ,was added to an 
equal volume of diluted Trypan blue.  Both chambers of the haemocytometer (Iwaki, 
Tokyo, Japan) were then filled by capillary action and the chambers were viewed under a 
microscope with a 10X ocular and a 10X objective.   
 
Cells were then counted in each of the 1mm2 squares only if less than 10% of the 
cells represent clumps and each square has a cell density of between 20 to 50 cells (if not 
repeat with a suitable dilution factor).  The number of cells per ml would be equal to the 
average count per square multiplied by 10,000.  Subsequently, the total number of cells 
can be calculated by multiplying the number of cells per ml with the dilution factor and 
the total volume of the sample cell suspension.  Triplicates were done to check 
reproducibility. A total of 1 x 105 cells were used in the experiment for each flask. 
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3.5 Culture conditions and preparation of the Five Study Models  
As depicted in the figure 12 to figure 15, it clearly outlines the events and 
procurement of work to be done in the initial phase. The thawed out cells from the 
storage in the -80 freezer was passaged in 20ml of the growth media and be grown for a 
week to stabilize the culture of U937 macrophage cells. A total of seven 25cm2 flasks 
will be grown of which three belonged to our study model one ( which is our controls at 
the timings of 24hrs, 72hrs and 96 hrs); and one flask depicting the conditions as shown 
by the remaining four study models each. A final volume of 7ml is being standardized 
throughout the seven flasks. The growth media is RPMI 1640 (Sigma-Aldridge, St. Louis, 










                            
 
 
FIGURE 12 A total of 7 models will be used; we can add 1 ml of cells ~ 1 x 105 cells 
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FIGURE 13 An illustration of the events occurring after 24 hours 
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DAY 05 96 hours 
 
 




FIGURE 15 An illustration of the events occurring on day 4, 96 hours 
Each of the initial flasks is seeded with an initial concentration of 1 x 105 
macrophage cells. Flasks containing 1 x 105 of young U937 cells were aliquot into 
standard 25cm2 Nunc cell culture flasks. As 3 standard timings were used in this set of 
experiments, 24 hours (optimum time for the action of LDL); 72 hours (optimum time for 
the Chlamydia pneumoniae to work) and 96 hours (time for which a mixture for both 
samples to react best in, difference lies in the order whereby the components are added. 
Due to the free floating nature of the U937 cells, a substance known as cell tak adhesive 
will be used to help convert the suspended macrophages to form a monolayer for ease of 
quantification and detection of the CP. Of the seven flasks, flask 4 and 6 were added with 
low density lipoprotein to reach a concentration of 100µg per ml of media. As the final 
amount of media in the flask is standardized at 7ml, approximately 700µg of low density 
lipoprotein was added to these two flasks respectively. Flask 5 and 7 were infected with 
an equal number of the bacteria, Chlamydia pneumoniae, as that of the amount of U937 
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The flasks were then incubated in a humidified incubator at 37oC in 5% CO2. On 
day 1, which is 24 hours, the Flask 1 and Flask 4 will be taken out from the incubator; the 
media is then harvested and divided into three portions, 500µl, 500µl and 6ml 
respectively. The first 500ul will be subjected to immunofluorescence staining to 
determine the presence of the bacteria, Chlamydia pneumoniae in our models. The 
second 500µl will be treated using oil red staining to determine the presence of the foam 
cells and the final 6 ml will be then subjected to RNA extraction as required for the 
differential display reverse transcription polymerase chain reaction experiments. 
Furthermore, Flask 6 (U937 cells with LDL added) will be infected with Chlamydia 
pneumoniae and was incubated in a humidified incubator at 37oC in 5% CO2; for another 
72 hours before harvesting (see Figure 13). On day 3, 72 hours, Flask 2 and Flask 5 will 
be subjected to the same treatment as that for Flask 1 and 4 respectively. Flask 7 (U937 
cells with Chlamydia pneumoniae added) will be added with low density lipoprotein and 
was incubated in a humidified incubator at 37oC in 5% CO2; for another 24 hours before 
harvesting (see Figure 14). Finally, on day 4, 96 hours, the remaining 3 flasks (Flask 3, 6 
and 7) will be subjected to the same treatment as for the rest of the flasks (see Figure 15). 
 
3.6 Oil Red Detection of Foam Cells 
The cellular neutral lipid accumulation in macrophages can be visualized by using 
Oil Red O (Fisher Biotech BP112-10). A stock solution of Oil Red-O (Fisher Biotech 
BP112-10) is prepared as 0.5g in 100ml of isopropanol. From the stock solution, 60 ml of 
the stock solution is added to 40 ml of water (or that ratio), the precipitate is then 
removed by filtering through the Whatman paper #40.  
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This constitutes our working solution. The cells are then washed once with 
phosphate buffered saline, this is then followed by a fixation step in which the cells are 
treated with 3.7% Formaldehyde for 2 minutes. The fixed cells are then washed once with 
water. Next, the Oil Red-O working solution is added to the fixed cells and is incubated 
for an hour at room temperature. At the end of the incubation, the Oil Red-O working 
solution is aspirated away and then the stained cells are washed with water; and stored in 
water that has been pre-added with 0.02% Sodium Azide. The stained cells are then 
examined at x200 magnification scale on an inverted microscope. Microscopic pictures of 
the stained cells are then taken before all morphological detail is lost. The lipids will be 
stained red in colour in the macrophages.  
 
3.7 Immunofluorescence Staining and Detection of Chlamydia pneumoniae 
The culture are grown as the timing as depicted and stated in the five study 
models respectively. A square petric dish tray is lined with a moist sponge, which is all 
wrapped up in aluminium foil. The medium is poured off into a beaker and the pre coated 
with Cell-Tak cover slip, will cause the cells to be stuck on the cover slip will be placed 
in a vial with methanol. This step is to fix the cells. The cover slip is left to stand for ten 
minutes at room temperature, after which the methanol is poured away. The cover slip is 
then rinsed twice with PBS (NUMI, NUS, Singapore) to prevent the cells from drying out 
during this step. The cover slip culture is then transferred onto a labeled glass slide with 
cells facing upwards. Excess PBS (NUMI, NUS, Singapore) is wiped away on slides, 
without drying out the cells. 30µl of the IF reagent is dropped onto cells, and the IF 
reagent is spread outwards using a wire loop.  
Materials and Methods 
 
53 
The cover slip is then incubated for 15 minutes at 36° C in the dark. After the 
incubation time is up, the cells washed in PBS (NUMI, NUS, Singapore) and then air dry 
in the dark at room temperature.  A small drop of mounting medium onto a slide and the 
cover slip with cell surface facing downwards is placed onto the mounting medium. 
Finally, the cover slip is viewed under ultra violet light for the presence of inclusion 
bodies using 20 x (200 magnification) and the amount of inclusion bodies present is the 
total amount counted for 10 fields. However, do note that a 40 x magnification is used for 
confirmation of inclusion bodies. This procedure is repeatedly done for all the five study 
models, at the various timings. 
 
3.8 RNA Extraction and Quantification 
Total RNAs from cells at the various post infection time-points for each of the 
five study models were extracted using the SV Total RNA Extraction kit (Promega Corp, 
WI, USA).  All the reagents used in the following protocol are found in the kit.  The 
U937 human macrophage cells were harvested and 1.0 X 105 to 1 X 106 cells were 
collected in a sterile 1.5ml eppendorf tube and 175µl of SV RNA Lysis Buffer was added 
to the washed and pelleted cells and minimized by pipetting.  The resultant mixture was 
passed through a 20’ gauge needle and a 1ml syringe for 5 times to facilitate the lysis as 
well as to shear genomic DNA.  350µl of SV RNA Dilution Buffer was then added and 
mixed by inverting the tube for 5 times.  This was then placed in a heating block at 70oC 
for 3 min, after which the mixture was centrifuged at 14,000g for 10 min at room 
temperature. The cleared lysate solution was then transferred to a fresh eppendorf tube 
and 200µl of 95% ethanol to the cleared lysate and mixed by pipetting 4 times.   
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This was then transferred to the Spin Column Assembly and centrifuged at 
14,000g for 1 min.  Next, the Spin Basket was removed from the Spin Column Assembly 
and the liquid from the Collection Tube was discarded.  The Spin Basket was then 
replaced and 600µl of SV RNA Wash Solution was added to the Spin Column Assembly 
to be centrifuged at 14,000g for 1 min.  The Collection Tube was emptied as before and 
DNase incubation was performed by adding 50µl of the DNase incubation mix (40µl 
Yellow Core Buffer, 5µl 0.09M MnCl2 and 5µl of DNase I enzyme) and left at room 
temperature for 15min.  Next, 200µl of SV DNase Stop Solution was added to the Spin 
Basket and centrifuged at 14,000g for 1 min.  Following that, 600µl of SV RNA Wash 
Solution was added and centrifuged at 14,000g for 1 min.  The Collection Tube was then 
emptied and 250µl of SV RNA Wash Solution was added and centrifuged at 14,000g for 
2 min.  After which, transfer the Spin Basket from the Collection Tube to the provided 
Elution Tube and add 50µl of Nuclease-Free Water to the membrane and centrifuge at 
14,000g for 1min.   
 
This was repeated again to maximize the elution from the membrane.  The Spin 
Basket was then discarded and the Elution Tube capped and the purified RNA stored at -
70oC. The amount of RNA present was quantified by doing a 100-fold dilution of total 
RNA and read in a spectrophotometer (Shimadzu-UVmini-1240, Shimadzu Corp, Tokyo, 
Japan) at wavelengths of 260nm and 280nm.  Pure RNA preparations will have a ratio of 
OD260/OD280 equal to 2.0.  An adsorption of 1 OD at 260nm is equivalent to 40µg/ml of 
RNA. 
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3.9 Differential Display Reverse Transcription Polymerase Chain Reaction 
Reverse transcriptase PCR has also indicated that the organisms are viable in 
atherosclerotic plaques of the carotid artery (Esposito G., et al., 1999). In my study, 
techniques such as Differential Display Reverse Transcription Polymerase Chain 
Reaction (DDRT-PCR) technique, (Liang, P., et al., 1995; Zhu, H., et al, 1997; Leong, 
W.F., et al, 2002; Liew, J.L. and Chow T.K., 2004) were adopted as a means to study the 
transcriptomics of the Chlamydia pneumoniae and its interaction with human 
macrophages in the presence of low density lipoprotein differential display RT PCR was 
then used as a means of methods of obtaining valuable information regarding the various 
genes in play with the infection state as depicted in our choice of the fourth and fifth 
model. Furthermore, I have also incorporated the usage of real time PCR to validate the 
results that were obtained from the initial Differential Display RT-PCR experiments done. 
An effective method for analysis of gene expression is through differential display. An 
analysis of changes in gene expression in Chlamydia pneumoniae infected macrophages 
would be helpful to understanding the molecular nature of mitogenic signals. The 
RNAimage kit (GenHunter Corp, TN, USA) was used for the differential display RT-
PCR experiments.  All the reagents were provided by the manufacturer.  First strand 
cDNA synthesis was performed with each of the 3 poly (T) anchored primers (Table 1).  
For each of the three distinct anchored primers, a total of 19µl of reaction was made 
comprising of 4µl of 5X RT buffer, 1.6µl of dNTP (250µM), 2µl of anchored primer 
(2µM), total RNA of 200ng and topped up with RNase-free water.   
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A thermocycler (GeneAmp 9700, Perkin-Elmer, Cambridge, UK) was then 
programmed to 65oC for 5min, 37oC for 70min, 75oC for 5min and then held at 4oC.  
After the tubes have been at 37oC for 10min, the reaction was paused and 1µl of MMLV 
reverse transcriptase was added to each tube and mixed by gentle tapping before 
returning to the thermocycler. 




Table 1 List of anchored primers for differential display RT PCR. 
  
Next, PCR was performed by pairing each of the 3 different anchored first-strand 
cDNAs with their respective anchored primer and each of 8 distinct random primers 
(Table 2) in the presence of Redivue 33P-dATP (Amersham Pharmacia Biotech, Little 
Chalfont, UK).  In essence, this would generate a total of 24 (3 anchored primers paired 
with 8 random primers) sets of radio-labeled PCR products for further analysis.  A 20µl 
reaction consists of 10µl of ddH20, 2µl of 10X PCR buffer (Promega Corp, WI, USA), 
1.6µl of dNTP (25µM), 2µl of a random primer (2µM), 2µl of anchored primer (2µM), 
2µl of first-strand cDNA (with the same anchored primer), 0.2µl of radio-labeled dATP 
and 0.2µl of Taq DNA polymerase (Promega Corp, WI, USA). The mixture was then 
mixed by gentle pipetting and put into a thermocycler (GeneAmp 9700, Perkin-Elmer, 
Cambridge, UK) programmed at 94oC for 1min; 40 cycles of 94oC for 30sec, 40oC for 
2min, 72oC for 30sec; and then followed by 72oC for 5min and subsequently held at 4oC. 
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Table 2 List of random primers for Differential Display RT PCR. 
 
 A 6% denaturing polyacrylamide gel in TBE buffer (Appendix 1) was cast 
overnight to ensure that it had solidified before use.  The gel was pre-run for 30min 
before use and the urea in the wells flushed out before loading the samples.  3.5µl of each 
sample was mixed with 2µl of stop solution (Appendix 1) and incubated at 80oC for 2min 
and immediately snap-cooled in ice before loading.  The electrophoresis was performed 
at constant power of 60 watts for about 3.5 hours.  The gel was then transferred onto a 
Whatman filter paper, covered with clear film (Saran) wrap and dried for 20min at 80oC 
in a gel dryer (Biorad Gel Dryer 583, Bio-Rad, Hercules, CA, USA). The gel was then 
placed in a film cassette in contact with a Fuji medical X-ray film.  Masking tape was 
used to make the contact secure and cuts along the edges were made for orientation 
purposes.  After 2 days exposure at 4oC, the film was developed using a M35 X-OMAT 
Kodak Developer (Eastman Kodak Co, NY, USA).   
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The autorad was then inspected for differentially expressed genes by looking at 
the corresponding rows that were run. The autoradiogram was then orientated onto the 
dried gel and bands of interest were located by punching through the film with a needle at 
the 4 corners of each band.  Typically, at least 2 bands representing the same gene were 
cut out with a clean Swann-Morton surgical blade and the excised gel slices together with 
the Whatman paper were deposited into a sterile 1.5ml eppendorf tube.  30µl of ddH2O 
was added into the tubes and left at room temperature for 10min and then the cap was 
sealed with parafilm M (American National Can, IL, USA) before boiling at 95oC for 
15min.  The tubes were centrifuged at maximum speed for 2min to collect condensation 
and pellet the gel and paper debris.  The resultant supernatant was then transferred into a 
new 1.5ml eppendorf tube and kept at -20oC.  
 
Re-amplification of the eluted PCR products from the sequencing gel was then 
performed in a 40µl reaction that consists of: 20.4µl of ddH2O, 4µl of 10X PCR buffer 
(Promega Corp, WI, USA), 3.2µl of dNTP (250µM), 4µl each of the corresponding 2µM 
random and anchored primers, 4µl of eluted PCR product and 0.4µl of Taq DNA 
polymerase (Promega Corp, WI, USA).  The thermocycler (GeneAmp 9700, Perkin-
Elmer, Cambridge, UK) was programmed at 94oC for 1min; 40 cycles of 94oC for 30sec, 
40oC for 2min, 72oC for 30sec; and then followed by 72oC for 5min and subsequently 
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3.10 Agarose Gel Electrophoresis  
PCR products were electrophoresed in a 1.6% agarose gel containing Ethidium 
Bromide (Appendix 1) for the visualization of DNA bands. 10µl of the initial PCR 
products or 0.1µg/µl of DNA ladder (100bp or 1kb+ ladders, Invitrogen Corp, CA, USA) 
were mixed with 1µl of 10X gel loading buffer (Appendix 1) before loading into the 
wells.  The gel was run at 160V for 2 hours or until the bromophenol blue dye front has 
reached about 1.5cm from the end of the gel.  The gel was then washed and cooled with 
ddH2O before being viewed over a UV transilluminator and the digitized images captured 
by a Kodak DC290 digital camera (Eastman Kodak Co, NY, USA). 
 
3.11 Elution of PCR Products from Agarose Gels  
Targeted and selected DNA bands in the gel were excised using Swann-Morton 
carbon steel sterile surgical blades.  The blades and the transilluminator were cleaned and 
disinfected with 70% ethanol before use.  For every band that is to be cut out, a new 
blade or at least a newly cleaned, with 70% ethanol, blade must be used.  This is to 
prevent cross-contamination of the desired selected PCR products.  The excised gel slice 
was then transferred into a 2.0ml Spin-X (Corning-Costar, NY, USA) centrifuge tube 
filter and 30µl of 1X TE buffer (Appendix 1) was added before letting it stand for 5 
minutes at 55oC before centrifugation at 14,000rpm for 10 min (Beckman Microfuge E, 
Beckman Coulter Inc, CA, USA).  After which, the internal filter tube was discarded and 
the eluted DNA kept at 4oC until further use. 
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3.12 Purification of Optimized PCR Products 
The QIAquick Gel Extraction kit (Qiagen GmbH, Hilden, Germany) was used 
and all the reagents used were provided by the manufacturer.  DNA fragments between 
70bp to 10kb can be purified from cut out gel slices using this kit.  As per previously 
described method, DNA in the agarose gel was excised using Swann-Morton carbon steel 
sterile surgical blades.  The blades and the transilluminator were first cleaned with 70% 
ethanol before use.  A new blade or a newly wiped blade must be used for every band 
that is to be excised.  The excised gel pieces were then weighed and 3 volumes of Buffer 
QG was added to 1 volume of gel slice (100mg ~ 100µl). The mixture was then incubated 
at 55oC for 10 minutes or until the gel pieces were completely dissolved.  The color of the 
mixture must remain yellow (pH ≤ 7.5).  If the color changed to violet (higher pH), 10µl 
of 3M NaOAc, pH 5.0 must be added to equilibrate the pH back to 7.5 or lower.  Next, 1 
volume of isopropanol was added to the sample and mixed.  The mixture was transferred 
to the QIAquick column and placed in a 2ml collection tube that comes with the kit.  The 
resultant assembly was then centrifuged at 14,000rpm for 1 minute (Beckman Microfuge 
E, Beckman Coulter Inc, CA, USA).  The flow-through was discarded and the QIAquick 
column placed back in the same collection tube.  An additional 500µl of Buffer QG was 
added to the QIAquick column and centrifuged at 14,000rpm for 1 minute to ensure the 
removal of all traces of agarose. The flow-through is again discarded and the QIAquick 
column placed back into the collection tube.  Next, 750µl of Buffer PE was added to the 
QIAquick column to wash the DNA and the mixture allowed standing for 5 minutes 
before centrifugation at 14,000rpm for 1 minute.   
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The flow-through was discarded and the QIAquick column placed back into the 
same collection tube to be centrifuged at 14,000rpm for another 1 minute.  The residual 
flow-through was discarded and the QIAquick column placed into a clean 1.5ml 
eppendorf tube.  30µl of Buffer EB was then added to the centre of the membrane of the 
column and allowed to stand for 2 minutes.  Finally, DNA is eluted by centrifuging the 
above setup for 1 minute at 14,000rpm.  The flow-through contains the eluted DNA and 
it is stored at -20oC. 
 
3.13 Automated Cycle sequencing 
Automated Cycle sequencing is used as less starting template is required at the 
start of the reaction due to linear amplification of the reaction.  The advantages of 
automated cycle sequencing as compared to the manual method are that it is less 
hazardous and furthermore does not generate any radioactive waste. Furthermore, the 
results obtained are more accurate and reliable. The ABI prism Big Dye Terminator 
Cycle Sequencing Ready Reaction kit version 3.0 (Perkin-Elmer, Cambridge, UK) was 
used. 8µl of the terminator ready reaction mix (Appendix) , 30-90ng of purified PCR 
product and 3.2µl of primer (1pmol) were added and ddH2O was topped up to a final 
volume of 20µl.  The mixture was then mixed and centrifuge.  The GeneAmp 9700 
thermocycler (Perkin-Elmer, Cambridge, UK) was set to 30 cycles of 96oC for 10s, 
annealing temperature of primer for 5s and extension at 60oC for 4 minutes.  For difficult 
templates, the denaturing step can be lengthened by 10 seconds. After the reaction, the 
mixture was transferred into a 0.6ml eppendorf tube.  Into each tube, 3µl of 3M NaOAc, 
pH 4.6 was added together with 62.5µl of 95% ethanol and 14.5µl of ddH2O.  
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The tube was then vortexed briefly and left at room temperature for 15 minutes to 
precipitate the extension products.  After incubation, the mixture was centrifuged at 
14,000rpm for 20 minutes.  The supernatant was then removed and the pellet washed 
with 250µl of 70% ethanol and mixed briefly.  This was followed by centrifugation at 
14,000rpm for 10 minutes.  The supernatant was discarded and the pellet dried over a 
heat block at 55oC.  After drying, the sample in the eppendorf tube was sent to NUMI, 
NUS for automated sequencing. Both the sequencing chromatogram and the sequence 
data files are subsequently obtained from NUMI. Both the homology searches and 
identification of the genes of interest were done by utilizing the NCBI-BLAST website 
(http://www.ncbi.nlm.nih.gov/BLAST/). 
 
3.14 Reverse Transcription (cDNA conversion) 
Total RNA (5µg) was mixed with 0.3µg of random hexamer oligonucleotides 
(Invitrogen Corp, CA, USA) or with the anchored primers as per differential display 
protocol and incubated at 70oC and quickly chilled on ice.  The contents were collected 
by brief centrifugation and the following were added: 4µl of 5X First strand Buffer, 2µl 
of 0.1M dithiothreitol, 1µl of 10mM dNTP mix, 1µl of Superscript II (Invitrogen Corp, 
CA, USA) and topped up to 20µl with RNase-free water.  The reaction was then 
incubated at 42oC for 60 minutes and heat inactivated at 70oC for 5 minutes.  The 




Materials and Methods 
 
63 
3.15 Semi quantitative Conventional RT-PCR 
Reverse transcription of the pooled total RNAs via anchored primers were 
performed as described previously.  Gene target fragments of interest were then amplified 
by RT_PCR using individual pairs of gene-specific primers (Table 3) via thermal cycling 
at 94oC for 1 minute followed by 25 to 35 cycles of 94oC for 30 seconds, 55oC for 15 
seconds and 72oC for 30 seconds at the exponential phase of amplification that was 
empirically determined for each case. 
 
Gene Primer Sequence (5’-3’) 
G3DPH G3DPHF ACCACAGTCCATGCCATCAC 
G3DPH G3DPHR TCCACCACCCTGTTGCTGTA 
CDC27 CDC27F ATGACAGATGCGGATGACACAC 
CDC27 CDC27R CAGTCAGGGTCCAATGAAAGTG 
ε-TUBULIN ETUF AACACAGTCTTTACCTCGCCTG 
ε-TUBULIN ETUR GTCTTCCAGCCTTCTTGATTCC 
PPP2R2A PPPF AACCCACTTCCTGCTTAGTTGAG 
PPP2R2A PPPR GAACACCACAGTGATGAATCCAC 
EIF3S10 TIF3F GACGATAGGGATAGGGATGACC 
EIF3S10 TIF3R TCATCTTTCCTGTCATCAGCAC 
IF2 IF2F TCAGGGTGTTGAAGTGCCATC 
IF2 IF2R TTCTGGTTCAACAGGAGGTGG 
α-NAC NACF TTCGGCAGGTTACAGGAGTTAC 
α-NAC NACR TGCTTGCTGGGATAAATCTTCG 
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Gene Primer Sequence (5’-3’) 
EGR1 EGR1F GATGAACGCAAGAGGCATACC 
EGR1 EGR1R GGACGGGTAAGAGGTAGCAAC 
ELP2 EP2F CCACTGATGACTGTATTGAGCAC 
ELP2 EP2R CTTTCCACACTCCAATCCTACTG 
IKCYTO IKCYTOF  GCAGCTGGGAGATTTCTTTG 
IKCYTO IKCYTOR  ATACTGGAATGCAGCCTTGG 
NUC2 NUC2F  GACAGATGCGGATGACACAC 
NUC2 NUC2R  TTGCACTGCCTTTCATTCTG 
GDBR1 GDBR1F  ACCCCGACAGTCCTCTCTTT 
GDBR1 GDBR1R  AGTGGAACAACGCCACCTAC  
BCL2A1 
 
BCL2A1F  GGCTGGCTCAGGACTATCTG  
BCL2AI BCL2AIR  CCCAGTTAATGATGCCGTCT  
CAMP CAMPF  CAACCAAGGCGGCTACTAAG  
CAMP CAMPR  CTGGGCAAGAGTGAGACTCC  
RPL27A RPL27AF  TACCACCCAGGCTACTTTGG  
RPL27A RPL27AR  AATTTGGCCTTCACGATGAC  
CDC2 CDC2F  TGCAGTCATGAGTCGAGGTC  
CDC2 CDC2R  GTTCCAGGATCGGTTTCTCA  
COX2 COX2F  GGCCACCAATGGTACTGAAC  
COX2 COX2R  CGGGAATTGCATCTGTTTTT  
TUBE1 TUBE1F  AGTCGGTGGTCGTACAGGTC  
TUBE1 TUBE1R  CACCATCACCAACCACTCTG  
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Gene Primer Sequence (5’-3’) 
FLOT1 FLOT1F  CCAGCCTGAACCATGTTTTT  
FLOT1 FLOT1R  CCATGGCGAGTGTAAACCTT  
IRS2 IRS2F  GCATTCCAGCCCCTATGTTA  
IRS2 IRS2R  AGTGTCGAGGGAGCAGAAAA  
ATP6VOE VOF  TGCCTTGGTTCATCCCTAAG  
ATP6VOE VOR  CTTCTTCCTCAAGGCCAATG 
EEF1A1 EEF1A1F  AAGCTCTTCCTGGGGACAAT  
EEF1A1 EEF1A1R  CGTGTGGCAATCCAATACAG  
HSPC150 HSPC150F  TCCCAGGCAGCTCTTAGTGT  
HSPC150 HSPC150R   GCAGGTCATCCATTTGGTCT 
HCA58 HCA58F  GTCAGGCTGGTCTCGAACTC  
HCA58 HCA58R  GGTGGCTCACGGACTGTAAT  
BLAME BLAMEF  TCGATTGTTCCCAGATCCTC  
BLAME BLAMER  GAGGCCAGTTTTGCATGATT  
RPC62 6C67F  TGTGTGTCCTCGTCCAACAT  
RPC62 6C67R  CCATCCTCCATGGTCTCTGT  
ACTG1     ACTG1F      TCTGTGGCTTGGTGAGTCTG  
ACTG1 ACTG1R  AGTAACAGCCCACGGTGTTC  
C1QBP     C1QBPF      TCCAGAGGATGAGGTTGGAC  
C1QBP C1QBPR  TCGGCAAGGAAATCCATTAG  
CGGBP CGGBPF  TCTGTTGGTCAATGCTGCTC  
CGGBP CGGBPR  AGCAAGGGAATAAGGGAGGA  
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Gene Primer Sequence (5’-3’) 
STATIP1 STATIP1F  GTGCTCTATGACCCCCTGAA  
STATIP1 STATIP1R   CACCGCATAAACAGGTCCTT  
TPM1 TPM1F  GCTGGTTGAGGAAGAGTTGG  
TPM1 TPM1R   GCTTTGCCTCTTTCAGTTGG  
CTSH CTSHF  ACGGAGGAGTACCACCACAG  
CTSH CTSHR   GCAATTCTGAGGCTCTGACC  
GPR6 GPR6F  GCCAGAAACTTCGCTTTCAG  
GPR6 GPR6R   GCGGACTTCTGAGTTTTTGC  
CDC42 CDC42F  CAGCACGATGTCTTTGGAGA  
CDC42 CDC42R   GAGGGAGATGGCATTTTTGA  
K = G, T; R = A/G; W = A/T; Y = C/T 
Table 3.  List of primers used in semi quantitative and real-time RT-PCRs. 
 The target bands were visualized and the captured densitometric scan was 
performed using the GS-700 Imaging Densitometer and the Quantity One software (Bio-
Rad, Hercules, CA, USA). 
 
3.16 Real-time RT-PCR 
The cDNAs from the semi quantitative RT-PCR experiments were used 
(100ng/reaction).  The selected genes and primer pairs from the semi quantitative PCR 
experiments were used with the LightCycler-FastStart DNA Master SYBR Green I 
reaction mix (Roche Molecular Biochemicals, Mannheim, Germany) and the LightCycler 
system (Roche Molecular Biochemicals, Mannheim, Germany) was used to monitor the 
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SYBR Green signal at the end of each extension period.  Due to the sensitivity of the real 
time PCR experiments, to prevent carryover contamination which may disrupt and affect 
the authencity of the obtained results; aerosol-resistant tips were used in all steps. Real 
time polymerase chain reaction was performed in a 20µl reaction that consists of: 14.2µl 
of ddH2O, 2.4µl of MgCl2 (Roche Molecular Biochemicals, Mannheim, Germany), 0.7µl 
each of the corresponding pairs of primers, 1µl of the template and 1µl of SYBr enzyme 
(Roche Molecular Biochemicals, Mannheim, Germany). Preparation of the Real time 
PCR mixture was performed on a separate pre PCR workbench, which is situated away 
from the post PCR workbench. For each sample, the threshold cycle (CT) was analyzed 
for each gene of interest as well as for the G3DPH  housekeeping gene using the the 
LightCycler (Roche Molecular Biochemicals, Mannheim, Germany)  analysis software.  
The difference between their CT values (∆CT) was determined. For each gene of interest, 
normalization was performed against the control sample at the respective timings of 24, 
72 and 96 hours (Model 1 whereby U937 cells were present) as the reference, with its 
∆CT value subtracted from the ∆CT values of the other study models respectively at the 
timings, Model 2 at time 24 hours, Model 3 at time 72 hours and Model 4 and 5 at time 
96 hours, to find the ∆∆CT or D value for each sample. Finally, the 2-D value was 
calculated to obtain its relationship at each time point with respect to the reference 
sample to reflect the relative expression of each sample (Leong, P.W.F. et al, 2002). The 
t-test was then performed using Microsoft Excel XP software to ascertain the statistical 
significance of the differences between the normalized relative expression values for each 
gene at various time points. The P value obtained is less than 0.05 to be significant. The 
Light Cycler DNA Amplification Kit SYBR Green target fragments of interest were then 
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subjected to real time analysis amplified by RT_PCR using individual pairs of gene-
specific primers (Table 3) via thermal cycling at 94oC for 1 minute followed by 25 to 35 
cycles of 94oC for 30 seconds, 55oC for 15 seconds and 72oC for 30 seconds at the 
exponential phase of amplification that was empirically determined for each case. 
 
3.17 Flow Cytometry Analysis 
The percentage of foam cells were analyzed with an Epics Elite ESP flow 
cytometer (Beckman Coulter Inc, CA, USA) with at least 1.0 X 105 cells per sample.  The 
WINMDI 2.8 software (http://facs.scripps.edu/software.html) was then used to evaluate 
the amount of foam cells present and also can be used to calculate the percentage of 
infected and uninfected foam cells and the mean percentages and standard deviations 




The raw data of our experimental models are subjected to processing and analysis 
by using bioinformatical tools that are available on the websites. The cDNAs from the 
semi quantitative RT-PCR experiments were used (100ng/reaction).  The selected genes 
and the cDNAs from the semi quantitative RT-PCR experiments were used 
(100ng/reaction).  Throughout the entire project, extensive usage of the bioinformatics 
was adopted to allow me to elucidate the functions of the various genes obtained, and 
subjected to further analysis and grouping. 
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A lot of websites are available over the internet that can provide various 
bioinformatics tools, softwares, and to list them all down is impossible. Thus, some of the 
more commonly ones and of which are visited to and services provided by these websites 
that have been used in the computational analysis of the data obtained are listed in the 
table below: - 
 













http:// www.expasy.ch  
Genomics and Proteomics tools 
 
http:// bic.nus.edu.sg 












http:// www.ncbi.nih.gov /gorf/gorf.html 










BCM Search Launcher: 

















4.1 Detection of Chlamydia Pneumoniae in the Infected Cells in Study Models 3,  
4 and 5 and Detection of Foam Cells formation in Study Models 2, 4 and 5.  
Immunofluorescence studies were done on the five depicted models after the 
bacterial infection of the U937 macrophages with Chlamydia pneumoniae in the presence 
and absence of low density lipoprotein as shown in Figure 16 (i), (ii), (iii) and (iv). From 
the immunofluorescene staining, Chlamydia pneumoniae particles were found both 
within the infected cells (Figure 16) and indicating the presence of Chlamydia 
pneumoniae in the cells.  
Figure 16. Immuno fluorescence staining showing the presence of CP infection of 
the U937 macrophages.  
 
Figure 16 (i) This illustrated the appearance of the three control flasks (uninfected) 
harvested at timings 24, 72 and 96 hours and also that of the flask added with low 





Figure 16 (ii) This denotes the flask infected with Chlamydia pneumoniae only which 
is harvested at timing of 72 hours.  
 
Figure 16 (iii) This denotes the flask infected with Chlamydia pneumoniae for a 
period 72 hours, and then low density lipoprotein is added for another 24 hours 





Figure 16 (iv)This denotes the flask that was inoculated with low density lipoprotein 
for 24 hours before the flask containing both macrophages and low density 
lipoprotein was infected with Chlamydia pneumoniae and then allowed to grow for 
another 72 hours being the flask is harvested at timing of 96 hours. The green 
fluorescence indicates the presence of the Chlamydia pneumoniae. 
 
Oil Red O Staining which allows the identification of the foam cells was noted. 
Red coloration around the boundaries is a good indication of the uptake of the low 
density lipoproteins into the macrophages, resulting in the formation of foam cells 








Figure 17. Foam cell detection done on the five study models using Oil Red O.  
 
Figure 17 (i) This illustrated the appearance of the three control flasks (uninfected) 
harvested at timings 24, 72 and 96 hours and also that of the flask added with 
Chlamydia pneumoniae only and harvested at timing of 72 hours  
 
Figure 17 (ii) This denotes the flask inoculated with Chlamydia pneumoniae only 





Figure 17 (iii) This denotes the flask infected with Chlamydia pneumoniae for a 
period 72 hours, and then low density lipoprotein is added for another 24 hours 
being harvested at the timing of 96 hours.  
 
Figure 17 (iv) This denotes the flask that was inoculated with low density lipoprotein 
for 24 hours first, then followed by infection with Chlamydia pneumoniae for 
another 72 hours being the flask is being harvested at end timing of 96 hours. The 




4.2 DD RT PCR reveals Expression Responses of Multiple Known and Novel 
Genes in U937 cells infected with Chlamydia Pneumoniae and/or Low Density 
Lipoproteins.  
 
A total of 20 fields were used for each counting for the sample of cells obtained 
from the various flasks at the stipulated timings, and the infection ratio measured for 
Chlamydia pneumoniae against the human macrophages is one to one. mRNA expression 
profiles of the five study models at the various time points of 24, 72 and 96 hours 
following infection were analyzed via DD RT PCR with 24 combinations of primer pairs. 
Results of these duplicate experiments were reproducible and reliable. Among a total of 
235 differentially expressed ESTs selected and sequenced, 190 were matched to known 
genes whereas, 45 were not matched (unknown). All the sequences were subjected to a 
search of the GenBank database using the BLAST program, which is based on the results 
obtained and the functions of the genes, they were than further classified into groupings 
which best describes their putative roles in the infected cells. DD-RT PCR is a useful 
method for acquiring an unbiased sampling of the repertoire of expressed transcripts.  
The mechanisms of the pathological effects of Chlamydia pneumoniae infection are 
indeed very complex, and this “infectomics” survey offers some insight into the effects 
and interactions of Chlamydia pneumoniae replication with respect to the host cell, as 
well as the cellular response to infection. The results of the differential experiments being 





Table 5. The differential expression profiles for the 29 selected genes from the series 
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Note:-C24, C72 and C96 denote the control flask (macrophages alone) profiles 
harvested at time 24, 72 and 96 hours. LDL24 denotes the profile of cDNA from 
macrophages of that contains only macrophages added with low density lipoproteins and 
harvested at time 24 hours. CP72 denotes the profile of cDNA from macrophages of that 
contains only macrophages infected with Chlamydia pneumoniae alone and harvested at 
time 72 hours. UCL denotes the profile of cDNA from macrophages of that contains 
macrophages infected with Chlamydia Pneumoniae first for 72 hours then followed by 
addition of LDL for another 24 hours before harvesting at 96 hours. ULC denotes the 
profile of cDNA from macrophages of that contains macrophages added with LDL for 24 
hours first then followed by infection with Chlamydia Pneumoniae for another 72 hours 





Table 6. List of 29 Isolated ESTs Showing Significant Homology with 29 Human 
cDNAs in the Nonredundant Database.  
Clone  Approx. Accession Description of Best hit 
ID Size (bp) no.  
UBIQUITINATION   
CPLDL002 226 S78234 nuc2 homolog 
CPLDL065 184 NM_001256.2 Homo sapiens cell division cycle 27 (CDC27), 
CPLDL109 
217 NM_014176.1 
Homo sapiens HSPC150 protein similar to ubiquitin-conjugating 
enzyme (HSPC150),  
CPLDL202 171 NM_148979.1  Homo sapiens cathepsin H (CTSH), transcript variant 2 
    
CELL PROLIFERATION  
CPLDL007 127 NM_016172.1 Homo sapiens putative glialblastoma cell differentiation-related 
(GDBR1), mRNA 
CPLDL008 102 NM_004049.2 Homo sapiens BCL2-related protein A1 (BCL2A1), mRNA 
CPLDL025 241 NM_000990.2 Homo sapiens ribosomal protein L27a (RPL27A), mRNA 
CPLDL028 144 AF512554.1 Homo sapiens cell division cycle 2, G1 to S and G2 to M (CDC2) 
gene 
CPLDL054 154 AK026536.1 Homo sapiens cDNA: FLJ22883 fis, highly similar to 
MTHSCOXII , Homo sapiens mito coxII mRNA for cytoC oxidase 
II subunit 
CPLDL075 305 AY034001.1  Homo sapiens NAC alpha mRNA 
CPLDL076 149 XM_007095.6  Homo sapiens insulin receptor substrate 2 (IRS2) 
CPLDL123 
113 BC002586  
Homo sapiens, Similar to polymerase (RNA) III (DNA directed) 
(62kD) (RPC62) 
CPLDL179 295 NM_018255.1  Homo sapiens signal transducer and activator of transcription 3 
interacting protein 1 (STATIP1),  
CPLDL210 880 NM_006449.3  Homo sapiens CDC42 effector protein (Rho GTPase binding) 3 
    
IMMUNE RESPONSE   
CPLDL001 228 BC013005 Homo sapiens, Similar to IK cytokine, down-regulator of HLA II 
CPLDL094 147 
NM_003945.2 
Homo sapiens ATPase, H+ transporting, lysosomal 9kDa, V0 
subunit e 
CPLDL110 304 HS1121G12  Human DNA sequence from clone RP5-1121G12 on chromosome 
20 Contains the 3' end of a gene encoding the hepatocellular 




Homo sapiens B lymphocyte activator macrophage expressed 
(BLAME), 
CPLDL119 
214 NM_002717.1  
Homo sapiens protein phosphatase 2 (formerly 2A), regulatory 
subunit B   
CPLDL171 339G NM_001212.3 Homosapiens complement component 1,q subcomponent binding 
protein(C1QBP) 
,nuclear gene encodes mito protein 
CPLDL206 103 HSU18549 Human GPR6 G protein-coupled receptor gene 
    
COMPONENTS OF PROTEIN TRANSLATION AND MODIFICATION 
CPLDL108 327 
NM_001402.4  
Homo sapiens eukaryotic translation elongation factor 1 alpha 
1(EEF1A1),  
CPLDL136 144 NM_015904.2 Homo sapiens translation initiation factor IF2 (IF2), mRNA 
    
MISCELLANOUS OR UNKNOWN FUNCTIONS 
CPLDL016 151 NM_006628.2 Homo sapiens cyclic AMP phosphoprotein, 19 kD (ARPP-19), 
mRNA 






 Table 6 above shows the functional grouping of the selected 29 genes based on 
their putative functions based on the bioinformatical analysis using the various website 
materials and software available. The accession numbers of the 29 selected genes are 
shown. A brief description of the 29 selected genes are provided in the table, allow the 
classification of the genes into the various sub group to be authenticated.  
 
Table 7 below shows the average densitometer readings of 29 selected genes. The 
various flasks used in the experiments are denoted with identification labels to allow easy 
understanding of the table. M124, M172 and M196 denote the control flask readings that 
were harvested at times 24, 72 and 96 hours respectively. 
 
M224 denotes the readings of macrophages to which were added with low density 
lipoproteins and harvested at time 24 hours. M372 denotes the profile of cDNA from 
macrophages of that contains only macrophages infected with Chlamydia Pneumoniae 
alone and harvested at time 72 hours. 
 
M496 denotes the profile of cDNA from macrophages of that contains 
macrophages infected with Chlamydia Pneumoniae first for 72 hours then followed by 
addition of LDL for another 24 hours before harvesting at 96 hours. M596 denotes the 
profile of cDNA from macrophages of that contains macrophages added with LDL for 24 
hours first then followed by infection with Chlamydia Pneumoniae for another 72 hours 




Table 7. Tabulated results of densitometer readings of the 29 selected genes that 
were selected based on their unique expression profile being noted as shown in the 
gel photos in table 5 and the densitometer readings as shown in the table below. 
 
Gene Densitometer Readings 
 M124 M172 M196 M224 M372 M496 M596 
IKCYTO 10.524 157.762 80.000 65.667 86.19 189.381 204.048 
NUC2 103.429 214.952 122.143 243.429 154.143 222.81 136.81 
GDBR1 223.000 171.81 203.619 194.905 186.81 70.286 0.000 
BCL2A1 222.14 245.33 228.79 237.24 254.17 253.378 254.585 
CAMP 255.000 255.000 255.000 254.714 255.000 232.381 86.714 
RPL27A 214.182 221.364 130.000 211.091 233.364 201.455 210.182 
CDC2 255.000 126.524 254.958 255.000 254.723 254.972 235.667 
COX2 206.767 252.217 49.852 136.578 250.205 26.068 35.280 
CDC27 189.667 195.048 106.006 62.476 186.762 43.422 74.905 
TUBE1 55.857 34.286 32.857 56.857 32.571 28.286 30.000 
FLOT1 56.000 32.857 31.286 56.571 33.714 30.714 30.429 
α NAC 216.809 191.798 135.562 197.469 151.166 116.485 103.853 
IRS2 216.809 133.375 123.067 187.624 170.744 92.246 55.922 
ATP6VOE 6.762 6.889 47.35 195.429 88.563 50.472 22.175 
EEF1A1 130.909 37.364 185.818 39.727 16.545 18.636 18.545 
HSPC150 125.727 36.545 215.364 49.455 39.909 42.727 21.273 
HCA58 85.333 37.048 121.905 16.905 30.095 13.619 56.333 
BLAME 7.963 16.094 14.731 15.176 17.704 218.012 249.98 
PPP2R2A 21.529 95.176 81.824 9.412 68.294 25.412 107.471 
RPC62 142.58 153.656 75.285 68.841 140.105 151.059 135.336 
IF2 12.476 15.714 112.286 15.81 18.095 66.429 64.81 
ACTG1     212.93 108.635 161.329 213.042 147.872 65.294 120.247 
C1QBP     218.817 184.695 216.904 211.777 205.442 141.905 204.476 
CGGBP 210.372 199.448 216.612 218.795 206.806 154.601 183.423 
STATIP1 169.674 72.039 210.824 197.949 80.427 67.066 105.601 
TPM1 140.005 68.755 233.583 168.563 94.104 50.472 87.52 
CTSH 176.545 73.909 121.237 255.000 181.636 55.909 106.818 
GPR6 69.667 63.333 114.778 159.556 232.667 185.889 177.33 








Gene Primer sequences (5’ → 3’) Target  
 Sense Antisense Size (bp) 
G3DPH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 160 
IRS2 GCATTCCAGCCCCTATGTTA AGTGTCGAGGGAGCAGAAAA 216 
FLOT1 CCAGCCTGAACCATGTTTTT CCATGGCGAGTGTAAACCTT 191 
TUBE1 AGTCGGTGGTCGTACAGGTC CACCATCACCAACCACTCTG 162 
COX2 GGCCACCAATGGTACTGAAC CGGGAATTGCATCTGTTTTT 229 
CDC2 TGCAGTCATGAGTCGAGGTC GTTCCAGGATCGGTTTCTCA 240 
RPL27A TACCACCCAGGCTACTTTGG AATTTGGCCTTCACGATGAC 242 
CAMP CAACCAAGGCGGCTACTAAG CTGGGCAAGAGTGAGACTCC 188 
BCL2A1 GGCTGGCTCAGGACTATCTG CCCAGTTAATGATGCCGTCT 228 
GDBR1 ACCCCGACAGTCCTCTCTTT AGTGGAACAACGCCACCTAC 213 
NUC2 GACAGATGCGGATGACACAC TTGCACTGCCTTTCATTCTG 226 
IKCYTO GCAGCTGGGAGATTTCTTTG ATACTGGAATGCAGCCTTGG 220 
α-NAC TTCGGCAGGTTACAGGAGTTAC TGCTTGCTGGGATAAATCTTCG 151 
IF2 TCAGGGTGTTGAAGTGCCATC TTCTGGTTCAACAGGAGGTGG 195 
PPP2R2A AACCCACTTCCTGCTTAGTTGAG GAACACCACAGTGATGAATCCAC 163 
CDC27 ATGACAGATGCGGATGACACAC CAGTCAGGGTCCAATGAAAGTG 203 
CTSH ACGGAGGAGTACCACCACAG GCAATTCTGAGGCTCTGACC 165 
GPR6 GCCAGAAACTTCGCTTTCAG GCGGACTTCTGAGTTTTTGC 225 
TPM1 GCTGGTTGAGGAAGAGTTGG GCTTTGCCTCTTTCAGTTGG 179 
STATIP1 GTGCTCTATGACCCCCTGAA CACCGCATAAACAGGTCCTT 142 
CGGBP TCTGTTGGTCAATGCTGCTC AGCAAGGGAATAAGGGAGGA 171 
C1QBP TCCAGAGGATGAGGTTGGAC TCGGCAAGGAAATCCATTAG 171 
ACTG1 TCTGTGGCTTGGTGAGTCTG AGTAACAGCCCACGGTGTTC 210 
RPC62 TGTGTGTCCTCGTCCAACAT CCATCCTCCATGGTCTCTGT 247 
BLAME TCGATTGTTCCCAGATCCTC GAGGCCAGTTTTGCATGATT 229 
HCA58 GTCAGGCTGGTCTCGAACTC GGTGGCTCACGGACTGTAAT 228 
HSPC150 TCCCAGGCAGCTCTTAGTGT GCAGGTCATCCATTTGGTCT 163 
CDC42 CAGCACGATGTCTTTGGAGA GAGGGAGATGGCATTTTTGA 183 
EEF1A1 AAGCTCTTCCTGGGGACAAT CGTGTGGCAATCCAATACAG 211 
ATP6VOE TGCCTTGGTTCATCCCTAAG CTTCTTCCTCAAGGCCAATG 207 
 
Table 8. List of selected cellular genes, with respective gene specific primers 
designed, that shows differential expression profiles in response to Chlamydia 
pneumoniae infection in the presence of low density lipoproteins, that were used for 
were evaluated by semi quantitative and real time RT-PCR. G3DPH was used as 




4.3 Semi Quantitative and Real Time RT- PCR analyses within the five model 
study highlights the regulation of various groups of genes in Chlamydia Pneumoniae 
infected cells and/or low density lipoproteins. 
Semi quantitative and real-time RT–PCR analyses highlight the differential 
expression of selected bacterial and cellular genes in Chlamydia pneumoniae infected 
U937 cells. To confirm our DD RT–PCR observations on the gene expression trends with 
respect to time of infection, semi quantitative classical and real-time RT–PCR 
experiments were performed using gene-specific primers to investigate the expression 
profiles of genes of interest as depicted in Table 1. These genes were chosen based on 
their differential expression which may suggest a role of which the genes of interest may 
partake. The genes were checked for homology matches and hits with the NCBI website. 
Most of the genes analyzed by semi quantitative and real-time RT–PCR (Fig. 3) exhibited 
similar expression trends compared to those with DD RT–PCR (Fig. 2), with only a few 
genes showing slight disparities that could be attributed to the use of gene specific 
primers in the former versus random primers in the latter, coupled with different thermal 
cycling conditions. 
 
mRNA expression profiles of the five study models at the various time points of 
24, 72 and 96 hours following infection were analyzed via DD RT PCR. The initial 
results obtained via DDRT PCR (see Table 1) were verified by semi quantitative as well 
as by real time RT-PCR done using the gene specific primers designed for each of the 
selected genes (see Table2). The results obtained were compared within the five study 




levels of these genes seem to be varied. The genes generally are found to be involved or 
part of the biochemical pathways like ubiquitination, cell proliferation, immune response, 
components of the protein translation and modification and structural proteins. These 
groups of differentially genes seem to suggest the importance of the control exhibited by 
the bacterial pathogen, Chlamydia pneumoniae during the course of infection and/or with 
low density lipoproteins.  
 
The expression trends of the genes analyzed by DDRT PCR, semi quantitative as 
well as real time RT PCR experiments revealed similar parallel expression profiles and 
pattern within the five study models for each of the selected 29 genes. The confirmative 
studies and similar results obtained via the real time RT-PCR assay verified the 
expression levels and profiles. Duplicate real time RT PCR experiments were performed, 
and the means of the relative expression values of the five study models were shown in 
Figure 5. The low variance of the expression data, p values of <0.05 were obtained and 
these values were considered statistically significant. The small differences between the 
mean expression values between the five study models were significant as these P-values 









Table 9. Tabulated results of real time CT values of the 29 selected genes subjected 
to the T test. 
Gene M2a P value M3b P value M4c P value M5c P value 
IRS2 1.59 0.025 1.63 0.005 -4.155 0.024 -2.990 0.004 
FLOT1 -1.22 0.034 -1.78 0.007 1.434 0.007 1.474 0.006 
TUBE1 -1.20 0.026 -1.69 0.014 1.366 0.026 1.390 0.003 
COX2 1.14 0.033 3.10 0.018 -6.255 0.001 -5.169 0.007 
CDC2 1.17 0.014 2.58 0.005 1.270 0.005 1.235 0.032 
RPL27A -17.57 0.0008 33.48 0.007 -1.490 0.011 1.266 0.040 
CAMP 2.08 0.007 -23.26 0.0008 -9.000 0.004 1.206 0.0007 
BCL2A1 -1.23 0.040 1.16 0.015 23.507 0.0002 26.723 0.0003 
GDBR1 2.73 0.001 -4.07 0.009 -12.168 0.008 -15.780 0.008 
NUC2 1.22 0.039 -4.01 0.001 -1.526 0.029 1.630 0.029 
IKCYTO 1.60 0.003 -16.68 0.001 3.053 0.037 2.742 0.020 
α-NAC 1.49 0.006 1.74 0.036 -1.564 0.037 -1.886 0.022 
IF2 -1.87 0.014 -1.51 0.002 -1.717 0.003 -2.235 0.002 
PPP2R2A -7.43 0.008 -2.55 0.013 -2.540 0.028 2.888 0.014 
CDC27 -4.11 0.005 1.21 0.047 -1.16 0.029 1.028 0.030 
CTSH 4.45 0.005 1.22 0.033 -4.272 0.002 -1.310 0.039 
GPR6 1.58 0.017 1.97 0.032 1.986 0.038 1.741 0.040 
TPM1 5.37 0.004 1.16 0.0100 1.169 0.044 1.500 0.041 
STATIP1 -1.46 0.018 7.21 0.0006 -5.502 0.0002 -6.386 0.008 
CGGBP 1.53 0.026 -1.21 0.0006 2.136 0.018 2.346 0.033 
C1QBP 1.43 0.035 1.82 0.006 -1.202 0.094 1.361 0.032 
ACTG1 6.36 0.042 6.08 0.0164 -10.267 0.005 -2.938 0.019 
RPC62 -2.43 0.002 1.41 0.019 1.986 0.012 1.765 0.028 
BLAME -71.75 0.003 -139 0.0007 14.774 0.002 16.167 0.0003 
HCA58 -1.70 0.002 1.31 0.016 -1.357 0.020 -7486 0.0007 
HSPC150 1.17 0.010 -12.25 0.006 -12.424 0.006 -23.103 0.008 
CDC42 1.39 0.019 1.29 0.014 1.847 0.006 1.449 0.003 
EEF1A1 -1.68 0.010 -2.49 0.012 -2.969 0.004 -1.873 0.006 
ATP6VOE 1.30 0.004 2.42 0.002 -2.558 0.012 -2.540 0.017 
a Values obtained are normalized to the controls at 24 hours model 1. 
b Values obtained are normalized to the controls at 72 hours model 1. 
c Values obtained are normalized to the controls at 96 hours model 1. 
 
The results are depicted as an average of two sets of real time PCR results shown, 
calculated with the t test which is statistically proven. M124- study model 1, M172- study 
model 1, M196- study model 1, M2- study model 2 LDL with macrophages for 24 hours, 
M3- study model 3 Macrophages infected with C.P. for 72 hours, M4- study model 4 
Macrophages added with LDL for 24 hours then followed by infection with C.P. for a 
further 72 hours, M5- study model 5 Macrophages infected with C.P. for 72 hours then 




4.4 Detailed information of the 29 genes that had been selected for analysis. 
The selected 29 genes were then subjected to bioinformatical analysis and the 
possible identities and hits to the various gene sequences obtained from the previous DD 
RT-PCR experiments. The functions of the 29 selected genes are elaborated as below. 
 
4.4.1 Similar to IK cytokine, down-regulator of HLA II, Homo sapiens. 
HLA class II molecules play a central role in regulating host immune responses 
against microbial infections because they present foreign antigens to CD4+ T 
lymphocytes. In monocytes, instead, a high basal class II expression was found and it was 
further induced by IFN-  (up to twofold) and especially by IFN-  (up to fivefold). In 
granulocyte-macrophage colony-stimulating factor (GM-CSF) differentiated human 
macrophages, basal HLA class II protein expression levels were high but IFN-  
stimulation was able to further enhance their expression. Accordingly, class I and II 
mRNA expression was elevated by IFN- , whereas IFN-  practically had no effect on 
HLA class I mRNA levels. The function of this compound is yet to be elucidated and it is 
reported to be in the nucleus whereby it could bind to chromatin. IK cytokine is reported 
to be ubiquitous, in terms of tissue specificity. These results suggest that IK cytokines are 
important regulators of HLA genes and responsible for the down regulation of HLA 
antigen expression during Chlamydia pneumoniae bacterial infection. 
 
4.4.2 Nuc2 homolog 
Nuc is a nuclear protein with DNA binding activity; and furthermore this protein 




SV40 large T antigen binds. The yeast nuc2+ gene encodes a highly conserved protein of 
a tetratricopeptide repeat (TPR) family. nuc2 is a novel cell cycle regulator essential for 
three events; firstly for exit from the mitotic metaphase, secondly for DNA replication 
restraint under nutrient starvation and thirdly for inhibition of septation and cytokinesis 
until the completion of mitosis. This proposed theory is supported as firstly, the nuc2 
mutant is sterile even at the permissive temperature and septation occurs in the absence of 
chromosome separation at the restrictive temperature. Furthermore, the nuc2 mutant fails 
to arrest at the G1 phase upon nitrogen starvation at the permissive temperature which is a 
prerequisite for conjugation. Upon starvation, however, the nuc2 mutant ceased division 
normally and induced starvation-dependent gene expression. Therefore, the nuc2 mutant 
is deficient only for failure to block DNA replication upon starvation. At the lower 
restrictive temperature, the nuc2 mutant showed a 'cut' phenotype where septation and 
cytokinesis takes place without the completion of mitosis. Ectopic over expression of the 
nuc2+ gene caused multiple rounds of S and M phases in the complete absence of septum 
formation. 
 
4.4.3 Glialblastoma Cell Differentiation Factor-Related Gene mRNA GDBR1 
Glialblastoma Cell Differentiation Factor-Related Gene, GBDR1, is an 
intracellular signaling molecule that may play a role in the regulation of endothelial cell 
growth. Phosphorylation assays which were done in vitro determined that GBDR1 is a 
substrate for CK2. 2 CK2 phosphorylation sites are situated normally near a putative 




Immunofluorescence and biochemical data revealed that the GBDR1 protein is 
not entirely localized in the cytosolic fraction, suggesting that it may interact with another 
protein(s). Vascular endothelial cells (VEC) transduce mitogenic and chemo attractant 
signals in response to erythropoietin (Epo). GBDR1 was ubiquitously expressed in 
human tissues by northern blot analysis. In Southern blot analysis, GBDR1 cDNA 
identified a single gene on chromosome 9. Since analysis of the amino acid sequence 
revealed several putative phosphorylation sites for different protein kinases, the GBDR1 
protein was expressed and purified from bacterial extracts and, as predicted, casein kinase 
II phosphorylated GBDR1 in vitro.  
 
4.4.4 Homo sapiens, BCL2-related protein A1 (BCL2A1), mRNA 
Programmed cell death, in this case referring to apoptosis, plays an important role 
in embryonic development, deletion of auto reactive T lymphocytes, and homeostasis. 
Apoptosis is defined as a form of programmed cell death induced by external or internal 
signals that trigger the activity of proteolytic caspases, which result in cell death. 
Apoptosis begins internally with condensation and subsequent fragmentation of the cell 
nucleus (blebbing) while the plasma membrane remains intact. Other characteristics of 
apoptosis include DNA fragmentation and the exposition of phosphatidylserine. Genes 
regulating apoptosis include p53, a tumor suppressor gene, MYC, a proto-oncogene, and 
BCL2. BCL2 is an integral inner mitochondrial membrane protein, and is unique among 
proto-oncogene as it is being localized in mitochondria and interfering with programmed 
cell death independent of promoting cell division. Over expression of BCL2 blocks the 




The oncogenic potential of BCL2 has been proven by gene transfer studies (Reed 
J.C., et al., 1988). BCL2 acts by inhibiting cell loss by apoptosis (programmed cell death) 
rather than by stimulating cell production. The action of BCL2 in protecting cells from 
apoptosis is not by altering mitochondrial function as human mutant cell lines that lack 
mitochondrial DNA can still be induced to die by apoptosis. These human mutant cell 
lines can be protected from apoptosis by the over expression of BCL2 (Jacobson M. D., 
et al., 1993). BCL2 regulates a caspase activation program independently of the 
cytochrome c/APAF1/caspase-9 apoptosome; which means that the cell death pathway 
controlled by BCL2 does not require caspase-9 or its activator APAF1. This apoptosome 
seems to amplify rather than initiate the caspase cascade (Marsden V. S., et al., 2002). 
The function of BCL2 is that it retards apoptosis which is induced by IL-3 deprivation. It 
may function in the response of hemopoietic cells to external signals and in maintaining 
endothelial survival during infection. This protein is intracellular and restricted to the 
hematopoietic compartment. Studies done have shown that it can be expressed in 
peripheral blood, spleen, and bone marrow, at moderate levels in lung, small intestine and 
testis, at a minimal levels in other tissues. Furthermore, interestingly, it can also be found 
in vascular smooth muscle cells and hematopoietic malignancies. The A1 protein, a 
member of the BCL2 family of apoptosis regulators by the predicted protein sequence, 
although regulated differently from BCL2, has similar anti apoptotic activity (Lin E.Y., et 
al., 1993). The human homolog of this A1 protein is on chromosome 15. The human 
BCL2A1 gene is mapped to 15q24.3 by fluorescence in situ hybridization analysis (Choi 
S.S., et al., 1997). Development as well as maintenance of many adult tissues is achieved 




and programmed cell death. BCL2 is one such mammalian gene that has been identified; 
it functions as a repressor of programmed cell death.  
 
4.4.5 Homo sapiens, Cyclic AMP phosphoprotein, 19 kD (ARPP-19) mRNA 
Phosphoproteins may act as intracellular messengers in the central nervous system. 
Receptor-mediated phosphorylation and dephosphorylation of such proteins are important 
for the regulation of neuronal function. ARPP19 is a splice variant of ARPP16. 
Compared with ARPP16, ARPP19 has N-terminal and shares considerable homology, 
except in the N-terminal region, with 16 additional amino acids that encode for alpha-
endosulfine (Heron L., et al., 1998). The main functions of cyclic AMP phosphoprotein 
include intracellular signal transduction, as a transcription factor, and lastly involved in 
apoptosis. Cellular location is reported to be cytoplasmic, nuclear. Intracellular in 
cytoplasm and potassium channel regulator activity, coupled wit receptor binding. 
Involved in cell growth, maintenance and metabolism; positive regulation of 
gluconeogenesis.  
 
4.4.6 Homo sapiens, ribosomal protein L27a (RPL27A), mRNA 
The mammalian ribosome is a macromolecular assembly of 4 RNA species and 
approximately 80 different proteins. The ribosomal genes occur in 150 to 300 copies in 
the human genome. The human RPL27A gene is mapped to 11p15 from the results 
obtained by somatic cell hybrid and radiation hybrid mapping analyses.  RPL27A 
contributes to the structural integrity of the ribosome, as a structural constituent of 




4.4.7 Homo sapiens, cell division cycle 2, G1 to S and G2 to M (CDC2) 
CDC2, cell division cycle 2, G1 to S and G2 to M, is located in the human 
chromosomal location 10q21.1 (Nazarenko S., et al., 1991). CDC2 belongs to the 
SER/THR family of protein kinases, and the CDC2/CDKX subfamily. It plays a key role 
in the control of the eukaryotic cell cycle. It is required in higher cells for entry into S-
phase and mitosis. CDC2 is a catalytic subunit of a protein kinase complex, called the M-
phase promoting factor; that induces entry into mitosis and is universal among 
eukaryotes. P34 (CDC2) is a component of the kinase complex that phosphorylates the 
repetitive carboxyl-terminus of RNA polymerase II. The subunit forms a stable structural 
component but non-covalent complex with a regulatory subunit, B1 of the M phase 
promoting factor (MPF) and with cyclin A. CDC2 is found to be complexing with cyclin 
B1 (M phase promoting factor (MPF) component) and continually shuttling between the 
nucleus and cytoplasm, maintained in an inactive state by phosphorylation by WEE1 and 
MYT1, it is also required for fragmentation in mitosis through interaction with the 
cis-Golgi matrix protein GM130.Its sub cellular location is found to be nuclear. CDC2 is 
involved in a variety of functions namely, it is activated by CDC25 phosphatase and acts 
as an histone 1-kinase (H1K), and secondly, it is involved in cell cycle regulation (G1 to 
S and G2 to M transition). Furthermore, it is found to be phosphorylating JUNB and 
lowering its level in mitotic and early G1 cells and lastly it is a putative up regulated c-
Myc target gene. CDC2 protein regulation is as follows, it is activated by 
phosphorylation of tyrosine Y15 and threonine T14 by CDK7. Furthermore, it is inhibited 
through phosphorylation on Y15 by WEE1; and the phosphorylation of Y15 has a key 




It is maintained in an inactive state by phosphorylation of WEE1 and MYT1. The 
human homolog of the cdc2 gene was obtained by complementation of a yeast 
temperature-sensitive mutant deleted for cdc2 function; and it is found to contain an open 
reading frame of about 800 bp (Lee M. G. and Nurse P., 1987). The CDC2 homolog in 
human system seem to be regulated by phosphorylation of the CDC2 gene product, a 
protein kinase of molecular weight 34,000, designated p34(cdc2). Overexpression of 
ERBB2 inhibits Taxol-induced apoptosis and also transcriptionally up regulates 
CDKN1A, which associates with CDC2, inhibits Taxol-mediated CDC2 activation, 
delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis. Taxol 
activates CDC2 kinase in cancer cells, leading to cell cycle arrest at the G2/M phase and, 
subsequently, apoptosis. A chemical inhibitor of CDC2 and a dominant-negative mutant 
of CDC2 blocked Taxol-induced apoptosis in these cells (Yu, D., et al., 1998). Cdc2 is 
expressed in post mitotic granule neurons of the developing rat cerebellum and that Cdc2 
mediates apoptosis of cerebellar granule neurons upon the suppression of neuronal 
activity. Cdc2 catalyzes the phosphorylation of the Bcl2 antagonist of cell death protein, 
(BAD) at a distinct site, ser128, and thereby induces BAD-mediated apoptosis by 
opposing growth factor inhibition of the apoptotic effect of BAD. Phosphorylation of 
BAD ser128 was found to inhibit the interaction of growth factor-induced ser136-
phosphorylated BAD with 14-3-3 proteins (Konishi Y., et al., 2002). A novel Bcl2-
binding protein, termed Bad for 'Bcl2 antagonist of cell death.' Bad heterodimerized 
strongly with BclX, less strongly to Bcl2, and did not bind to other members of the 
family. At similar levels of expression, Bad countered the death repressor activity of 




Functional studies revealed that when Bad dimerized with BclX, it displaced Bax 
and restored its apoptosis-inducing ability. Bad may influence the effectiveness of Bcl2 
versus BclX in repressing cell death (Yang E., et al., 1995). BCL2 associates in vivo with 
a 21-kD program partner, BAX. BAX shows extensive amino acid homology with BCL2 
and forms homodimers and heterodimers with BCL2 in vivo. When BAX predominates, 
programmed cell death is accelerated, and the death repressor activity of BCL2 is 
countered. The ratio of BCL2 to BAX determines survival or death following an 
apoptotic stimulus (Oltavi Z.N., et al., 1993). Interestingly, BAX is a primary-response 
gene for p53 and is involved in a p53-regulated pathway for induction of apoptosis 
(Miyashita and Reed J.C., 1995). 
 
4.4.8 Homo sapiens, mito coxII mRNA for cytoC oxidase II subunit (COX II) 
Cytochrome c oxidase subunit II (COII or MTCO2) is 1 of 3 mitochondrial DNA 
encoded subunits (MTCO1, MTCO2, MTCO3) of respiratory Complex IV; which is 
found within the mitochondrial inner membrane. Complex IV is the third and final 
enzyme of the electron transport chain of mitochondrial oxidative phosphorylation. The 
energy released is used to transport protons across the mitochondrial inner membrane. 
Subunit II contains one redox center, CuA, and collects electrons from ferrocytochrome b; 
which are then transferred to cytochrome a of subunit I and on to the cytochrome a3-CuB 
binuclear reaction center. Cytochrome c interacts with subunit II through the association 
of a ring of lysines around the heme edge of cytochrome c with carboxyls in subunit II 




Deficiency of cytochrome c oxidase (COX) causes a clinically heterogeneous 
variety of neuromuscular and non-neuromuscular disorders in childhood and adulthood 
and theoretically can result from either nuclear or mitochondrial mutations with obvious 
differences in mode of inheritance. In the COX protein, a structural association of COX II 
with COX I is necessary to stabilize the binding of heme a3 to COX. The MTCO2 gene 
encompasses 708 nucleotide pairs (nps) of continuous mtDNA sequence, lacking introns, 
and encoding a single polypeptide. Cleavage at the tRNAs releases transcript 16, the 
MTCO2 mRNA. Mounting evidence suggests that defects in energy metabolism 
contribute to the pathogenesis of Alzheimer disease. Cytochrome c oxidase (CO) is 
kinetically abnormal, and its activity is decreased, in brain and peripheral tissue in late-
onset AD. CO is encoded by both the mitochondrial and the nuclear genomes. Its 
catalytic centers, however, are encoded exclusively by 2 mitochondrial genes, the 
MTCO1 gene and the MTCO2 gene, encoding CO subunits I and II, respectively. 
Specific missense mutations in MTCO1 and MTCO2 but not MTCO3 were found to 
segregate at a higher frequency with AD compared with other neurodegenerative or 
metabolic diseases. Furthermore, it was suggested that a CO defect may represent a 
primary etiologic event, directly participating in the cascade of events that resulted in AD 
(Davis R. E., et al., 1997). Hirano M., et al., 1997 and Wallace D. C., et al., 1997 
presented evidence that the missense mutations were related to Alzheimer disease were in 
fact located in mtDNA pseudo genes that are embedded in the nuclear genome where 
they have been transferred as part of the extensive transfer of genetic material from the 




4.4.10 Homo sapiens, Cell Division Cycle 27 (CDC27), anaphase-promoting 
complex, subunit 3; APC3 
The anaphase-promoting complex (APC) functions as a protein ubiquitin ligase 
and is the cell cycle-regulated component of the mitotic cyclin degradation system that 
governs exit from mitosis. The anaphase-promoting complex (APC) consists of at least 8 
protein subunits, including APC5, CDC27 (APC3), CDC16 (APC6), and CDC23 (APC8). 
Cdc27 is a component of the anaphase-promoting complex which catalyses the formation 
of cyclin B-ubiquitin conjugate.  Furthermore, it also interacts with mitotic checkpoint 
proteins such as Mad2, p55CDC and BUBR1.  Interestingly, cdc27 is a substrate of 
caspase-3. It is located at 17q21.3 of the homo sapien. It is also found to be expressed in 
the pancreas, brain, kidney, eyes and also in the lung. It is also found in the muscular 
skeletal tissue. It is found to be located intracellular in the nucleus. It belongs to the 
CDC27/NUC2 family. Its basic function is of a regulatory nature; as it may be involved 
in controlling the timing of mitosis. It is mainly a structural component of the anaphase 
promoting complex that controls anaphase initiation and late mitotic events (Tugendreich 
S., et al., 1993).  
 
4.4.10 Homo sapiens, Flotillin 1 
Flotilin 1 (Flot1) encodes a 428-amino acid protein with a predicted molecular 
mass of 47 kD. It contains 2 hydrophobic domains and several potential phosphorylation 
sites. Flot1 shares 47% amino acid identity with both mouse and human FLOT2. It acts as 
a scaffolding protein within caveolar membranes, thus it is commonly located as the 




in the formation of caveolae or caveolae-like vesicles. Flot1 can be found as a 47-kD 
protein in caveolin-rich membrane domains isolated from human lung, it is also 
expressed in adipose tissue, heart, skeletal muscle. Furthermore, it belongs to the band 7 / 
mec-2 family which is a flotillin subfamily. The stable transfection of Flot1 in COS-1 
cells induced filopodia formation and changed the epithelial morphology to that of 
neuronal cells (Hazarika, P., et al., 1999). Human epidermal surface antigen-1(ESA1 or 
FLOT2) was identified as a 35-kD antigen by means of a mouse monoclonal antibody 
raised against human keratinocytes (Cho Y.-J., et al., 1995). Flot2 consistently co purifies 
with Flot1 and with caveolin-1 in the purification of caveolin-rich membranes (Bickel 
P.E., et al., 1997). Interestingly, Flotillin forms a ternary complex with CAP and the CBL 
protooncogene product, directing the localization of the CAP-CBL complex to a lipid raft 
sub domain of the plasma membrane. Localization of the CBL-CAP complex to lipid 
rafts generates a pathway that is crucial in the regulation of glucose uptake (Baumann C. 
A., 2000). 
 
4.4.11 Homo sapiens, tubulin, epsilon 1 (TUBE1) 
Microtubules are constituent parts of a diverse variety of eukaryotic cell structures, 
e.g., the mitotic apparatus, cilia, flagella, and elements of the cytoskeleton. They consist 
principally of 2 soluble proteins, alpha- and beta-tubulin, each with a molecular weight of 
about 55,000. They are transcribed from different genes. The human DNA contains about 
14 copies per genome of alpha- and beta-tubulin genes. The microtubule is formed by the 
arrangement of 13 parallel protofilaments arising from end-to-end aggregation of the 




(MAPs, dynein, kinesin) and are involved in structures responsible for cellular movement 
such as flagella or cilia. Microtubules of the ciliary axoneme are more permanent than 
cytoplasmic and spindle microtubules (Lewis S. A. and Cowan N. J., 1990). TUBE, a 
475-amino acid protein, has a calculated molecular mass of 53 kD. TUBE contains the 
conserved GTP-binding domain shared with other tubulins, but it lacks the highly acidic 
C terminus characteristic of alpha-tubulin and beta-tubulin. Alpha-tubulin genes can be 
classified based on homology of their encoded C-terminal motifs to those of mouse 
alpha-tubulin genes; as a large proportion of the diversity of alpha-tubulins is clustered at 
the C-terminal region and is conserved across species. Some human alpha-tubulin genes 
have a fourth intron, also at an identical position. Relative to other tubulins, it also has a 
26-amino acid insertion between helices 6 and 7. Localization of TUBE within the 
centrosome of dividing osteogenic sarcoma cells was dependent on the cell-cycle stage 
(Chang P. and Stearns T., 2000). In cells with only 1 centrosome, TUBE roughly co 
localized with gamma-tubulin, but in cells with duplicated centrosomes, TUBE often 
labeled only 1 of the pair, with variable labeling of the second centrosome. Gamma-
tubulin homogeneously labeled both. TUBE is found to associate with the older of the 2 
centrosomes in a newly duplicated pair and later associates with both. The TUBE gene is 
mapped to chromosome 6q21 by genome sequence analysis (Chang P. and Stearns T., 
2000). TUBE 1 is associated with pericentriolast material and centrosomal. It is a 
microtubule and has microtubule- based movement; and henceforth a structural 





4.4.12 Homo sapiens, NAC alpha mRNA nascent polypeptide-associated 
complex, alpha polypeptide. 
The NAC complex at the ribosome protects nascent polypeptides from premature 
interactions with cytosolic proteins.  The complex inhibits the binding of ribosomes that 
translate non-secretory proteins to translocation sites in the membrane of the endoplasmic 
reticulum. NAC releases the nascent chain when binding for cytosolic proteins such as 
the signal recognition particle (SRP) or chaperones is completed.  Thus, NAC protects 
nascent polypeptides from premature interactions with cytosolic proteins.  NAC may also 
function in co-translational protein import into mitochondria.  Newly translated NAC 
proteins travel into the nucleus to bind stoichiometrically to ribosomal subunits and then 
leave the nucleus together with these subunits to concentrate in the cytosol. This 
hypothetical protein is found so far only in the Archaea. Its C-terminal domain of about 
40 amino acids is homologous to the C-termini of the nascent polypeptide-associated 
complex alpha chain (alpha-NAC) and its yeast ortholog Egd2p and to the huntingtin-
interacting protein HYPK. It shows weaker similarity, possibly through shared structural 
constraints rather than through homology, with the amino-terminal domain of elongation 
factor Ts. NAC bound ubiquitously to nascent polypeptides unless a signal peptide was 
fully exposed. NAC did not bind to fully emerged signal peptides. In the absence of NAC, 
the signal recognition particle interacted with polypeptides even in the absence of a signal 
peptide and allowed mistargeting of the protein to the SRP receptor at the endoplasmic 
reticulum membrane. Readdition of purified NAC prevented mistranslocation 
(Wiedmann B., et al., 1994). The signal recognition particle (SRP) is a ribonucleoprotein 




complex consists of a 7S (or 7SL) RNA and 6 different proteins, SRP9, SRP14, SRP19, 
SRP54, SRP68 and SRP72. SRP has at least 3 distinct functions that can be associated 
with the protein subunits: signal recognition, translational arrest, and ER membrane 
targeting by interaction with the docking protein. SRP54 binds to SRP RNA via the M-
domain, but only in the presence of RNA-bound SRP19, and that it associates with the 
signal peptide of nascent polypeptide chains. RNA interaction requires the presence of a 
loop in the C-terminal M-domain. Signal peptide recognition most likely involves 
methionine-rich loop (Gowda K., et al., 1997). In order to translocate membrane or 
secretory proteins across the endoplasmic reticulum (ER) membrane, the signal sequence 
of a nascent peptide is recognized by a signal recognition particle (SRP), by which the 
nascent peptide associated with a ribosome can bind to the ER membrane receptor (or 
docking protein). SRP is released from both the ribosome and the signal sequence. The 
signal sequence lies near an integral, glycosylated ER membrane protein commonly 
referred to as the signal sequence receptor (SSR) (Chinen K., et al., 1995). Alpha-NAC 
plays a role in preventing nascent polypeptides from binding inappropriately to 
membrane-targeting apparatus during translation, but is also active as a transcription 
regulator. NACA protein is specifically expressed in bone during development and acts 
as a transcriptional co activator in conjunction with acidic activators (Yotov W. V. and 
St-Arnaud R., 1996). It is mapped to the chromosomal gene location 12q23 to 12q24.1. 
 
4.4.13 Homo sapiens, insulin receptor substrate 2 (IRS2) 
Insulin receptor substrate-2 (IRS-2) is a multisite docking protein implicated in 




receptors. Alignment of the sequences of IRS2 and IRS1 demonstrated a highly 
conserved N terminus containing a pleckstrin-homology domain and a phosphotyrosine-
binding (PTB) domain, and a poorly conserved C terminus containing several tyrosine 
phosphorylation motifs. The protein insulin receptor substrate-1 (IRS1) acts as an 
interface between signaling proteins with Src homology-2 domains (SH2 proteins) and 
the receptors for insulin (INS), IGF2, growth hormone (GH1), several interleukins (IL4, 
IL9, IL13) and other cytokines. It regulates gene expression and stimulates mitogenesis 
and appears to mediate insulin/IGF1-stimulated glucose transport. Thus, this could 
suggest that IRS2 may be essential for signaling by several receptor systems (Sun X.J., et 
al., 1995). Insulin, IGF-I, and IGF-II enhanced the growth of both cell lines, stimulated 
tyrosine phosphorylation of IRS-2, and increased IRS-2-associated phosphatidylinositol 
(PI) 3-kinase activity. The mitogenic effects of insulin, IGF-I, and IGF-II were markedly 
attenuated by the PI 3-kinase inhibitor LY 294002. Total RNA extracted from normal and 
cancerous tissues revealed that IRS-2 mRNA levels were increased in the cancer tissues 
by northern blot analysis. In the normal pancreas, IRS-2 immunoreactivity was present at 
low levels in some ductal and acinar cells and at moderate levels in a heterogeneous 
pattern in all of the endocrine islets. In the pancreatic cancers, IRS-2 was abundant in the 
ductal-like cancer cells. Thus in conclusion, IRS-2 may enhance the mitogenic signaling 
via the PI 3-kinase pathway, leading to excessive growth stimulation as IRS-2 is found to 
be over expressed in human pancreatic cancer. Furthermore, it may mediate the control of 
various cellular processes by insulin. IRS2 may be involved in other diseases that 
commonly affect human beings. One good example is its association between type II 




polymorphism of IRS2 appears to be protective against type II diabetes in a co dominant 
fashion. Furthermore, dysfunction of IRS2 may contribute to the pathophysiology of 
human type II diabetes. As indicated, insulin receptor substrates (IRS proteins) mediate 
the pleiotropic effects of insulin and insulin-like growth factor-1 (IGF1), including 
regulation of glucose homeostasis and cell growth and survival. By contrast, both IRS1 
and IRS2 function in peripheral carbohydrate metabolism, but IRS2 has the major role in 
beta-cell development and compensation for peripheral insulin resistance. IRS2 integrates 
the effects of insulin in peripheral target tissues with Igf1 in pancreatic beta cells 
(Withers D.J., et al., 1998). IRS2 plays a crucial role in the regulation of beta-cell mass as 
the results from a gene targeting study conducted on IRS2-deficient mice had developed 
diabetes due to inadequate beta-cell proliferation combined with insulin resistance in the 
liver (Kubota N., et al., 2000). IRS2 expression promoted beta-cell growth and 
development, up regulated beta-cell gene expression, and inhibited caspase-mediated 
apoptosis of beta cells. The up regulation of IRS2 was found to promote glucose 
tolerance in old mice and prevented diabetes in IRS2-null mice and in obese mice. The 
IRS2 signaling cascade may be a 'master regulator' of beta-cell function (Hennige A. M., 
et al., 2003). IRS2-deficient mice were observed to display increased adiposity with 
increased serum leptin level, suggesting leptin resistance before the mice developed 
diabetes. An increased expression of sterol regulatory element-binding protein-1 
(SREBP1), a downstream target of insulin, was found in IRS2-deficient mouse liver 
which concludes that IRS2 gene disruption results in leptin resistance, causing SREBP1 
gene induction, obesity, fatty liver, and diabetes (Tobe K., et al., 2001). Sterol regulatory 




control cholesterol homeostasis by stimulating transcription of sterol-regulated genes. 
Sterol regulatory element-1 (SRE1), a decamer (5-prime-ATC-ACCCCAC-3-prime) 
flanking the low density lipoprotein receptor gene, activates transcription in sterol-
depleted cells and is silenced by sterols. SREBP1 contains a basic helix-loop-helix 
leucine zipper (bHLH-Zip) motif, but it differs from other bHLH-Zip proteins in its larger 
size (1,147 amino acids) and target sequence. SREBP1 is synthesized as a 125-kD 
precursor that is attached to the nuclear membrane and endoplasmic reticulum (ER). 
Cholesterol homeostasis in animal cells is achieved by regulated cleavage of SREBPs, 
membrane-bound transcription factors. Proteolytic release of the active domains of 
SREBPs from membranes requires a sterol-sensing protein called SREBP cleavage-
activating protein (SCAP), which forms a complex with SREBPs. SCAP is a membrane 
protein with multiple membrane-spanning segments, some of which show a highly 
significant resemblance to the membrane-spanning segments of HMG CoA reductase, an 
enzyme whose degradation is regulated by sterols. SCAP appears to be a central regulator 
of cholesterol metabolism in animal cells (Hua X., et al., 1996). In sterol-depleted cells, 
the membrane-bound precursor is cleaved to generate a soluble N-terminal fragment that 
translocates to the nucleus. The SCAP will escort the SREBPs from the endoplasmic 
reticulum (ER) to the Golgi, where SREBPs are cleaved by site-1 protease (S1P). Site-1 
protease initiates the release of transcription factors from membranes by sterol-regulated 
proteolysis by cleaving SREBPs in the ER luminal loop between 2 membrane-spanning 
regions. Transport-dependent proteolysis may be a common mechanism to regulate the 
processing of membrane proteins as the relocation of inactivation of S1P obviated the 




al., 1999). The soluble N-terminal fragment, which includes the bHLH-Zip domain, 
activates transcription of the genes for the LDL receptor and HMG-CoA synthase. Sterols 
inhibit the cleavage of SREBP1, and the 68-kD nuclear form is rapidly catabolized, 
thereby reducing transcription. N-acetyl-leucyl-leucyl-norleucinal (ALLN), an inhibitor 
of neutral cysteine proteases, blocked the breakdown of the 68-kD form and 
superinduced sterol-regulated genes. Sterol-regulated proteolysis of a membrane-bound 
transcription factor is a novel mechanism by which transcription can be regulated by 
membrane lipids (Wang X., et al., 1994). The synthesis of cholesterol and its uptake from 
plasma LDL are regulated by 2 membrane-bound transcription factors, SREBP1 and 
SREBP2. The human SREBP1, a protein that binds SRE1, activates transcription, and 
thereby mediates the final regulatory step in LDL metabolism (Yokoyama C., et al., 
1993). The low density lipoprotein receptor is a cell surface receptor that plays an 
important role in cholesterol homeostasis. The low density lipoprotein receptor is 
synthesized as a 120-kD glycoprotein precursor that undergoes change to a 160-kD 
mature glycoprotein through the covalent addition of a 40-kD protein (Tolleshaug H., et 
al., 1982). The human LDL receptor is an 839-amino acid protein rich in cysteine, with 
multiple copies of the Alu family of repetitive DNAs (Yamamoto T., et al., 1984). The 
LDL receptor has a DNA sequence homology of with the epidermal growth factor 
receptor (EGF) (Russell D. W., et al., 1984). LDL receptor is a mosaic protein built up of 
exons shared with different proteins like C9 component of complement, a repeat 
sequence in the precursor for EGF, proteins of the blood clotting system and lastly non 
repeated sequences that are shared only with the EGF precursor (Sudhof T. C., et al., 




LDLR gene was regionalized to 19p13.1-p13.3 (Lindgren V., et al., 1985). LDL binding 
to cultured fibroblasts in a manner consistent with a receptor, and that this binding 
resulted in suppression of cholesterol synthesis by the cell via repression of HMG CoA 
reductase. This signifies the importance in cholesterol metabolism. Normally, LDL is 
bound at the cell membrane and taken into the cell ending up in lysosomes where the 
protein is degraded and the cholesterol is made available for repression of microsomal 
enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-
limiting step in cholesterol synthesis. Interestingly, Hepatitis C virus (HCV), the principal 
viral cause of chronic hepatitis, is not readily replicated in cell culture systems, making it 
difficult to ascertain information on cell receptors for the virus. Evidence had shown that 
HCV and other viruses enter cells through the mediation of LDL receptors. Absence of 
LDL receptors have been observed in cells known to be resistant to infection by one of 
these viruses, bovine viral diarrheal virus (BVDV). Endocytosis via the LDL receptor 
was shown to be mediated by complexing of the virus to very low density lipoprotein 
(VLDL) or LDL, but not high density lipoprotein (HDL). LDL receptor may be the main 
but not exclusive means of cell entry of these viruses (Agnello V., et al., 1999). 
Substitution of cysteine for tyrosine in the cytoplasmic domain of LDL receptors impedes 
their internalization. Furthermore, another important association that is of great interest 
especially to my field of study is its association of IRS2 with obesity. Insulin, in a 
concerted interaction together with leptin and other neuropeptides, may modulate the 
hypothalamic control of appetite and reproductive endocrinology of females (Burks D.J., 
et al., 2000). IRS2 is a potential regulator of glucose homeostasis and IRS2 could be 




obesity, which is an important link to my studies. Obesity is defined as a complex 
disorder associated with insulin resistance and glucose intolerance. IRS2 is an influential 
gene in severe obesity and glucose intolerance based on a study done on a Caucasian 
population of obese women with class II or class III obesity (Lautier C., et al., 2003). 
Chronic hyperinsulinemia was shown to downregulate the mRNA for IRS2, an essential 
component of the insulin-signaling pathway in liver, thereby producing insulin resistance 
based from studies conducted on lipodystrophic and obese mice. Insulin continues to 
stimulate production of SREBP1c, a transcription factor that activates fatty acid synthesis 
in the lacking of IRS2. The combination of insulin resistance (inappropriate 
gluconeogenesis) and insulin sensitivity (elevated lipogenesis) establishes a vicious cycle 
that aggravates hyperinsulinemia and insulin resistance in lipodystrophic and obese mice 
(Shimomura I., et al., 2000). This may suggest some association in our study in which 
one of the main component added is low density lipoprotein, which is found in high 
levels in obese humans and a main constituent of foam cells formation which eventually 
leads to the excessive accumulation triggering the onset of the disease of atherosclerosis. 
Lack of IRS2 will results in higher levels of lipids, in other words, increase in LDL 
that equates to greater foam cells formation. This will eventually cause the 
deposition of foam cells on the arterial walls which eventually leads to the 
disease of atherosclerosis. The results obtained from both the DDRTPCR, and 
semi quantitative real time PCR indicates a down regulation. A possible 
hypothesis would be that IRS2 gene could be downregulated in the presence of 
the Chlamydia pneumoniae, which in turn will lead to the increase in foam cell 




4.4.14 Homo sapiens, ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e 
(ATP6V0E) 
Proton-translocating adenosine triphosphatases have fundamental roles in energy 
conservation, secondary active transport, the acidification of intracellular compartments, 
and cellular pH homeostasis. They fall into three broad classes, called F, P, and V, of 
which the vacuolar type (V-ATPases) is both the most recently recognized and the least 
well characterized. ATPases of this class occur in endomembranes bounding the acidic 
compartments of animal, plant, and fungal cells and also in the plasma membranes of 
some specialized cell types. Most V-ATPases  subunit composition depends on the source 
of the enzyme, and tissue-specific isoforms exist. The V-type ATPases are structurally 
similar to those of the F-type, having a transmembrane proton-conducting sector and an 
extramembrane catalytic sector. By analogy with the two sectors of F-ATPases, these are 
termed V0 and V1, respectively. The V-type (vacuolar) ATPases are responsible for 
acidifying a variety of intracellular compartments in eukaryotic cells.  
 
This gene encodes a component of vacuolar ATPase (V-ATPase), a multi subunit 
enzyme that mediates the acidification of eukaryotic intracellular organelles. V-ATPase 
dependent, organelle acidification is necessary for such intracellular processes as protein, 
sorting, zymogen activation, and receptor-mediated endocytosis. V-ATPase is comprised, 
of a cytosolic V1 domain and a transmembrane V0 domain. The V1 domain consists of, a 
hexamer of three A and three B subunits plus the C, D, and E subunits. It contains the 
ATP catalytic site, thus plays a role as hydrogen ion transporter, ie hydrogen-transporting 




encoded protein is part of the V0 subunit. Genomic mapping puts the chromosomal 
location on 5q35.3. It is potentially found in the integral membrane.  
 
4.4.15 Homo sapiens, eukaryotic translation elongation factor 1 alpha 1(EEF1A1) 
Elongation factor 1 alpha is one of the genes activated in human melanoma cells 
by the tumor-promoting phorbol ester. EEF1A shows 73% and 63% on amino acid and 
nucleotide sequences homology respectively with known sequences of elongation factors. 
Phorbol ester induction will result in a 3- to 5-fold increase in cytoplasmic elongation 
factor 1 alpha mRNA. The alpha subunit of elongation factor-1 (EEF1A) is involved in 
the binding of aminoacyl-tRNAs to 80S ribosomes. During the process, GTP is 
hydrolyzed into GDP. EEF1A promotes the GTP-dependent binding of aminoacyl-tRNA 
to the A-site of ribosomes during protein biosynthesis. EEF1A has domains that bind 
guanine nucleotides, 80S ribosomes, and aminoacyl-tRNAs. Also, EEF1A interacts with 
the beta subunit of EEF1 to exchange bound GDP for GTP (Brands, J. H. G. M., et al., 
1986). It is found specifically in the brain, placenta, lung, liver, kidney, and pancreas but 
barely detectable in the heart and sketetal muscle. The EEF1A1 gene is mapped to 
chromosome 6q14 (Lund A., et al., 1996). Elongation factor gene showed multiple 
chromosomal localizations, with peak hybridization on the chromosomes 1, 2, 4, 5, 6, 7, 
and 15. The estimate of the gene copy number in humans is more than ten copies per 
(haploid) genome. The cellular mRNA content of elongation factor 1 alpha is 30 times 
higher compared with the phorbol ester-inducible single-copy gene transcripts coding for 




in translation elongation factor activity. It belongs to the GTP-binding elongation factor 
family, and the subfamily of EF-TU/EF-1A  
 
4.4.16 Homo sapiens, HSPC150 protein similar to ubiquitin-conjugating enzyme 
(HSPC150) 
HSPC150 catalyzes the covalent attachment of ubiquitin to other proteins. It is 
involved in the second step of Ubiquitin conjugation pathway. It belongs to the ubiquitin-
conjugating enzyme family (by similarity). The catalytic activity is depicted as follows:-  
ATP + ubiquitin + protein lysine = AMP + diphosphate + protein N-ubiquityllysine. 
Furthermore, HSPC150 is a cysteine residue is required for ubiquitin- thiolester 
formation. Ubiquitin cycle is the cyclical process by which one or more ubiquitin 
moieties are added to (ubiquitination) and removed from (deubiquitination) a protein.  
ubiquitin conjugating enzyme activity functions to link the ubiquitin to lysine residues on 
a target protein. This function may be performed alone or in conjunction with E3, 
ubiquitin-protein ligase. Ligase is described as the enzyme that catalyzes the joining of 
two molecules coupled with the breakdown of a pyrophosphate bond in ATP or a similar 
triphosphate. Ubl conjugation pathway is described as:-  protein involved in ubiquitin-
like modifier processing, activation, conjugation or deconjugation such as Ubl-activating 
enzymes (E1s), Ubl-conjugating enzymes (E2s), Ubl-protein ligases (E3s), some thiol 
proteases (Ubiquitin carboxyl-terminal hydrolases (UCH), Ubiquitin-specific processing 
proteases (UBP) and ubiquitin-like proteases) and the ubiquitin-like modifier proteins. 
Besides signaling proteolysis, ubiquitination for example can be a signal for trafficking, 




4.4.17 Homo sapiens, hepatocellular carcinoma-associated antigen 58 (HCA58) 
Hepatocellular carcinoma-associated antigen 58 (Glioma-expressed antigen 2) 
(Transcription factor TZP) (Novel zinc finger protein); has a size of 115385 Da and 1012 
amino acids. It is most probable that HCA58 is located in the nuclear. It could function as 
a possible transcription factor. It contains 1 A.T hook DNA-binding repeat, 1 PHD-type 
zinc finger and 1 C2H2-type zinc finger. It is commonly associated with glioblastoma, 
and may serve as diagnostic marker in glioblastoma. Antibodies against C20orf104 are 
present in sera from patients with hepatocellular carcinoma, glioblastoma and childhood 
medulloblastula who developed different autoantibodies. HCA58 is expressed in heart, 
kidney, liver, lung, pancreas, placenta, spleen and testis. HCA58 is not expressed in brain, 
skeletal muscle, colon, ovary, prostate, small intestine and thymus. Interestingly, it is 
expressed in colon and ovary cancer cell line, giving a clear indication of onset of disease 
as it is normally not being found or expressed in the normal state. Autoantibodies are 
often detected in hepatocellular carcinoma (HCC), and these responses may represent 
recognition of tumor Ags that are associated with transformation events. HCA58 was 
identified to be expressed in colon and ovarian cancer cell lines but not in the normal 
tissue counterparts. In addition, abundant expression of complement inactivation factors 
was found in HCC. These results indicate a broad range expression of autoantigens in 
various organs and tissues of HCC patients, which then suggest an involvement of the 
study of autoantigens in the transformation, metastasis, and immune evasion in HCC 






4.4.18 Homo sapiens, B Lymphocyte Activator Macrophage Expressed (BLAME) 
B lymphocyte activator macrophage expressed (BLAME) is a novel cell surface 
protein member of the CD2 family. The CD2 family is a growing family of Ig domain-
containing cell surface proteins involved in lymphocyte activation. BLAME shares the 
structural features of the CD2 family containing an IgV and IgC2 domain and clusters 
with the other family members on chromosome 1q21. BLAME was originally cloned 
from a human MLR library. The open reading frame encodes a 28 amino acid protein 
with a 22 amino acid leader sequence predicted by signal P. The mature protein is a type 1 
transmembrane protein with a 212 amino acid extracellular domain, 21 amino acid 
transmembrane domain, and a short 31 amino acid cytoplasmic tail. The extracellular 
domain was shown to contain the two Ig-like domains typical of the CD2 family, an N-
terminal IgV-like fold that does not contain the conserved disulfide bonds, and a 
membrane proximal C2-like fold. BCM-like membrane protein precursor was recently 
entered in to the public data base (GenBank accession number AAF67470) and is 
identical with BLAME except for one amino acid (S99 to G). BLAME is found to be 
expressed in lymphoid tissue and, more specifically, in some populations of professional 
APCs, activated monocytes, and dendritic cells. BLAME may play a role in B lineage 
commitment and/or modulation of signal through the B cell receptor. Clustal analysis of 
the human CD2 family shows BLAME to be most closely related to CD48. Comparison 
of the extracelluar domain of the mature protein shows BLAME to be most closely 
related to CD58. Interestingly, CD48 and CD58 are currently the only two members of 
the family that, like BLAME, have no cytoplasmic signaling motifs. Annotated as an 




CD2, 19A (GenBank accession number CAB81950) was included in this analysis. The 
human BLAME mapping indicated that the gene was located at chromosomal location 
hu1q21 (with synteny to mouse chromosome 3). This region of chromosome 1 (1q21–24) 
also contains multiple other family members: CD48, CD84, CD150, CD244, and Ly-9. 
The possibility of a direct interaction between B cells and other APCs has been well 
established (Dubois B., et al., 1999). Henceforth, BLAME expression could be 
modulating the signal through the B cell receptor complex by binding to a presumed 
receptor on B cells and acting as a costimulator or an adhesion molecule. Although 
overexpression of a cell surface gene may lead to constitutive signaling, without the 
necessity of interaction with a ligand/coreceptor, this seems unlikely in this case because 
BLAME does not contain the signaling motifs usually used by this family. However, 
BLAME may associate itself with another chain that does contain a signaling domain. A 
specific example would be that BLAME has been postulated to be the ligand for either of 
these two genes, CD84 and Ly-9, or for a novel CD2 family member. CD84 and Ly-9 are 
expressed on B cells and currently of unknown function; they would be found at the 
location of chromosome 1q21–23. Both of these receptors contain long cytoplasmic 
domains that include the TxYxxV/I/A motifs and may be likely to bind to a non signaling 
ligand, BLAME. The ligand/receptor pairs within the CD2 family are genetically linked, 
and this has been validated by Kingsmore S.F., et al., 1989. 
 
4.4.19 Homo sapiens, Protein Phosphatase 2 (formerly 2A), regulatory subunit B   
Protein phosphatase 2A (PP2A), a heterotrimeric serine/threonine phosphatase, 




complex set of regulatory subunits controlling its function and localization. The PP2A 
complex consists of 3 subunits, a catalytic subunit (C), a structural subunit (A), and a 
highly variable regulatory subunit (B). The B-subunit family is involved in enzyme 
activity and substrate specificity. The product of this gene belongs to the phosphatase 2 
regulatory subunit B family. Protein phosphatase 2 is one of the four major Ser/Thr 
phosphatases, and it is implicated in the negative control of cell growth and division. It 
consists of a common heteromeric core enzyme, which is composed of a catalytic subunit 
and a constant regulatory subunit; that associates with a variety of regulatory subunits. 
The B regulatory subunit might modulate substrate selectivity and catalytic activity. 
Furthermore, it also might direct the localization of the catalytic enzyme to a particular 
sub cellular compartment. This gene encodes a gamma isoform of the regulatory subunit 
B55 subfamily. Alternatively spliced transcript variants encoding different isoforms have 
been identified. The subunit pp2a consists of a common heterodimeric core enzyme, 
composed of a 36 kda catalytic subunit (subunit c) and a 65 kda constant regulatory 
subunit (pr65 or subunit a), that associates with a variety of regulatory subunits. Proteins 
that associate with the core dimer include three families of regulatory subunits b (the 
r2/b/pr55/b55, r3/b''/pr72/pr130/pr59 and r5/b'/b56 families), the 48 kda variable 
regulatory subunit, viral proteins, and cell signaling molecules. Obesity has been under 
the strong influence of genetic factors; with up to 40% of the variation in body fat content 
being attributed to genetic factors. Genes that are involved in the regulation of 
catecholamine function may be of particular importance for human obesity because of the 
central role catecholamines play in energy expenditure, both as hormones and as 




through lipolysis in fat cells. The beta-2 adrenoceptor is a major lipolytic receptor in 
human fat cells and it consists of the ADRB2. Interestingly, there seems to be a 
significant association between the gln27-to-glu polymorphism of the ADRB2 gene and 
obesity. The gln27 allele was present in 52% of obese subjects and in 70% of non obese 
subjects. Genetic variation in the ADRB2 gene may be of major importance for obesity, 
energy expenditure, and lipolytic ADRB2 function in adipose tissue (Large, V., et al., 
1997). Some individuals have resistance to the lipolytic effects of catecholamines and 
that this is the result of decreased ADRB2 expression in fat cells (Lonnqvist F., et al., 
1992). Activated beta-2-adrenergic receptor binds beta-arrestin-1, which then binds c-src 
at its amino terminus. This interaction targets the complex to clathrin-coated pits and 
allows for beta-2-adrenergic activation of the MAP kinases ERK1 and ERK2 (Luttrell, L. 
M., et al., 1999). Beta-2 adrenergic receptor is directly associated with the class C L-type 
calcium channel Ca (V) 1.2. This complex also contains a G protein, an adenylyl cyclase, 
cAMP-dependent kinase, and the counterbalancing phosphatase PP2A (Davare M.A., et 
al., 2001). Highly localized signal transduction was found starting from the receptor to 
the channel. The assembly of this signaling complex provides a mechanism that ensures 
specific and rapid signaling by a G protein-coupled receptor. Agonist stimulation of 
endogenous or transfected beta-2 adrenergic receptors led to rapid ubiquitination of both 
the receptors and the receptor regulatory protein, beta-arrestin. Moreover, proteosome 
inhibitors reduced receptor internalization and degradation, thus implicating a role for the 
ubiquitination machinery in the trafficking of the beta-2 adrenergic receptor. Receptor 
ubiquitination required beta-arrestin, which bound the E3 ubiquitin ligase MDM2.  The 




beta-2 adrenergic receptor and indicated that ubiquitination of the receptor and of beta-
arrestin have distinct and obligatory roles in the trafficking and degradation of this 
prototypic G protein-coupled receptor (Shenoy S. K., et al., 2001). 
 
4.4.20 Homo sapiens, Similar to Polymerase (RNA) III (DNA directed) (62kD) RNA 
polymerase III subunit RPC62 
RNA polymerase III, one of three eukaryotic nuclear RNA polymerases, is a multi 
subunit complex; it produces tRNAs and some of the snRNAs. Two large subunits 
comprise the most conserved portion including the catalytic site and share similarity with 
other eukaryotic and bacterial multi subunit RNA polymerases. The remainder of the 
complex is composed of smaller subunits (generally ten or more), some of which are also 
found in RNA polymerase I and others which are found in all three nuclear RNA 
polymerases. Although the core is competent to mediate ribonucleic acid synthesis, it 
requires additional factors to select the appropriate template. RPC62 is a subunit on this 
RNA polymerase III. Thus, the function and process is associated and related to RNA 
polymerase III. The molecular function of RNA polymerase III is involved in the DNA-
directed RNA polymerase activity, and this comprises of the Catalysis of the reaction: 
nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1), while utilizing a DNA 
template: i. e. the catalysis of DNA-template-directed extension of the 3'-end of an RNA 
strand by one nucleotide at a time, as in it can initiate a chain 'de novo'. Basically, it is 






4.4.21 Homo sapiens, Translation Initiation Factor IF2 (IF2), mRNA 
The human translation initiation factor 2 (IF2) or also known KIAA0741 contains 
3 motifs characteristic of GTP-binding proteins and has long N-terminal poly-glu and 
poly-lys stretches. The GTP-binding domains of human IF2 share 70% and 54% identity 
with those of the yeast and archaeal IF2 proteins, respectively. The expression of 
KIAA0741 was detected in all tissues tested except spleen, with highest levels in brain, 
followed by heart and testis by RT-PCR analysis. An intact GTP-binding domain is 
required for translation promotion (Lee J. H., et al., 1999). IF2 catalyzes the first 
regulated step of protein synthesis initiation, promoting the binding of the initiator tRNA 
to 40S ribosomal subunits. To be exact, IF2 was found to   direct the binding of met-
tRNA to the ribosomal P site. IF2 contains an EFTU GTP-binding domain.  It is 
intimately involved in polypeptide synthesis as it binds to charged tRNAs. This gene 
encodes a protein that functions as a translation initiation factor and is universally 
conserved. It encodes one of the two proteins identified as translation initiation factors, 
the other factor being a complex composed of three subunits. These translation factors act 
independently of each other, however, their function is the same: to position the initiator 
methionine trna on the start codon of the mrna in association with the 40S ribosomal 
subunit and GTP so that translation initiates accurately. It functions in general translation 
initiation by promoting the binding of the formylmethionine-tRNA to ribosomes. IF2 
seems to function along with eIF-2. Translation initiation requires the delivery of the 
initiator methionine tRNA to the 40S ribosomal subunit. The initiator methionine tRNA 
is delivered by the heterotrimeric complex EIF2 in a ternary complex with GTP that 




for the AUG start codon. The translation initiation factor eIF2 is involved in the 
regulation of translational initiation. Binding occurs as a ternary complex of methionyl-
tRNA, eIF2, and GTP. eIF2 is composed of 3 non identical subunits, alpha, beta and 
gamma. The rate of formation of the ternary complex is modulated by the 
phosphorylation state of eIF2-alpha. The IF2 gene is mapped to chromosome 2 (Nagase 
T., et al., 1998). 
 
4.4.22 Homo sapiens, Actin, Gamma 1 (ACTG1) 
Actins are highly conserved proteins that are involved in various types of cell 
motility and are ubiquitously expressed in all eukaryotic cells. In vertebrates 3 main 
groups of actin isoforms, alpha, beta and gamma have been identified. The alpha actins 
are found in muscle tissues and are a major constituent of the contractile apparatus. The 
beta and gamma actins co-exist in most cell types as components of the cytoskeleton and 
as mediators of internal cell motility. Actin is a structural constituent of the cytoskeleton 
Actin is the major component of the thin filaments of muscle cells and of the cytoskeletal 
system of non muscle cells. The amino acid sequences of muscle and cytoskeletal actin 
isoforms are very similar and well conserved in evolution. Microfilaments, which are 
involved in cell motility, organelle transport, cytokinesis, and muscle contraction, are 
linear polymers of actin (Erba H.P., et al., 1986). The ACTG1 gene is mapped to the 
chromosomal location of 17q25. Polymerization of globular actin (G-actin) leads to a 
structural filament (F-actin) in the form of a two-stranded helix. Each actin can bind to 4 
others. Actin-based propulsion was driven by the free energy released by ATP hydrolysis 




In mammalian non muscle cells, 2 classes of actin are recognized on isoelectric 
focusing gels: beta and gamma. These 2 isoforms differ by 4 amino acid substitutions at 
the conserved NH2-end of the molecule. They are co expressed in non muscle cells. The 
beta-isoform is always expressed in excess of the gamma-isoform. We conclude that, 
whereas the cytoskeletal beta- and gamma-actins are truly co expressed, their mRNA 
levels are subject to differential regulation between different cell types. The human 
gamma-actin gene has been cloned and sequenced, and its chromosome location has been 
determined. The gene is located on human chromosome 17, unlike beta-actin which is on 
chromosome 7. Comparison of the human beta- and gamma-actin genes reveals that non 
coding sequences in the 5'-flanking region and in intron III have been conserved since the 
duplication that gave rise to these two genes. Such conserved non coding sequences may 
contribute to the co expression of beta- and gamma-actin or to the unique regulation and 
function of the gamma-actin gene (Erba H.P., et al., 1988).  
 
4.4.23 Homo sapiens, Complement Component 1, q subcomponent binding 
protein(C1QBP) 
Complement component 1, Q subcomponent binding protein (C1QBP) is 
described as, mitochondrial precursor (Glycoprotein gC1qBP) (GC1q-R protein) 
(Hyaluronan-binding protein 1) (p32) (p33).The human complement subcomponent C1q 
associates with C1r and C1s in order to yield the first component of the serum 
complement system. The protein encoded by this gene is known to bind to the globular 
heads of C1q molecules and inhibit C1 activation. This protein has also been identified as 




protein. However, the main function of this gene has not yet been elucidated. It is found 
to be localized predominantly in mitochondrial matrix, and putatively involved in 
nucleus-mitochondrion interactions. The protein contains a hyaluronic acid-binding 
domain as found in a protein called hyaladherin. The protein contains a potential tyrosine 
sulfation site, 3 predicted N-linked glycosylation sites, and at least 1 potential 
phosphorylation site for kinases like ERK, CDC2 and casein kinase II (Deb T. B. and 
Datta K., 1996). The functions of C1q, the recognition subunit of the first component of 
the classical pathway of complement activation, are regulated by 2 distinct types of 
proteins that bind either the collagen or the globular domain (Ghebrehiwet, B., et al., 
1994). The replication of human immunodeficiency virus-1 (HIV-1) is blocked in mouse 
cells at the levels of entry, transcription, and assembly, with the latter effect possibly 
resulting from excessive splicing of HIV-1 transcripts. They determined that transfection 
of human C1QBP, but not mouse C1qbp, which they called p32, blocked excessive 
splicing of viral genomic RNA. Mouse C1qbp has aspartic acid at position 35 of the 
mature processed protein, whereas human C1QBP has glycine at this position. 
Furthermore it was showed that the aspartic acid in mouse C1qbp is responsible for the 
posttranscriptional block to HIV replication (Zheng Y.-H., et al., 2003). Thus, by 
studying and observing the involvement of this protein in a viral example for example 
HIV; we can infer a possible mode of interaction or involvement of this particular protein 
in our case study. Transit peptide refers to proteins which have an N-terminal pre 
sequence which directs them to an organelle (chloroplast, mitochondria, micro body, 
cyanelle). The transit peptide is required for their transport across the relevant 




4.4.25 Homo sapiens, trinucleotide repeat DNA binding protein p20-CGGBP 
(CGGBP)gene 
The 5'-(CGG) (n)-3'-binding protein (CGGBP) gene contains 4 exons, with the 
entire open reading frame located within exon 4. The promoter region contains CAAT 
boxes and several Sp1-binding sites. The promoter regions of the CGG triplet repeat 
binding protein 1 (CGGBP1) is unmethylated in human cells, and in vitro methylation 
inactivated the promoter in a reporter assay. CGGBP1 is bound to 5'-(CGG) (n)-3'-repeats 
in vitro with n equal to or greater than 5. This mRNA is found to be expressed in a 
number of human tissues and the p20-CGGBP gene is conserved among mammals. It 
also bound interrupted repeats. CGGBP gene is mapped to near the centromere on human 
chromosome 3p (Naumann F., et al., 2004). The p20-CGGBP protein, a 166-amino acid 
protein, contains a putative nuclear localization signal. The p20-CGGBP binding was 
severely inhibited by complete or partial methylation of the binding motif. The CGGBP1 
protein exerts an important function that controls the transcription and replication of the 
fragile X mental retardation (FMR1) gene and possibly other genes. The p20-CGGBP 
protein is mapped to human chromosome 3 pter 12- p11.1 (Deissler H., et al., 1997). 
Autonomous expansions of trinucleotide repeats with the general structure (CGG) n are 
associated with several human genetic disorders. The human nuclear 5'-(CGG)(n)-3'-
binding protein (CGGBP1) influences the expression of the fragile X mental retardation 
(FMR1) gene by specifically interacting with the 5'-(CGG)(n>5)-3' repeat in its 5' 
untranslated region. The human CGGBP1 genes, including promoters and large parts of 
the untranslated regions, are highly conserved. A sequence of 235 nucleotides 5' 




Complete in vitro methylation inactivates the promoter, which is unmethylated in human 
cells as shown by bisulfite genomic sequencing (Deissler H., et al., 1997). 
 
4.4.25 Homo sapiens, signal transducer and activator of transcription 3 interacting 
protein 1 (STATIP1) 
Human Elongator complex can exist in two forms: a six-subunit complex, holo-
Elongator, which has histone acetyltransferase activity, directed against histone H3 and 
H4, and a three-subunit core form, which does not have histone acetyltransferase activity 
despite containing the catalytic Elp3 subunit. Elongator is a component of early 
elongation complexes formed in HeLa nuclear extracts and can interact directly with 
RNA polymerase II in solution. Several human homologues of the yeast Elongator 
subunits were identified as subunits of the human Elongator complex, including StIP1 
(STAT-interacting protein 1) and IKAP (IKK complex-associated protein). RNA 
polymerase II (RNAPII) transcription can be reconstituted in vitro with a minimal set of 
general transcription factors, such as TBP, TFIIB, TFIIF, TFIIE, and TFIIH. Each of 
these factors is absolutely required for promoter-specific initiation of transcription under 
most conditions. The human holo-Elongator is a histone acetyltransferase complex, which 
in addition to human ELP3 (hELP3) contains IKAP, human StIP1, human ELP4 (hELP4), 
and two additional proteins as subunits. The identification of IKAP as an Elongator 
subunit suggests a connection between Elongator and human disease. The human 
Elongator complex has the ability to associate with RNAPII both in solution and in 
elongation complexes. The human Elongator complex may serve a role in RNAPII-




identified through its interaction with the transcriptional activator signal transducer and 
activator of transcription 3 (STAT3). STIP1 could be involved in nuclear migration 
during cell division; furthermore it may participate in targeting cytoplasmic dynein to 
microtubule plus ends, thereby playing an essential role in dynein-mediated microtubule 
sliding. It is predominantly found in the cytoplasm and localized to the plus end of 
microtubules (by similarity). Cytosolic paf-ah ib is formed of three subunits of 45 kda 
(alpha), 30 kda (beta) and 29 kda (gamma), whereby the catalytic activity of the enzyme 
resides in the beta and gamma subunits, and the alpha subunit has regulatory activity.  
The preferential association of StIP1 with inactive (i.e., unphosphorylated) Stat3 suggests 
that it may contribute to the regulation of Stat3 activation. Consistent with this possibility, 
StIP1 also exhibits an affinity for members of the Janus kinase family. Overexpression of 
the Stat3-binding domain of StIP1 blocks Stat3 activation, nuclear translocation, and 
Stat3-dependent induction of a reporter gene. These studies indicate that StIP1 regulates 
the ligand-dependent activation of Stat3, potentially by serving as a scaffold protein that 
promotes the interaction between Janus kinases and their Stat3 substrate. The ability of 
StIP1 to associate with several additional members of the signal transducer and activator 
of transcription family suggests that StIP1 may serve a broader role in cytokine-signaling 
events. The ability of IFN-  to rapidly induce new genes led to the identification of the 
signal transducer and activator of transcription (STAT) family of transcription factors. 
Subsequent studies determined that IL-6, as well as all other cytokines, transduce vital 
signals through members of the STAT family. On binding ligand, receptor-associated 
kinases from the Janus kinase (JAK) family become activated. STATs are in turn 




phosphorylation event. Activated STATs are released from the receptor and dimerize. 
These dimers then translocate to the nucleus and bind to members of the interferon-
gamma activation site (GAS) family of enhancers. One member of the STAT family, 
Stat3, has been implicated in a wide range of biological processes including 
nephrogenesis, gliogenesis, hepatogenesis, T cell proliferation, inflammation, and 
oncogenesis. Many of these Stat3-dependent responses are triggered by members of the 
IL-6 family of cytokines, which transduce their signals through a common gp130 receptor 
chain.Some of these molecules potentiate the transcriptional activity of Stat3 whereas 
others antagonize Stat3-dependent signals. Stat3 consists of several conserved domains 
that are important for STAT function, for example DNA binding, linker, Src homology 
2, and transcriptional activation domains. Stat3-Interacting Protein StIP1, StIP1 is a novel 
protein that consists of 12 WD40 repeats. These repeats have been shown to mediate the 
formation of multiprotein complexes that play important roles in the regulation of signal 
transduction, transcription, and targeted proteolysis. Biochemical studies suggest that 
StIP1 may regulate the activation of Stat3 as well as other STATs. The ability of protein 
kinases to change the activation state of substrates has led to their exploitation in 
signaling cascades. Both the number and complexity of kinases has increased markedly 
during the evolution of more complex organisms. In many cases, a single kinase has 
evolved to regulate more than one signaling pathway. To determine whether StIP1 might 
interact with other components of the JAK-STAT signaling cascade, three JAKs that are 
important in IL-6 signaling were evaluated. Not only did these studies confirm an 
interaction with these JAKs, but domain-mapping studies also indicate that they exhibit a 




unphosphorylated Stat3, thus StIP1 may play a role early in the ligand-dependent 
activation of Stat3. Overexpression of StIP1, or StIP1 domains that bind inactive Stat3, 
leads to a block in IL-6-dependent Stat3 activation. Moreover, the affinity of StIP for 
other STATs suggests that it may serve a similar role for other STATs. Furthermore, 
StIP1 functions as a scaffold protein, potentiating the interaction between Stat3 and JAKs. 
Once phosphorylated, Stat3 loses its affinity for StIP1 and dissociates from the receptor 
complex. Evidences are as follows: The interaction between Stat3 and StIP1 depends on 
the phosphorylation state of Stat3. Second, StIP1 exhibits a distinct pattern of affinity for 
the JAK kinases. Third, StIP1 is a cytosolic protein. Fourth, overexpression of StIP1 
domains block IL-6-stimulated Stat3 activation, preventing dimerization/DNA binding, 
nuclear translocation, and the induction of a reporter gene.  
 
4.4.26 Homo sapiens, tropomyosin 1 (alpha) (TPM1) 
Tropomyosins are ubiquitous proteins of 35 to 45 kD associated with the actin 
filaments of myofibrils and stress fibers. In vertebrates, 4 known tropomyosin genes code 
for diverse isoforms that are expressed in a tissue-specific manner and regulated by an 
alternative splicing mechanism (Lees-Miller J.P. and Helfman D.M., 1991). The 
vertebrate alpha-tropomyosin gene consists of 15 exons; 5 exons are found in all 
transcripts, while 10 exons are alternatively used in different alpha-tropomyosin RNAs 
(Lees-Miller J.P. and Helfman D.M., 1991). The striated muscle isoform is expressed in 
both cardiac and skeletal muscle tissues. It is mapped to human chromosome 15q22.1. 
The TPM1 gene is mapped more precisely to 15q22.1 (Tiso N., et al., 1997). 




a helical coiled coil binding to actin in the troponin complex (thin filamant) 
that regulates calcium-dependent binding of actin and myosin and muscle 
contraction. TPM1 is a heterodimer consisting of an alpha and a beta chain. It binds to 
actin filaments in muscle and nonmuscle cells. Furthermore, TPM1 plays a central role, 
in the association with the troponin complex, in the calcium dependent regulation of 
vertebrate striated muscle contraction. Smooth muscle contraction is regulated by 
interaction with caldesmon. In nonmuscle cells is implicated in stabilizing cytoskeleton 
actin filaments. It has unknown molecular, unknown biological process and unknown 
cellular component. It is a structural constituent of muscle that is involved in the 
regulation of muscle contraction. It is involved in the muscle development especially in 
the regulation of the heart. It is part of the cytoskeleton, muscle thin filament 
tropomyosin, and consists of the kinesin complex. actin binding. Defects in TPM1 are 
one of the causes of familial hypertrophic cardiomyopathy (FHC) which is an autosomal 
dominant disorder characterized by increased myocardial mass with myocyte and 
myofibrillar disarray. Familial hypertrophic cardiomyopathy can be caused by mutations 
in the genes for beta cardiac myosin heavy chain, alpha-tropomyosin, or cardiac troponin 
T. Human TPM1 gene is associated with type 3 familial hypertrophic cardiomyopathy 
(CMH3).However, mutations in the TPM1 gene are a rare cause of CMH, accounting for 
approximately 3% of cases(Watkins H., et al., 1995). Familial hypertrophic 
cardiomyopathy is found out to be a disease of the sarcomere as mutations occurring in 
either alpha-tropomyosin, or cardiac troponin T or beta myosin heavy chain will cause 





4.4.27 Homo sapiens, cathepsin H (CTSH), transcript variant 2 
Cathepsin H (CTSH) belongs to the peptidase family C1. Cathepsin H is part of 
the papain superfamily and it is ubiquitously expressed. Furthermore, it is also involved 
in matrix degradation during endochondral ossification Cathespin H is important for the 
overall degradation of proteins in lysosomes. It acts as a catalyst in the hydrolysis of 
proteins, acting as an aminopeptidase (notably, cleaving Arg-|-Xaa bonds) as well as an 
endopeptidase. It is a cysteine-type endopeptidase or also known as a cysteine proteinase. 
It is located in the lysosome. The subunit is composed of a minichain and a large chain. 
The large chain may be split into heavy and light chain. All chains are held together by 
disulfide bonds (Fuchs R. and Gassen H., 1989).  
 
4.4.28  Homo sapiens, GPR6 G protein-coupled receptor gene 
Many cell membrane receptors are members of the G protein-coupled receptor 
family. A variety of extracellular signals are transmitted into cells through integral 
membrane receptors coupled to heterotrimeric G proteins. Such G protein-coupled 
receptors are critical for the normal functions of many cell types: neurons, endocrine cells, 
cardiac and smooth muscle cells, and sensory cells for detection of light, taste, and smell. 
G-protein coupled receptors are receptors which transduce extracellular signals across the 
cell membrane. At the external side they receive a ligand (a photon in case of opsins), and 
at the cytosolic side they activate a guanine nucleotide-binding (G) protein. These 
receptors are hydrophobic proteins characterized by the presence of 7 transmembrane 
domains and numerous conserved amino acids, ie.that cross the membrane seven times. 




found as the cause of human diseases. Song Z.-H., et al., 1995 isolated cosmids 
containing human genes for 3 orphan G protein-coupled receptors, GPR12, GPR6, and 
GPR3. GPR6, has a single exon encoding a putative 362 amino acid protein. GPR6 
belongs to family 1 of G-protein coupled receptors. Gene GPR6 encoded a receptor that 
shared shows close homology (71% similarity in the transmembrane regions) with the 
human orphan receptor GPR3 and was localized to chromosome 6q21 to 6q22.1 (Heiber 
M., et al., 1995). GPR6 transcripts were found to be predominantly expressed and 
abundant in the human putamen. GPR6 is an orphan receptor and located subcellularly as 
an integral membrane protein. GPR6 is involved in the G-protein coupled receptor 
protein signaling pathway ; specifically in G-protein coupled receptor activity.  
 
4.4.29 Homo sapiens, Cell division cycle 42 (CDC42) effector protein (Rho GTPase 
binding) 3 
CDC42, a small Rho GTPase, regulates the formation of F-actin-containing 
structures and the organization of the actin cytoskeleton through its interaction with the 
downstream effector proteins. CDC42 can alter regulation of normal cell growth and 
initiate tumourigenic signals. The protein encoded by this gene is a member of the Borg 
family of CDC42 effector proteins. Borg family proteins contain a CRIB (Cdc42/Rac 
interactive-binding) domain. They bind to, and negatively regulate the function of, 
CDC42. This protein can interact with CDC42, as well as with the ras homolog gene 
family, member Q (ARHQ/TC10). Expression of this protein in fibroblasts has been 
shown to induce pseudopodia formation or more correct known to cause the formation of 




protein).Cdc42 is a member of the p21 Rho family of small GTPases that act downstream 
of cell surface receptors to regulate the formation of different F-actin-containing 
structures. Cdc42 regulates actin polymerization to induce the assembly of filopodia, 
which are thin actin filaments that project from cells. Cdc42 can also regulate other 
biological processes such as cytokinesis and cell polarity. In mammalian cells, Cdc42 
regulates a number of polarized responses, including actin localization, nuclear 
displacement, protein trafficking, and directed cell movement. These studies suggest that 
Cdc42 regulates cell shape and polarity changes by coordinating actin changes with 
altered cell membrane assembly. The ability of Cdc42 to regulate the actin cytoskeleton 
and cell polarity in mammalian cells stems from its interaction with a large number of 
downstream effector proteins. One such effector protein, N-WASP, induces actin 
polymerization leading to filopodia formation. N-WASP mediates these actin changes by 
directly binding actin, the Arp2/3 complex, and by interacting with the actin-binding 
protein profilin. The p21-activated protein kinases (PAK) also mediate actin 
reorganization required for filopodia formation, cell motility, and neurite-outgrowth. 
Unlike N-WASP, PAKs mediate their biological activities by phosphorylating a number 
of cytoskeletal targets. A new family of effector proteins designated CEPs, are made up 
of Cdc42-binding proteins and MSE55. CEPs contain three regions of homology, 
including a Cdc42 binding domain and two unique domains called CI and CII. 
Experimental studies have shown that CEP3, CEP4, and CEP5 in NIH-3T3 fibroblasts 
induced pseudopodia formation. Therefore, CEPs may act downstream of Cdc42 to 
induce actin filament assembly leading to cell shape changes. CEPs might function in 




protrusion. CEPs may also represent targets of other Cdc42-related GTPases that 
normally function in fibroblasts to generate pseudopodia formation rather than filopodia 
formation. Consistent with this model, Cdc42 homologues such as TC10 and TCL 
interact with CRIB-containing proteins in vitro and induce actin structures that are 
distinct from Cdc42. Most importantly, CEPs are found out to be able to induce thin actin 
stress fibers in keratinocytes. From this, CEPs, acting as classical Cdc42 effector 
molecules, may be the ones that increase actin filament assembly to cause cell shape 
changes. This is an important discovery and could be one of the reasons or main players 
involved in the formation of foam cells from macrophages. By understanding this, we 
thus will be able to formulate a method and arrest the formation of foam cells by 














5.1 Overview of the initial results obtained 
The initial detection studies illustrate the presence of the Chlamydia pneumoniae 
being detected in the U937 human macrophages, in the presence of the low density 
lipoprotein which induces the formation of the foam cells. The oil red staining method 
was used to determine the uptake of the low density lipoprotein into the macrophages, 
and thereby inducing the formation of foam cells. The infection ratio adopted in my study 
done was one Chlamydia pneumoniae is to each U937 human macrophage cell. From the 
results obtained, it was noted that the order of the two main stimuli does not matter, as in 
the case of the fourth and fifth model in which either the infection of the Chlamydia 
pneumoniae is done first then followed by the addition of the other stimuli, which is the 
low density lipoprotein. The expression profiles as can be seen for the last two models 
were similar. This allow us to understand that the presence of the two stimuli, Chlamydia 
pneumoniae and low density lipoprotein are important and essential. Thus, with this point 
in mind we can further explore and compare the expression profiles obtained as 
compared to the other models namely models 2 and 3 in which a single stimulus, either 
only Chlamydia pneumoniae is added or low density lipoprotein is added. The difference 
of the expression profiles allows us to identify potential and interesting gene target for 
either for gene therapy or the development of drugs to prevent the expression of the gene 
or drugs to help stimulate the host immune system to counter the negative effects which 
may cause the onset of the disease of atherosclerosis which will lead eventually to heart 
attack. Heart attack is one of the number one killers in developing and developed 




5.2 An in depth look to the Differential Display Reverse Transcription PCR and 
Real Time Semi Quantitative PCR results obtained.  
In our study using the DD RT–PCR strategy, a whole repertoire of known genes 
whose expression profiles were unaltered, up regulated, or downregulated were 
characterized. Out of the whole repertoire, a total of 29 interesting genes were selected 
based on their functional homology hits and its DD RT-PCR expression profiles obtained 
in my five models study; in which the U937 macrophage cells were infected with 
Chlamydia pneumoniae in the presence of low density lipoproteins. The obtained results 
from the series of Differential Display Reverse transcription PCR were subjected to 
computational analysis using the available bioinformatics tools, after which potential 
gene targets were identified. A total of 29 genes were then selected based on the 
interesting expression profiles exhibited. These 29 genes were then subjected to real time 
polymerase chain reaction analysis to fortify our obtained results and also allow one to 
determine the importance of these selected genes. A total of 253 genes that were 
extracted from the differential display reverse transcription polymerase chain reaction, a 
total of 200 showed differential expression, and 53 showed unaltered expression levels. 
Out of the 200 genes, 29 differentially expressed genes that show interesting hits with the 
non redundant database of the NCBI website were selected for further studies. The 
various unique gene expression profiles of the repertoire of genes elucidated from the 
study will provide us with a useful tool or platform in looking at the treatment for the 
disease of atherosclerosis. The variation apparent between genetic backgrounds provides 
insights into the breadth of possible inflammatory responses generated on the five 




Through these, we will be able to categorize them via the general mode of work 
they display. Following which a brief insight into their specific mode of action will no 
doubt able to paint a more wholesome pictorial view of the possible genetic pattern of 
action occurring during the onset of the disease of atherosclerosis in the presence of both 
the Chlamydia pneumoniae and low density lipoprotein. Studies have shown the presence 
and increased levels of the serological levels of the bacterial pathogen, coupled with the 
presence of low density lipoprotein in which the intake or engulfment of the lipids into 
the macrophages will lead to the creation of foam cells. As mentioned earlier in the 
previous section, the accumulation of foam cells will cause the formation of the plaque, 
and thru the rupture of the plaque which cause the hardening of the accumulation. 
 
5.3 Relation of DDRTPCR results with Real Time PCR results 
Atherosclerosis is an inflammatory disease, under favorable conditions, the 
monocytes are able to adhere to the vascular endothelium and accumulate in the lesion-
prone arterial sites facilitated by adhesion molecules. Adherent monocytes differentiated 
into macrophages by modulators of inflammation such as monocyte chemoattractant 
protein 1 and macrophage colony stimulating factor produced by smooth cells. The low 
density lipoproteins undergo oxidation and are taken up by these macrophages to become 
foam cells. This will then in turn activate the local inflammatory response. The sites of 
plaque rupture of atherosclerosis plaque within the coronary arteries are found mainly to 
consist of activated macrophages and smooth muscle cells which seem to be indicative of 
the inflammatory response. Furthermore the quantity of matrix degrading enzymes and 




vulnerability of the plaque which will subsequently rupture and lead to the onset of 
atherosclerosis. This often leads to the end result of myocardial infarction which is fatal. 
DDRTPCR has enabled us to probe and understand the whole range of cellular genetic 
phenomena that occurs between Chlamydia pneumoniae, and U937 cells. Coupled with 
the five study models, a suitable and logical analysis of the differential expression of 
certain genes can be derived, leading to the grouping of the 29 selected bands based on 
the functional study. This set of 29 genes is a small fraction of the entire repertoire of 
cellular gene expression events that occurs in the presence or absence of the bacterial 
pathogen and low density lipoprotein. The results obtained coupled with a through 
understanding of the functions; and the expression patterns compared with the normal 
macrophages and infected foam cells which are formed by the uptake of oxidized low 
density lipoprotein. This could tell us more of the interacting role that the bacterial 
pathogen has to play during the start right up to the onset of the heart attack. Due to the 
slow progressive nature of the onset of the disease, which is fatal once detected, 
molecular tools could be used to check the presence and the various expression profiles 
of the biochemical gene markers. The 29 selected genes provide an interesting picture 
relating to the various mechanisms that the bacterial pathogen seems to partake with 
relation to the atherosclerosis nature. Chlamydia pneumoniae seems to exhibit various 
defensive mechanisms to ensure its survival. The etiological significance of Chlamydia 
pneumoniae in atheromatous lesions can be thus be elucidated, confirming its importance 






Ubiquitination is defined as the inactivation of a protein by the attachment to it of 
ubiquitin. Ubiquitin is a small molecule which acts as a tag by which the protein-
transport machinery ferries a protein to the proteosome for degradation. Ubiquitination 
requires ATP and three different enzymes, an ubiquitin activating enzyme (E1), an 
ubiquitin conjugating enzyme (E2) and an ubiquitin ligase (E3). The process of 
ubiquitation entails the attachment of the ubiquitination conjugate proteins which attaches 
itself to unnecessary proteins and transferred to the proteomesome which breakdown the 
proteins. The presence of Chlamydia pneumoniae in the foam cells appears to have down 
regulatory effect on the expression levels of nuc2, CDC27, CTSH, FLOT1 and HSPC150, 
five of the genes whose primary functions falls to be in this ubiquitination. The down 
regulatory expression profiles prevents the transcription of these proteins, and this in turn   
ensure more macrophages to be produced, and prevent the removal of the existing 
macrophages which will be accumulated at the infected site which in turn will provoke an 
inflammatory response that allows the further development and progression of the plaque. 
nuc2 is a novel cell cycle regulator essential for three events; firstly for exit from the 
mitotic metaphase, secondly for DNA replication restraint under nutrient starvation and 
thirdly for inhibition of septation and cytokinesis until the completion of mitosis 
(Kumada K., et al., 1995). Nuc is a nuclear protein with DNA binding activity, and it 
shows strong similarity to the cdc27 gene. The results shows an increase in the 
expression levels in the model with LDL, but constant expression level for the model 
with Chlamydia pneumoniae and increase in the gene expression level for the last two 
models. These results could denote a transient expression level initially, the duration of 




The presence of an increased amount of dead cells compared to the rest of the 
models may play a role in the up regulated expression, as the cells may find themselves 
in an undesirable environment as the nutrients in the media may be depleted at the end of 
96 hours. The up regulation of nuc2 will ensure the cell cycle to be completed and exited 
from the cell cycle; all the three main functions of nuc2 seems to complement one 
another and contributes to the overall defense mechanism that any particular cells will 
exhibit under undesirable conditions. Cdc27 is mainly a structural component of the 
anaphase promoting complex that controls anaphase initiation and late mitotic events 
(Tugendreich S., et al., 1993). This protein was shown to interact with mitotic checkpoint 
proteins including Mad2, p55CDC and BUBR1, and thus may be involved in controlling 
the timing of mitosis. Cysteine-dependent proteases (Cathepsin) H, is a lysosomal 
cysteine proteinase involved in physiological events such as intracellular protein 
catabolism and prohormone activation. Mature active forms of Cathepsin H are located 
predominantly in lysosomes, where they play an important role in regulating intracellular 
protein degradation and turnover. Furthermore, HSPC150 is a cysteine residue that is 
required for the ubiquitin-thiolester formation. It catalyzes the covalent attachment of 
ubiquitin to other proteins and mainly involved in the second step of Ubiquitin 
conjugation pathway. It belongs to the ubiquitin-conjugating enzyme family (by 
similarity). A significant event characteristic of the event of the progression of the 
atherosclerosis entails the accumulation of macrophages to the site of endothelial 
dysfunction, which will ultimately take up oxidized low density lipoprotein found there 




Foam cells are found to be one of the main constituents of the layer of plaque 
formed which through cycles of plaque rupture and accumulation of new formed foam 
cells, the artery eventually gets closed up and lead to the onset of heart attack. Thus, cell 
proliferation is another important group as this will control the formation of new 
macrophages which will get activated to the site, and results obtained through analysis 
and comparison between the five models of study. The following genes, GDBR1, 
BCL2A1, RPL27a, CDC2, COXII, α- NAC, IRS2, RPC62, STATIP1 and CDC42, are 
categorized into be under this grouping based on the association of the differential 
expression patterns which plays a part in the overall progression of cell proliferation, 
namely, macrophages.  
 
Glialblastoma Cell Differentiation Factor-Related Gene, GBDR1, is an 
intracellular signaling molecule that may play a role in the regulation of endothelial cell 
growth (Li C.Y., et al., 2000). RPC62 is found to be closely associated and related to 
RNA polymerase III. RPC62 forms part of the DNA-directed RNA polymerase III 
complex, involved in the regulation of transcription from Pol III promoter. From the 
results, it shows a distinct increase of genetic expression almost 2 folds, the results thus 
suggests that an increase of RNA polymerase will be then activated. This will help to 
increase the overall amount of protein synthesis occurring, which will eventually 
promotes the proliferation of macrophages, which will be attracted to the site. The 
presence of an increased amount of RPC62 present caused by an increase in the 
expression of the gene; allow the continuous proliferation of macrophages which will 




The main function carried out by RPL27a is to contribute to the structural 
integrity of the ribosome and it is involved mainly in ribosomal binding. The results 
obtained from the DDRTPCR and Real Time PCR results seems to suggest that the 
ribosomal protein synthesis persists up to late times of infection while b-actin synthesis is 
strongly inhibited. This is not due to a selective degradation of some mRNAs because 
ribosomal protein mRNAs appear to be degraded at a rate similar to that of b-actin 
mRNA. In addition, these newly synthesized ribosomal proteins are assembled into 
ribosomes, although their relative rate of incorporation into new ribosomes appears 
somewhat modified. Although such acceleration of ribosome biogenesis still remains to 
be proved, two other conclusions can be drawn from these results. First, there is a 
translational control leading to the persistence of ribosomal protein synthesis, thus 
involving some selectivity in the cellular mRNAs which are translated. This translational 
control probably requires mechanisms different from those allowing translation of 
bacterial mRNA during the shutoff of host cell protein synthesis. A selective re-initiation 
of translation might remain possible after Chlamydia pneumoniae infection for ribosomal 
protein mRNA but not other cellular mRNAs such as b-actin mRNA. The 5´-terminal 
polypyrimidine tract of each ribosomal protein mRNA may be responsible for such a 
translational control. Since ribosome biogenesis persists after infection by Chlamydia 
pneumoniae, viral protein synthesis could take place, at least in part, on these newly 
synthesized and assembled ribosomes. Thus, the relatively constant expression levels of 





CDC42 is a small Rho GTPase that regulates the formation of F-actin-containing 
structures and the organization of the actin cytoskeleton through its interaction with the 
downstream effector proteins. Cdc42 also alters the regulation of normal cell growth and 
initiate tumourigenic signals. In mammalian cells, Cdc42 regulates a number of polarized 
responses, such as actin localization, nuclear displacement, protein trafficking and 
directed cell movement. In this case, from the DDRTPCR results, one of the genes of 
interest appears to be the CEP3 which belongs to the new family of effector proteins 
designated CEPs, that are made up of Cdc42-binding proteins and MSE55. CEPs contain 
three regions of homology, including a Cdc42 binding domain and two unique domains 
called CI and CII. Firstly, CEPs may act downstream of Cdc42 gene to induce actin 
filament assembly leading to cell shape changes. Secondly, CEPs might function in 
fibroblasts at specific membrane sites resulting in a net effect of directed membrane 
protrusion. Lastly, CEPs may also represent targets of other Cdc42-related GTPases that 
normally function in fibroblasts to generate pseudopodia formation rather than filopodia 
formation. The Rho-GTPases mediate signaling pathways that regulates various cellular 
activities such as gene expression, cell cycle progression and cytoskeletal organization 
(Van Aelst and D’Souza-Schorey, 1997). The up regulation of effectors proteins of cdc42 
during the infection process signifies the importance and its main role in contributing to 
the onset of atherosclerosis. cdc2 is involved mainly in the M-phase entry which is the 
second mitotic checkpoint. cdc2 is a catalytic subunit of a protein kinase complex, called 





It plays a key role in the control of the eukaryotic cell cycle and is required in 
higher cells for entry into S-phase and mitosis. The cdc2 gene produces p34cdc2, which is 
a serine-threonine protein kinase that complexes with cyclin to form the M phase 
promoting factor (MPF) component. Chromosomal condensation, cytoskeletal 
reorganization, nuclear envelope breakdown and cell shape changes are the cellular 
events have been associated with the onset of the protein kinase activity of the cdc2 
product. Each of these events is clearly required for cell division to occur. Furthermore, 
the substrates of the p34cdc2 protein kinase are proteins involved in the maintenance of the 
cell in the G2-phase. The phosphorylation of these proteins may change their functions 
and permit the cell to enter the M-phase. The key substrates of p34cdc2 protein kinase are 
firstly, histone (H1) in which the phosphorylation of this protein may be important for 
chromosomal condensation to occur. Secondly, centrosomal proteins which are 
associated with centrioles that are the organizing center of the cell for microtubules 
associated with the cytoskeleton. Thirdly, the phosphorylation of the mitotic-specific sites 
of p60src may influence the cytoskeleton and lead to changes in the cell shape. Lastly, the 
key substrates includes lamin, associated with the nuclear envelope, and other DNA 
binding proteins that need to be released for chromosomal condensation to occur. The 
presence of an up regulation of the expression profile shown in the various models 
throughout provides us with an insight pertaining to our five models treatment study. This 
is because, similar to the mode of the action of that of cdc42, the up regulation of cdc2 
will allows the increase in the cell proliferation, which is beneficial to the Chlamydia 





Cdc2 catalyzes the phosphorylation of the Bcl2 antagonist of cell death protein, 
(BAD) at a distinct site, ser128, and thereby induces BAD-mediated apoptosis by 
opposing growth factor inhibition of the apoptotic effect of BAD. Phosphorylation of 
BAD ser128 was found to inhibit the interaction of growth factor-induced ser136-
phosphorylated BAD with 14-3-3 proteins (Konishi Y., et al., 2002). A novel Bcl2-
binding protein, termed Bad for 'Bcl2 antagonist of cell death.' Bad heterodimerized 
strongly with BclX, less strongly to Bcl2, and did not bind to other members of the 
family. At similar levels of expression for BclX and Bcl2, Bad was found to counter the 
death repressor activity of BclX, but not that of Bcl2. Functional studies revealed that 
when Bad dimerized with BclX, it displaced Bax and restored its apoptosis-inducing 
ability. Bad may influence the effectiveness of Bcl2 versus BclX in repressing cell death 
(Yang E., et al., 1995). BCL2 associates in vivo with a 21-kD program partner, BAX. 
BAX shows extensive amino acid homology with BCL2 and forms homodimers and 
heterodimers with BCL2 in vivo. When BAX predominates, programmed cell death is 
accelerated, and the death repressor activity of BCL2 is countered. The ratio of BCL2 to 
BAX determines survival or death following an apoptotic stimulus (Oltavi Z.N., et al., 
1993). BAX is a primary-response gene for p53 and is involved in a p53-regulated 
pathway for induction of apoptosis (Miyashita and Reed J.C., 1995).  The gene 
expression levels of the BCL2A1 gene in the results obtained from my experiments 
denotes a distinct up regulation, especially in the last two models in which both 
Chlamydia pneumoniae and low density lipoproteins are present. This is an interesting 
observation as BCL2 acts by retarding the onset of apoptosis; as such, this will lead to an 




Development as well as maintenance of many adult tissues is achieved by several 
dynamically regulated processes that include cell proliferation, differentiation, and 
programmed cell death. BCL2 is one such mammalian gene that has been identified; 
which functions as a repressor of programmed cell death. Human mutant cell lines can be 
protected from apoptosis by the overexpression of BCL2 (Jacobson M. D., et al., 1993). 
BCL2 acts by inhibiting cell loss by apoptosis (programmed cell death) rather than by 
stimulating cell production. BCL2 regulates a caspase activation program independently 
of the cytochrome c/APAF1/caspase-9 apoptosome; which means that the cell death 
pathway controlled by BCL2 does not require caspase-9 or its activator APAF1. This 
apoptosome seems to amplify rather than initiate the caspase cascade (Marsden V. S., et 
al., 2002).The A1 protein, a member of the BCL2 family of apoptosis regulators by the 
predicted protein sequence, although regulated differently from BCL2, has similar 
antiapoptotic activity (Lin E.Y., et al., 1993). The NAC complex at the ribosome protects 
nascent polypeptides from premature interactions with cytosolic proteins.  The complex 
inhibits the binding of ribosomes that translate non-secretory proteins to translocation 
sites in the membrane of the endoplasmic reticulum. NAC releases the nascent chain 
when binding for cytosolic proteins such as the signal recognition particle (SRP) or 
chaperones is completed.  α-NAC plays a role in preventing nascent polypeptides from 
binding inappropriately to membrane-targeting apparatus during translation, but is also 
active as a transcription regulator. α-NAC is found to be a transcriptional co-activator 
[Yotov et al., 1998]; and it enhances the activity of the homodimeric c-Jun activator to 




The down regulation of α-NAC prevents the onset of apoptosis which it is 
associated with and this ensures the survival of the existing foam cells at the infected site. 
Studies have reported that the process of atherosclerosis is an inflammatory response, 
which releases cytokines which provokes the onset of the inflammatory response that 
initiates chemoattractants that entices the influx of macrophages to the site of which the 
macrophages will be transformed into foam cells after the uptake of the oxidized low 
density lipoproteins. The genes are differentially expressed and fall under in this category 
are ATP6V0E, HCA58, BLAME, PPP2R2B, C1QBP, GPR6 and similar to IK cytokine.  
 
B lymphocyte activator macrophage expressed (BLAME) is a novel cell surface 
protein member of the CD2 family. The CD2 family is a growing family of Ig domain-
containing cell surface proteins involved in lymphocyte activation. Members of the CD2 
family are a subset of the Ig superfamily which functions as co receptors for lymphocyte 
activation and/or adhesion.  Henceforth, BLAME expression could be modulating the 
signal through the B cell receptor complex by binding to a presumed receptor on B cells 
and acting as a costimulator or an adhesion molecule. Although overexpression of a cell 
surface gene may lead to constitutive signaling, without the necessity of interaction with a 
ligand/coreceptor, this seems unlikely in this case because BLAME does not contain the 
signaling motifs usually used by this family. However, BLAME may associate itself with 
another chain that does contain a signaling domain. A specific example would be that 
BLAME has been postulated to be the ligand for either of these two genes, CD84 and Ly-
9, or for a novel CD2 family member. CD84 and Ly-9 are expressed on B cells and 




An up regulation of the expression of BLAME, with relation to its primary 
function and due to the presence of a large quantity of B cells (macrophages) at the 
infected site, an up regulation of BLAME correlates with the results obtained in our study. 
Vacuolar H_-ATPases (V-ATPases) are highly conserved proton pumps that couple 
hydrolysis of cytosolic ATP to proton transport out of the cytosol. The vacuolar (H+)-
ATPases (or V-ATPases) function in the acidification of intracellular compartments, 
vacuolar system, in eukaryotic cells. V-ATPase dependent organelle acidification is 
necessary for such intracellular processes as protein sorting, zymogen activation, and 
receptor-mediated endocytosis. They are essential for the normal function of secretory 
vesicles, the trans-Golgi network, endosomes, lysosomes, the yeast vacuole, and other 
intracellular membrane compartments. Interestingly, V-ATPases are found to partake an 
important role in the infectivity and pathogenicity of HIV. CD4 is the primary receptor 
for the human immunodeficiency virus (HIV). Nef is an accessory protein of human and 
simian immunodeficiency viruses (HIV and SIV) that is required for efficient viral 
infectivity and pathogenicity. It decreases the expression of CD4 on the surface of 
infected cells. Nef is a 27-35-kDa myristoylated, membrane-associated protein encoded 
by primate lentiviruses (HIV-1, HIV-2 and SIV). It is expressed abundantly early in the 
viral replicative cycle. Nef plays a critical role in viral pathogenesis and promotes the 
progression to AIDS. In cell culture Nef enhances virion infectivity in a single round of 
replication. It also increases viral spread in some primary cell systems, in particular in co-
cultures of immature dendritic cells with T cells. The mechanism of action of Nef, 




By interacting with molecules associated with the T cell antigen receptor, Nef 
activates infected cells. Nef also decreases the expression of class I major 
histocompatibility complex determinants on the cell surface, thus protecting infected cells 
from cytotoxic T cells. Finally, Nef internalizes CD4, which is the major receptor for HIV 
and SIV, thus preventing the super infection of infected cells and interference with virus 
release and infectivity. Because CD4 is also critical for host immune responses, its 
absence on infected cells could contribute to the pathogenesis of AIDS. The ATP6V0E 
gene could exhibit a similar mode of action as that of which it takes in the HIV virus in 
our interaction of Chlamydia pneumoniae and U937 macrophages and/or with low 
lipoprotein. 
 
In order to ensure its survival of the bacterial pathogen, Chlamydia pneumoniae in 
my case, the bacterial pathogen will have to find various means and ways of avoiding the 
host removal of itself either physically or by the immune response triggered as the first 
line of defense that each and every host possess. A unique insight to the mechanism of 
escape from immuno recognition, or the shutting down of the humoral response can be 
obtained by the understanding of the HLA class II gene regulation by the effects of the IK 
cytokine. Furthermore, the IK cytokine gene expression profile obtained thru the series of 
experiments conducted may complete the picture of the events occurring in the human 
body, focusing on the mechanism of the immune responses generated by the infection of 
Chlamydia pneumoniae, in the presence of low density lipoproteins. By pursuing this 
mode of action, the bacterial pathogen, Chlamydia pneumoniae may ensure its survival 




The role of HLA class II antigens in the control of the immune response is 
determined not only by the genetic polymorphism of these molecules, but also by their 
density on the cell surface. The protein, IK cytokine (down-regulator of HLA II), 
encoded by this gene was identified by its RED repeat, a stretch of repeated arginine, 
glutamic acid and aspartic acid residues. The protein localizes to discrete dots within the 
nucleus, excluding the nucleolus. Its function is unknown. This gene maps to 
chromosome 5; however, a pseudogene may exist on chromosome 2. . The characteristics 
of RED and its nuclear localization implicate it as a regulatory protein, possibly involved 
in transcription. IK is a molecule implicated, via HLA class II down regulation, in vitro 
CD34+ progenitor proliferation and differentiation. According to the traditional view of 
autocrine or paracrine cytokine binding, fixation of the ligand to its extracellular receptor 
induces a cascade of downstream transduction signals responsible for activation of 
transcription factors and subsequent mitogenic responses. IK acts on CD34+ progenitor 
differentiation by a synergistic or agonistic effect with exogenous growth factors. 
Hepatocellular carcinoma-associated antigen 58 could function as a possible transcription 
factor. Autoantibodies are often detected in hepatocellular carcinoma (HCC), and these 
responses may represent recognition of tumor Ags that are associated with transformation 
events. HCA58 was identified to be expressed in colon and ovarian cancer cell lines but 
not in the normal tissue counterparts. In addition, abundant expression of complement 
inactivation factors was found in HCC. These results indicate a broad range expression of 
autoantigens in various organs and tissues of HCC patients, which then suggest an 
involvement of the study of autoantigens in the transformation, metastasis, and immune 




G protein-coupled receptor 6 (GPR6), has a single exon encoding a putative 362 
amino acid protein, belongs to family 1 of G-protein coupled receptors. GPR6 is an 
orphan receptor and located as an integral membrane protein; and most importantly, 
GPR6 is involved in the G-protein coupled receptor protein signaling pathway; 
specifically in G-protein coupled receptor activity (Heiber M., et al., 1995; Song, Z.-H., 
et al., 1995). G protein coupled activity is important, as it plays a part in the initial 
adherence of to the cell membrane and the onset of the cell proliferation pathway, cells 
must be adhered properly to the cell membrane before activation of the cell growth. 
Phosphoprotein phosphatases comprise a large family of enzymes that hydrolyze the 
phosphoester bonds of phosphoserines, phosphothreonines or phosphotyrosines. While 
many phosphatases inhibit the activities of phosphorylation cascades, some activate them. 
The tyrosine phosphatase CD45, for example, activates Src family tyrosine kinases by 
dephosphorylating an inhibitory phosphotyrosine residue (Mayer R. E., et al., 1991). 
Phosphoserine/threonine phosphatases comprise two gene families of metallo-enzymes: 
phosphoprotein phosphatase P (PPP) family and phosphoprotein phosphatase M family 
(PPM). Its diverse functions in the cell are determined by its association with a highly 
variable regulatory and targeting B subunit.  These results suggest that these B subunits 
share a common core structure and mode of interaction with the PP2A holoenzyme (Zhao 
Y., et al 1997). Complement component 1, Q subcomponent binding protein (C1QBP) is 
described as, mitochondrial precursor (Glycoprotein gC1qBP) (GC1q-R protein) 
(Hyaluronan-binding protein 1) (p32) (p33).The human complement subcomponent C1q 
associates with C1r and C1s in order to yield the first component of the serum 




heads of C1q molecules and inhibit C1 activation (Ghebrehiwet B., et al., 1994). 
Complement activation not only causes cell lysis, but other effects as well. Some of these 
include: contraction of smooth muscle, release of histamine from mast cells and platelets, 
enhanced phagocytosis, chemotaxis of phagocytes, and activation of lymphocytes and 
macrophages. The cellular responses of neutrophils and monocytes to C5a include (1) 
degranulation and lysosomal enzyme release; cell adherence, and chemotactic migration. 
The acute inflammatory response is characterized by symptoms of redness, pain, 
swelling, and heat due to the action of C4a, C3a, C5a, and histamine. Inflammation's 
primary goal is to set into motion a series of events that result in the elimination of 
foreign and damaged cells. This response can be mediated by the anaphylatoxins and 
their byproducts. Thus, without the expression of the C1QBP which activates the 
classical complement pathway, this will prevent or reduce the onset of the response 
which will eliminate the foreign particle (Chlamydia pneumoniae) and damaged cells that 
could be caused by plaque rupture. Without the removal of the damaged cells, the 
macrophages or foam cells will eventually remain at the infected site which in turn makes 
up the main bulk of the plaque formation. The intact endothelium provides a continuous 
boundary covering the vasculature, and characteristics by tight junctions which restricts 
the movement of macromolecules. There is also the presence of a complex micro 
vesicular system comprising caveolae and beaded transcellular channels. It is through this 
system that macromolecules such as LDL are believed to be transported from the blood to 






Vulnerable plaques tend to have thin fibrous caps, a high ratio of inflammatory 
cells to VSMCs in the fibrous cap, a lipid core that occupies more than 50% of the 
volume of the plaque, and high tissue content. Plaques that contain a heavy inflammatory 
cell infiltrate are at highest risk of rupture. Inflammatory cells act synergistically to 
promote plaque rupture by a number of different mechanisms. First, activated T-cells 
produce proinflammatory cytokines, which inhibits VSMC proliferation and shut down 
collagen synthesis. Thus VSMCs in the vicinity of activated T-cells in plaques are poorly 
able to lay down or repair extracellular matrix. Several genes associated with the 
structural proteins are found to be down regulated. These structural proteins are TUBE1, 
TPM1, ACTG1 and FLOT1. Flotillin 1 (FLOT1) was found to be a close homologue of 
ESA (also known as flotillin-2), and both belong to a new family of integral membrane 
proteins in caveolae. Flotillin and ESA are resident components of caveolae due to 
detection of the peptides in caveolin-rich membrane domains. Firstly, Flotillin(FLOT1) 
and ESA (FLOT2) may contribute to the structure of caveolae like caveolin. Caveolin 
monomers assemble into homo-oligomers that pack side-by-side to form a scaffold onto 
which signaling molecules can attach. The caveolin scaffold would then provide a 
mechanism for organizing these signaling molecules and sequestering them in a given 
functional state. Flotillin(FLOT1) and ESA (FLOT2) may be structural components of 
this scaffold or may form the backbone of a distinct part of the caveolae architecture, e.g. 
the caveolar neck. Secondly, Flotillin(FLOT1) and ESA (FLOT2) may participate in 
signaling, either as receptors or as membrane-bound effectors. Flotillin(FLOT1) and ESA 
(FLOT2) share a conserved tyrosine phosphorylation site. ESA (FLOT2) could function 




This hypothesis is based upon the ability of the ECS-1 monoclonal antibody to 
cause cell detachment when it is added to intact cultured keratinocytes. Thus, being in the 
same grouping, flotillin 1 (FLOT1) could also play a role in cell adhesion. Finally, 
Flotillin (FLOT1) and ESA (FLOT2) may cooperate to execute a coordinated function. 
The lateral association of lipids in the plasma membrane of mammalian cells is to form 
lipid micro domains. Another two important genes are found to be involved can be those 
that found to be components of the protein translation and modification. These are the 
IF2 and EEF1A1 genes. The human translation initiation factor 2 (IF2) or also known 
KIAA0741 contains 3 motifs characteristic of GTP-binding proteins and has long N-
terminal poly-glu and poly-lys stretches. An intact GTP-binding domain is required for 
translation promotion (Lee J. H., et al., 1999). IF2 catalyzes the first regulated step of 
protein synthesis initiation, promoting the binding of the initiator tRNA to 40S ribosomal 
subunits. IF2 contains an EFTU GTP-binding domain in which it is involved in 
polypeptide synthesis as it binds to charged tRNAs. The main function is to position the 
initiator methionine tRNA on the start codon of the mRNA in association with the 40S 
ribosomal subunit and GTP so that translation initiates accurately. It functions in general 
translation initiation by promoting the binding of the formylmethionine-tRNA to 
ribosomes. IF2 seems to function along with eIF-2. (Nagase T., et al., 1998). As 
mentioned the other gene that is classified under this grouping would be the EEF1A1. 
Elongation factor 1 alpha is one of the genes activated in human melanoma cells by the 
tumor-promoting phorbol ester. Phorbol ester induction will result in a 3- to 5-fold 
increase in cytoplasmic elongation factor 1 alpha mRNA. The alpha subunit of elongation 




During the process, GTP is hydrolyzed into GDP. EEF1A promotes the GTP-dependent 
binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.  
  
Lastly, two genes that are found to be of miscellaneous functions or no specific 
unique functions belongs to the Homo sapiens cyclic AMP phosphoprotein, 19 kD 
(ARPP-19), and Homo sapiens trinucleotide repeat DNA binding protein p20-CGGBP 
(CGGBP)gene. Phosphoproteins may act as intracellular messengers in the central 
nervous system. Receptor-mediated phosphorylation and dephosphorylation of such 
proteins are important for the regulation of neuronal function. ARPP19 is a splice variant 
of ARPP16. The main functions of cyclic AMP phosphoprotein include intracellular 
signal transduction, as a transcription factor, and lastly involved in apoptosis. ARPP-19 is 
found to be involved in cell growth, maintenance and metabolism; positive regulation of 
gluconeogenesis. CGGBP1 is bound to 5'-(CGG) (n)-3'-repeats in vitro with n equal to or 
greater than 5. The CGGBP1 protein exerts an important function that controls the 
transcription and replication of the fragile X mental retardation (FMR1) gene and 
possibly other genes. The p20-CGGBP protein is mapped to human chromosome 3 pter 
12- p11.1 (Deissler H., et al., 1997). A sequence of 235 nucleotides 5' upstream of 
CGGBP1 is essential for promoter activity in transfection experiments. Complete in vitro 
methylation inactivates the promoter, which is unmethylated in human cells as shown by 






The three possibilities that Chlamydia pneumoniae can act in the event of 
atherosclerosis; firstly, the organism could persists in vascular cells but does not 
contribute to pathologic abnormality. Secondly, the organism may cause the initial injury 
and induces the atherosclerotic process, or lastly it can accelerates the severity or 
progression of the disease. The data obtained from the DDRT PCR experiments done has 
shown control, exerted by the presence of Chlamydia pneumoniae and treatment of low 
density lipoproteins, in the various functions that were up regulated or down regulated in 
relation to the series of early events of lesion development. The early events in lesion 
development includes endothelial injury or activation resulting in monocytes/macrophage 
adherence to the endothelium, migration to the sub endothelium, uptake of oxidized low 
density lipoproteins transforming them into foam cells, and release of cytokines. The 
released cytokines could up regulate endothelial cell adhesion molecules leading to 
increased leukocytes adhesion. Platelet aggregation at the site of the endothelial damage 
results in the release of platelet derived growth factor, which stimulates smooth muscle 
cell proliferation. A cascade of interplay of major biochemical pathways could be 
affected, thus which we know are regulated by protein products which are expressed as a 
result of “switching” on of the genes respectively. The relevance of the results towards 
the early events is no doubt a small stepping stone for identifying potential gene targets 
for primary prevention and potential checkpoint indicators which we can use to monitor 
and administer appropriate treatment s early as possible. The results illustrated here are 
just a small subset of the possible large repertoire of genes affected by the presence of 
both the bacterial pathogen Chlamydia pneumoniae and low density lipoproteins which 




With the elucidation of the human genome projects and the various advances in 
molecular techniques and bioinformatics tools, one common strategy adopted by many is 
to investigate at the various events occurring at the basic molecular level between the 
various players identified to take part in any clinical significant events. The results depict 
small instances of interaction and control exerted by the bacterial pathogen towards the 
initiation or progression of atherosclerosis. LightCycler (Roche Diagnostics, Germany) 
combines rapid amplification and sequence-specific detection of amplicons in an 
automated and standardized format. The real time PCR results depicted in the earlier 
section had been tabulated in terms of the number of fold difference will no doubt allow 
further studies done, especially on genes which are reported to be down or up regulated 
respectively. For those genes which show relatively no change in expression levels could 
also be potential candidates as this signals that these genes are important to both 
uninfected and infected cells, the role which they partake could be a key to a further in 
depth understanding. The challenge is to understand and identify, through rigorous 
scientific investigation, at the molecular level of the potential genes which can carry the 
promise of real benefit in the treatment and prevention of congestive heart failure and 
cardiovascular disease, atherosclerosis in particular, which will lead to heart attacks 
which are the number one killer in many countries in the world. Furthermore, some of the 
genes derived shows no significant homology hits to the NCBI database or are not 
investigated in detail, as the results of these in addition to those that are shown in the 






5.4 Future Directions and considerations 
Future directions could be hinged upon two main considerations; firstly, a 
combination of morphological and physiological information may allow us to improve 
sensitivity in early atherosclerosis or in the assessment of therapeutic intervention. 
Secondly, this is the identification of unstable plaques to allow for risk stratification with 
respect to life threatening adverse cardiac events such as acute myocardial infarction. 
Micro array studies and further proteomics studies could be carried out to provide more 
insight to the study. Armed with a better grasp of the technological advances, we can able 
to use of molecular techniques and lead to gene informed therapy. Gene informed therapy 
will have its pros and cons, we can use this to identify significant early markers which we 
can use for prevention studies. Prevention is always better than cure so we can use what 
is presently available to us and utilize the full potential of this tool.  The main scientific 
and technological advances that have increased our ability to act so as to influence 
biology and explore in depth the various pathogenesis of diseases that have badgered 
mankind for the last millennium. Genetic engineering,  the transfer genes from one 
organism to another, would permit the genetic use of any living being to express part of 
the genetic program of another being, once tools had been created that could cut DNA, 
separate the genes, amplify them, determine their sequence and transfer them at will from 
one organism to another. The ultimate prize — that is, a world without cancer, without 
viral disease, without parasitic infestation and without bacterial infection — is probably 





We will have to accept that human vulnerability to disease is in fact part of the 
human condition. decoding the human genome will make it possible to predict the 
biological susceptibility of individuals to developing specific diseases, and thus to 
implement truly preventative medicine. The gene conferring susceptibility for this 
disorder is found in about one person in ten, and the disease itself strikes about one 
person in four hundred. If the genetic abnormality responsible for the condition can be 
detected even before the individual is affected, it is possible to prevent this overload of 
iron developing and therefore prevent the onset of symptoms: as the blood contains a 
high level of iron, all the person has to do to avoid the onset of hemochromatosis is to 
donate blood regularly. The purpose of science is to confirm the truth of phenomena and 
this leads onto the development of techniques and the valuation of their effects. However, 
science in itself cannot claim to decide what should be done, and in any case, is not 
capable of doing so. The question of how to use the power conferred by knowledge faces 
a being who claims to be free. This freedom to choose implies that all human power can 
be used to benefit or harm other. The potential genes of interest have been extracted by 
the methods proposed. This study supports the hypothesis that intracellular infection with 
Chlamydia pneumoniae may relate to the severity of atherosclerosis in some subjects.  
 
The challenge ahead is tough and arduous as we have increase the understanding 
of how the various parts of the immune system work together. This may require a new, 
integrated-systems approach to the problem of host defense against microbial pathogens, 
especially if infection with Chlamydia pneumoniae is added to the list of risk factors for 




measure in the prevention of atherosclerosis; which is the main cause of death in many 
parts of ASEAN, United States of America and the rest of the world. Inflammation due to 
infection taking place distantly may contribute to local pathology through cytokine 
secretion. The infectious agents are not sufficient causes of atherosclerosis. They act in 
concert with the known risk factors, such as heredity, smoking, diet, hypertension, etc. 
Moreover, in vitro and in vivo experiments provide possible pathophysiological 
mechanisms for the enhancement by Chlamydia pneumoniae of local lipid deposition and 
suggestive data for interaction between Chlamydia pneumoniae and other risk factors 
have been developed.  
 
There are three possibilities that Chlamydia pneumoniae can act in. The organism 
1) persists in vascular cells but does not contribute to pathologic abnormality, 2) causes 
the initial injury and induces the atherosclerotic process, or 3) accelerates the severity or 
progression of the disease. If the organism is involved, its role must fit within the context 
of events in atherogenesis. The early events in lesion development include endothelial 
injury or activation resulting in monocyte/macrophage adherence to the endothelium, 
migration to the sub endothelium, uptake of oxidized low-density lipoproteins 
transforming them into foam cells, and release of cytokines. These cytokines up regulate 
endothelial cell adhesion molecules leading to increased leukocyte adhesion. Platelet 
aggregation at the site of endothelial damage results in the release of platelet-derived 





Along with the recent technological advances, this had enabled the generation of 
data; increasing amount of evidence associating the linkage of Chlamydia pneumoniae 
infection with atherosclerosis. The focus of my study was with the ultimate goal of 
identifying and analyzing of which are the important genes that are behind the master 
play of the whole relationship; thus a probable insight to the exact mechanism of how 
Chlamydia pneumoniae enters the arterial wall. Following the knowledge gained from 
this insight, the data is further verified by latest technologies such as real time 
polymerase chain reactions and so on. This no doubt will set the stage whereby the key 
players will be selected and further work could be done to elucidate and form reasoning 
to which will reduce the amount of deaths resulting from heart attack, as in prevention or 
stop the condition of atherosclerosis. Confounding variables such as other cardiovascular 
risk factors should be controlled in order to strengthen the association. Further 
interventional studies are also required to establish the best antibiotic or antiviral regimen 
that will maximize efficacy and minimize adverse effects. This may prove the need of 
reducing or minimizing the effect of the bacteria Chlamydia pneumoniae. Thus through 
the study conducted may spark of an interest in the understanding of the essential genes 
that comes into play, as we will be able to invent or come up with new weapons in our 
ever growing arsenal against those deadly disease killers.  
 
In this genome era, the current challenges are many, for example, to understand 
the evolutionary history of bacterium; and we can identify the unique genes which often 
associated with unique functions. There will always be the need to identify the conserved 




the metabolism, physiology and lifestyle of the organism helps to allow one to design 
therapeutic drugs and target the weaknesses of the infection process. One of the main 
concern and objectives of my research study was to open up new and novel strategies in 
controlling or total eradication of diseases or at least allow new ways to control bacterial 
pathogens such as Chlamydia pneumoniae, which in our case is reputed to be closely 
associated with the onset of the event of atherosclerosis and thereby controlling and 
preventing the outbreak of diseases.  
 
One of the modern day challenges is to regulate the bacterial biological functions. 
The trend to look for molecular signatures will grow as genomics, proteomics, and DNA 
micro array technology mature. The overall research wills emphasis on the elucidation of 
the various molecular mechanisms of chlamydial pathogenesis. In which much focus is 
garnered on the various genes as stated in the discussion and its unique expression levels 
as shown during the process of infection. This stimulates an in vitro environment similar 
to the commonly seen in vivo model, atherogenesis in human beings. With these 
information found, one can proceed onwards in this directions to understand the various 
proteins that are produced and necessary for the diseased condition. This no doubt will 
add greater tools and knowledge for us in the long road ahead of completely subduing 
this disease, atherosclerosis. Infectious diseases are one of the leading causes of death in 
the world. This major medical concern is due to the continual emergence of new 
infectious diseases and reemergence of old pathogens, together with an increasing 




The generation of new anti-infective agents for resolving these medical problems 
has emerged as an urgent issue in modern medicine. The availability of genome 
sequences, coupled with the development of various high-throughput techniques and 
computational tools allow one to have new and possible integrative strategies for 
understanding the interplay between microbial pathogens and their hosts (infectomics). 
This will allow us the understanding of the importance of the pathogens and their hosts, 
which often results in the onset of infectious diseases. Both microbial and host 
infectomes, provide one with immense source of avenues in the long and arduous search 
for novel antimicrobial therapies. There are several major issues in the discovery and 
development of new drugs, from target discovery and validation to animal models and 
clinical trials. Such major issues could be settled if an in depth understanding of the 
interaction of the microbial pathogens and the hosts is at hand, highly effective routes of 
remedies or preventive measures could be deployed at the earlier stages before the 
condition worsens. However, infectomic approaches integrating genomics and 
proteomics. Recent advances in chemical, genomics and proteomics have no doubt 
revolutionized drug discovery research, as multiple genomic targets could be identified or 
serves as indication beacons which able to pre warn the clinicians and doctors of the 
emerging risk or potential leading to the onset of the diseased state, which is 
atherosclerosis in this research study conducted. The identification of small-molecule 
modulators of biological functions that are usually executed by large molecules (DNAs, 
RNAs, proteins and polysaccharides), and the process of transforming these into high-












Apfalter P., Loidl M., Nadrchal R., Makristathis A., Rotter M., Bergmann M., Polterauer 
P., Hirschl A.M., 2000. Isolation and Continuous Growth of Chlamydia pneumoniae 
from Arterectomy Specimens Eur J Clin Microbiol Infect Dis,19 :305–308 
 
Apfalter P., Blasi F., Boman J., Gaydos C.A., Kundi M., Maass M., Makristathis A, 
Meijer A, Nadrchal R., Persson K., Rotter M.L., Tong C.Y., Stanek G, Hirschl AM., 
2001. Multicenter comparison trial of DNA extraction methods and PCR assays for 
detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol 
39:519.524 
 
Agnello, V.; Abel, G.; Elfahal, M.; Knight, G. B.; Zhang, Q.-X., 1999. Hepatitis C virus 
and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Nat. 
Acad.Sci.96:12766-12771.  
 
Baumann, C. A.; Ribon, V.; Kanzaki, M.; Thurmond, D. C.; Mora, S.; Shigematsu, S.; 
Bickel, P. E.; Pessin, J. E.; Saltiel, A. R., 2000. CAP defines a second signalling pathway 
required for insulin-stimulated glucose transport. Nature 407: 202-207.  
 
Bauriedel G., Andrie R., Likungu J.A., Welz A., Braun P., Welsch U., Luderitz B.,  , 
1999Persistence of Chlamydia pneumoniae in coronary plaque tissue: a contribution to 
the infection and immune hypothesis concerning unstable angina. Deutsche Medizinische 
Wochenschrift; 124,47: 1408-1413. 
 
Berenson Gs, Radhakrishnamurthy B, Srinivasan SR, Vijayagopal P. 1986. Arterial wall 
proteoglycans- biologic properties related to pathogenesis of atherosclerosis. 
Atherosclerosis; VII N.H. Fidge and Nestel editors. 
 
Bickel, P. E.; Scherer, P. E.; Schnitzer, J. E.; Oh, P.; Lisanti, M. P.; Lodish, H. F., 1997. 
Flotillin and epidermal surface antigen define a new family of caveolae-associated 
integral membrane proteins. J. Biol. Chem. 272: 13793-13802.  
 
Blasi F., Boman J., Esposito G., Melissano G., Chiesa R., Cosentini R., Tarsia P., 
Tshomba Y., Betti M., Alessi M., Morelli N., Allegra L., 1999. Chlamydia pneumoniae 
DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. 
Journal of Infectious Diseases, Vol 180, Iss 6, pp 2074-2076.  
 
Bobryshev Y.V., Cao W.P., Phoon M.C., Tran D., Chow V.T.K., Lord R.S.A., Lu J., 
2004. Detection of Chlamydophila pneumoniae in dendritic cells in atherosclerotic 
lesions. Atherosclerosis 173:185-195. 
 
Boman, J., C. A. Gaydos, and T. C. Quinn. 1999. Molecular diagnosis of Chlamydia 





Boman J, Gaydos CA. 2000.Polymerase chain reaction detection of Chlamydia 
pneumoniae in circulating white blood cells. J Infect Dis.;181:S452-S454. 
 
Boman J., Hammerschlag M.R. 2002. Chlamydia pneumoniae and Atherosclerosis: 
Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies. Clin 
Microbiol Rev, 15(1):1-20. 
 
Bouillet, P.; Adams, J. M.; Strasser, A., 2002. Apoptosis initiated by Bcl-2-regulated 
caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. 
Nature419:634-637.  
 
Brands, J. H. G. M.; Maassen, J. A.; Van Hemert, F. J.; Amons, R.; Moller, W., 1986. 
The primary structure of the alpha subunit of human elongation factor 1: structural 
aspects of guanine-nucleotide-binding sites. Europ. J. Biochem. 155: 167-171.  
  
Burks, D. J.; Font de Mora, J.; Schubert, M.; Withers, D. J.; Myers, M. G.; Towery, H. H.; 
Altamuro, S. L.; Flint, C. L.; White, M. F. , 2000. IRS-2 pathways integrate female 
reproduction and energy homeostasis. Nature 407: 377-382.  
 
Camejo G. The interaction of lipids and lipoproteins with the intercellular matrix of 
arterial tissue: its possible role in atherogenesis. Adv lipid Res 1982;19:1 
 
Campbell L.A., Perez Melgosa M., Hamilton D.J., Kuo C.C., Grayston J.T., 1992. 
Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin 
Microbiol.;30:434-9. 
 
Campbell, L.A. 1999. How to design studies to confirm a link between bacterial infection 
and Atherosclerosis. Am. Heart J. 138:S552-553. 
 
Capaldi, R. A., 1990. Structure and function of cytochrome c oxidase. Annu. Rev. 
Biochem. 59: 569-596.  
 
Chang, P. and Stearns, T., 2000. Delta-tubulin and epsilon-tubulin: two new human 
centrosomal tubulins reveal new aspects of centrosome structure and function. Nature 
Cell Biol. 2: 30-35. 
 
Chinen, K.; Sudo, K.; Takahashi, E.; Nakamura, Y., 1995. 
Isolation and mapping of the human beta-signal sequence receptor gene (SSR2). 
Cytogenet. Cell Genet. 70: 215-217. 
 
Cho, Y.-J.; Chema, D.; Moskow, J. J.; Cho, M.; Schroeder, W. T.; Overbeek, P.; 
Buchberg, A. M.; Duvic, M., 1995. Epidermal surface antigen (MS17S1) is highly 





Choi, S. S.; Park, S. H.; Kim, U.-J.; Shin, H.-S. , 1997. Bfl-1, a Bcl-2-related gene, is the 
human homolog of the murine A1, and maps to chromosome 15q24.3. Mammalian 
Genome8:781-782.  
 
Chow V.T.K., Phoon M.C., 2001. Seroepidemiological survey of Chlamydia pneumoniae 
infection among Singapore university undergraduates: comparison between 
microimmunofluorescence and neutralization tests. World J Microbiol Biotechnol., 
17:773-8. 
 
Danesh J, Collins R, Peto R. 1997. Chronic infections and coronary heart disease: is there 
a link? Lancet; 350: 430–6. 
 
Davare, M. A.; Avdonin, V.; Hall, D. D.; Peden, E. M.; Burette, A.; Weinberg, R. J.; 
Horne, M. C.; Hoshi, T.; Hell, J. W. , 2001. A beta-2 adrenergic receptor signaling 
complex assembled with the Ca(2+) channel Ca(V)1.2. Science 293: 98-101. 
 
Davis R. E., Miller S., Herrnstadt C., Ghosh S. S., Fahy E., Shinobu L. A., Galasko D., 
Thal L. J., Beal M. F., Howell N., Parker W. D., 1997. Mutations in mitochondrial 
cytosome c oxidase genes segregate with late-onset Alzheimer disease. Proc. Nat. Acad. 
Sci. 94: 4526-4531.   
 
Deb, T. B.; Datta, K., 1996. Molecular cloning of human fibroblast hyaluronic acid-
binding protein confirms its identity with P-32, a protein co-purified with splicing factor 
SF2: hyaluronic acid-binding protein as P-32 protein, co-purified with splicing factor SF2. 
J. Biol. Chem. 271: 2206-2212.  
 
DeBose-Boyd, R. A.; Brown, M. S.; Li, W.-P.; Nohturfft, A.; Goldstein, J. L.; 
Espenshade, P. J., 1999. Transport-dependent proteolysis of SREBP: relocation of Site-1 
protease from Golgi to ER obviates the need for SREBP transport to Golgi. Cell 99: 703-
712.  
 
Deissler, H.; Wilm, M.; Genc, B.; Schmitz, B.; Ternes, T.; Naumann, F.; Mann, M.; 
Doerfler, W., 1997. Rapid protein sequencing by tandem mass spectrometry and cDNA 
cloning of p20-CGGBP: a novel protein that binds to the unstable triplet repeat 5-prime-
d(CGG)n-3-prime in the human FMR1 gene. J. Biol. Chem. 272: 16761-16768.  
 
Ditzel, H. J.; Masaki, Y.; Nielsen, H.; Farnaes, L.; Burton, D. R., 2000. Cloning and 
expression of a novel human antibody--antigen pair associated with Felty's syndrome. 
Proc.Nat.Acad.Sci.97:9234-9239.  
 
Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, Hammerschlag 
MR, Jackson LA, Kuo CC, Maass M, Messmer TO, Talkington DF, Tondella ML, Zaki 
SR., 2001. Standardizing Chlamydia pneumoniae assays: recommendations from the 
Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease 





Dubois, B., J. M. Bridon, J. Fayette, C. Barthelemy, J. Banchereau, C. Caux, F. Briere. 
1999. Dendritic cells directly modulate B cell growth and differentiation. J. Leukocyte 
Biol. 66:224 
 
Erba HP, Eddy R, Shows T, Kedes L, Gunning P., 1988. Structure, chromosome location, 
and expression of the human gamma-actin gene: differential evolution, location, and 
expression of the cytoskeletal beta- and gamma-actin genes. Mol Cell Biol. 
Apr;8(4):1775-89. 
 
Erba, H. P.; Gunning, P.; Kedes, L., 1986. Nucleotide sequence of the human gamma 
cytoskeletal actin mRNA: anomalous evolution of vertebrate non-muscle actin genes. 
Nucleic Acids Res. 14: 5275-5294.   
 
Fraser C.M., 2000. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia 
pneumoniae AR39. Nucleic Acids Research, Vol. 28, No. 6 1397-1406. 
Glass K.C., Witztum L.J., 2001. Atherosclerosis: The Road Ahead. Cell, Vol. 104, 503–
516. 
 
Fredricks D. N., and Relman D. A., 1999. Application of polymerase chain reaction to 
the diagnosis of infectious diseases. Clin. Infect. Dis. 29:475–488. 
 
Fuchs R, Gassen H., 1989. Nucleotide sequence of human preprocathepsin H, a 
lysosomal cysteine proteinase. Nucleic Acids Res. 17(22):9471.  
 
Gaydos, C. A., J. T. Summersgill, N. N. Sahney, J. A. Ramirez, and T. C. Quinn. 1996. 
Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, 
and aortic artery smooth muscle cells. Infect. Immun. 64:1614-1620. 
 
Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, Wang SP. 
1990. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect 
Dis; 161: 618–25. 
 
Ghebrehiwet, B.; Lim, B.-L.; Peerschke, E. I.; Willis, A. C.; Reid, K. B., 1994. Isolation, 
cDNA cloning, and overexpression of a 33-kDa cell surface glycoprotein that binds to the 
globular 'heads' of C1q. J. Exp. Med. 179: 1809-1821. 
 
Gowda, K.; Chittenden, K.; Zwieb, C., 1997. Binding site of the M-domain of human 
protein SRP54 determined by systematic site-directed mutagenesis of signal recognition 
particle RNA. Nucleic Acids Res. 25: 388-394.  
 
Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, et al., 
1992. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. 






Hazarika, P.; Dham, N.; Patel, P.; Cho, M.; Weidner, D.; Goldsmith, L.; Duvic, M., 1999. 
Flotillin 2 is distinct from epidermal surface antigen (ESA) and is associated with 
filopodia formation. J. Cell. Biochem. 75: 147-159.  
 
Heron, L.; Virsolvy, A.; Peyrollier, K.; Gribble, F. M.; Le Cam, A.; Ashcroft, F. M.; 
Bataille, D., 1998. Human alpha-endosulfine, a possible regulator of sulfonylurea-
sensitive K(ATP) channel: molecular cloning, expression, and biological properties. 
Proc. Nat. Acad. Sci. 95: 8387-8391. 
 
Heiber, M.; Docherty, J. M.; Shah, G.; Nguyen, T.; Cheng, R.; Heng, H. H. Q.; Marchese, 
A.; Tsui, L.-C.; Shi, X.; George, S. R.; O'Dowd, B. F. , 1995. Isolation of three novel 
human genes encoding G protein-coupled receptors. DNA Cell Biol. 14: 25-35.   
 
Hennige, A. M.; Burks, D. J.; Ozcan, U.; Kulkarni, R. N.; Ye, J.; Park, S.; Schubert, M.; 
Fisher, T. L.; Dow, M. A.; Leshan, R.; Zakaria, M.; Mossa-Basha, M.; White, M. F. 2003.  
Upregulation of insulin receptor substrate-2 in pancreatic beta-cells prevents diabetes. J. 
Clin. Invest. 112: 1521-1532.  
 
Hirano, M.; Shtilbans, A.; Mayeux, R.; Davidson, M. M.; DiMauro, S.; Knowles, J. A.; 
Schon, E. A., 1997. Apparent mtDNA heteroplasmy in Alzheimer's disease patients and 
in normals due to PCR amplification of nucleus-embedded mtDNA pseudogenes. Proc. 
Nat. Acad. Sci. 94: 14894-14899.  
 
Hockenbery, D.; Nunez, G.; Milliman, C.; Schreiber, R. D.; Korsmeyer, S. J., 1990. Bcl-
2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 
348:334-336. 
 
Hua, X.; Nohturfft, A.; Goldstein, J. L.; Brown, M. S., 1996. Sterol resistance in CHO 
cells traced to point mutation in SREBP cleavage-activating protein. Cell 87: 415-426.  
 
Jacobson, M. D.; Burne, J. F.; King, M. P.; Miyashita, T.; Reed, J. C.; Raff, M. C., 1993. 
Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361: 365-369. 
 
Jantos C.A., Roggendorf R., Wuppermann F.N., Hegemann J.H., 1998. Rapid detection 
of Chlamydia pneumoniae by PCRenzyme immunoassay. J Clin Microbiol 36:1890.1894 
John D Rutherford MB, ChB., 2000.Chlamydia Pneumoniae and Atherosclerosis. 
Current Atherosclerosis Reports 2:218-225 
 
Kahler J., Koster R., Braser J.H., Schafer P., Terres W., Hamm C.W., Meinertz T., 1999.  
Role of Chlamydia pneumoniae in the pathogenesis of coronary artery disease. Zeitschrift 
Fur Kardiologie, Vol 88, 11: p 885-895. 
 
Kenmochi N., Kawaguchi T., Rozen S., Davis E., Goodman N., Hudson T. J., Tanaka T., 





Kingsmore, S. F., M. L. Watson, W. S. Moseley, M. F. Seldin., 1989. Physical linkage of 
genes encoding the lymphocyte adhesion molecules CD2 and its ligand LFA-3. 
Immunogenetics 30:123. 
 
Koh W.P., Taylor M.B., Hughes K., Chew S.K., Fong C.W., Phoon M.C., et al., 2002. 
Seroprevalence of lgG antibodies against Chlamydia pneumoniae in Chinese. Int J 
Epidemiol, 31:1001-1007. 
 
Koh W.P., Taylor M.B., Chew S.K., Phoon M.C., Kang K.L., Chow V.T., et al., 2003. 
Chlamydia pneumoniae lgG seropositivity and clinical history of ischemic heart disease 
in Singapore. J Microbiol Immunol Infect, 31:1001-1007 
 
Konishi, Y.; Lehtinen, M.; Donovan, N.; Bonni, A., 2002. Cdc2 phosphorylation of BAD 
links the cell cycle to the cell death machinery. Molec. Cell 9: 1005-1016.  
 
Kornmann M, Maruyama H, Bergmann U, Tangvoranuntakul P, Beger HG, White MF, 
Korc M., 1998. Enhanced expression of the insulin receptor substrate-2 docking protein 
in human pancreatic cancer. Cancer Res.,58(19):4250-4. 
 
Kubota, N.; Tobe, K.; Terauchi, Y.; Eto, K.; Yamauchi, T.; Suzuki, R.; Tsubamoto, Y.; 
Komeda, K.; Nakano, R.; Miki, H.; Satoh, S.; Sekihara, H.; Sciacchitano, S.; Lesniak, 
M.; Aizawa, S.; Nagai, R.; Kimura, S.; Akanuma, Y.; Taylor, S. I.; Kadowaki, T., 2000. 
Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin 
resistance and lack of compensatory beta-cell hyperplasia. Diabetes. 49:1880-1889. 
 
Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. 1993. 
Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J 
Infect Dis. 167:841-849. 
 
Kuo C.C., Jackson L.A., Campbell L.A., Grayston J.T., 1995. Chlamydia 
pneumoniae .Clin Microbiol Rev;8:451-61. 
Kuo C.C., Gown A.M., Benditt EP, Grayston JT., 1993. Detection of Chlamydia 
pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. 
Arterioscler Thromb.;13:1500-1504.   
 
Kuoppa Y., Boman J., Scott L., Kumlin U., Eriksson I., and Allard A., 2002. Quantitative 
detection of respiratory Chlamydia pneumoniae infection by real-time PCR. J. Clin. 
Microbiol.; 40:2273-2274. 
 
Large, V.; Hellstrom, L.; Reynisdottir, S.; Lonnqvist, F.; Eriksson, P.; Lannfelt, L.; Arner, 
P., 1997. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity 







Lautier, C.; Ait El Mkadem, S.; Renard, E.; Brun, J. F.; Gris, J. C.; Bringer, J.; 
Grigorescu, F., 2003. Complex haplotypes of IRS2 gene are associated with severe 
obesity and reveal heterogeneity in the effect of gly1057asp mutation. Hum. Genet. 113: 
34-43.  
 
Lee, J. H.; Choi, S. K.; Roll-Mecak, A.; Burley, S. K.; Dever, T. E., 1999.Universal 
conservation in translation initiation revealed by human and archaeal homologs of 
bacterial translation initiation factor IF2. Proc. Nat. Acad. Sci. 96: 4342-4347.  
 
Lee M. G., Norbury C. J., Spurr N. K., Nurse, P., 1988. Regulated expression and 
phosphorylation of a possible mammalian cell-cycle control protein. (Letter) Nature 333: 
676-679.  
 
Lee, M. G.; Nurse, P., 1987. Complementation used to clone a human homologue of the 
fission yeast cell cycle control gene cdc2. Nature 327: 31-35. 
 
Lees-Miller, J. P.; Helfman, D. M., 1991. The molecular basis for tropomyosin isoform 
diversity.BioEssays13:429-437. 
 
Leong PWF, Liew K, Lim W, Chow VTK. 2002. Differential display RTPCR analysis of 
enterovirus-71-infected rhabdomyosarcoma cells reveals mRNA expression responses of 
multiple human genes with known and novel functions. Virology 295:147–159. 
 
Lewis S. A., Cowan N. J., 1990. Tubulin genes: structure, expression, and regulation. In: 
Avila, J. (ed.) : Microtubule proteins. Boca Raton: CRC Press, Inc. 1990. Pp. 37-66.  
 
Li, C.Y., Rodriguez M., Adamson, J. W. and Banerjee, D., 2000. Identification of a 
Glialblastoma Cell Differentiation Factor-Related Gene mRNA in Human Microvascular 
Endothelial Cells Genomics, 65(3):243-252 
 
Liang P, Pardee AB. 1995. Recent advances in differential display. Curr Opin Immunol 
7:274–280. 
 
Liew K.J.L and Chow V.T.K., 2004. Differential Display RT-PCR Analysis of ECV304 
Endothelialilike Cells Infected with Dengue virus type 2 reveals messenger RNA 
Expression profiles of multiple human genes involved in known and novel roles. J 
Medical Virology, 72:597-609. 
 
Lindgren, V.; Luskey, K. L.; Russell, D. W.; Francke, U., 1985. Human genes involved 
in cholesterol metabolism: chromosomal mapping of the loci for the low density 
lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA 
probes. Proc. Nat. Acad. Sci. 82: 8567-8571.  
 
Lin E. Y., Kozak C. A., Orlofsky A., Prystowsky M. B., 1997. The bcl-2 family member, 
Bcl2al, maps to mouse chromosome 9 and human chromosome 15. Mammalian Genome 




Lonnqvist, F.; Wahrenberg, H.; Hellstrom, L.; Reynisdottir, S.; Arner, P., 1992. Lipolytic 
catecholamine resistance due to decreased beta-2-adrenoceptor expression in fat cells. J. 
Clin. Invest. 90: 2175-2186. 
 
Lund, A.; Knudsen, S. M.; Vissing, H.; Clark, B.; Tommerup, N., 1996. Assignment of 
human elongation factor 1-alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 
to 20q13.3. Genomics 36: 359-361.  
 
Luttrell, L. M.; Ferguson, S. S. G.; Daaka, Y.; Miller, W. E.; Maudsley, S.; Della Rocca, 
G. J.; Lin, F.-T.; Kawakatsu, H.; Owada, K.; Luttrell, D. K.; Caron, M. G.; Lefkowitz, R. 
J. : Beta-arrestin-dependent formation of beta-2 adrenergic receptor-Src protein kinase 
complexes. Science 283: 655-661, 1999.  
 
Marsden, V. S.; O'Connor, L.; O'Reilly, L. A.; Silke, J.; Metcalf, D.; Ekert, P. G.; Huang, 
D. C. S.; Cecconi, F.; Kuida, K.; Tomaselli, K. J.; Roy, S.; Nicholson, D. W.; Vaux, D. L.;  
 
Melnick, S. L., E. Shahar, A. R. Folsom, J. T. Grayston, P. D. Sorlie, S.-P. Wang, and M. 
Szklo. 1993. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic 
carotid atherosclerosis. Am. J. Med. 95:499-504 
 
Miyashita, T.; Reed, J. C., 1995. Tumor suppressor p53 is a direct transcriptional 
activator of the human bax gene. Cell 80: 293-299.  
 
Movahed M.R., 1999. Infection with Chlamydia pneumoniae and atherosclerosis: a 
review. JSC Med Assoc ; 95(8): 303-8 
 
Nagase, T.; Ishikawa, K.; Suyama, M.; Kikuno, R.; Miyajima, N.; Tanaka, A.; Kotani, H.; 
Nomura, N.; Ohara, O. , 1998. Prediction of the coding sequences of unidentified human 
genes. XI. The complete sequences of 100 new cDNA clones from brain which code for 
large proteins in vitro. DNA Res. 5: 277-286.  
 
Naumann, F.; Remus, R.; Schmitz, B.; Doerfler, W., 2004. Gene structure and expression 
of the 5-prime-(CGG)n-3-prime-binding protein (CGGBP1). Genomics 83: 106-118.  
 
Nazarenko, S. A.; Ostroverhova, N. V.; Spurr, N. K., 1991. Regional assignment of the 
human cell cycle control gene CDC2 to chromosome 10q21 by in situ hybridization. 
Hum. Genet. 87: 621-622. 
 
Oltvai  Z. N.,  Milliman C. L., Korsmeyer S. J., 1993. Bcl-2 heterodimers in vivo with a 
conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.  
 
Opdenakker, G.; Cabeza-Arvelaiz, Y.; Fiten, P.; Dijkmans, R.; Van Damme, J.; 
Volckaert, G.; Billiau, A.; Van Elsen, A.; Van der Schueren, B.; Van den Berghe, H.; 
Cassiman, J.-J., 1987. Human elongation factor 1-alpha: a polymorphic and conserved 




Ralph,P., Moore,M.A.S., and Nillson,K. , 1976. Lysozyme synthesis by established 
human and murine histiocytic lymphoma cell lines. J. Exp. Med., 143: 1528-1533.  
Ramirez J.A., 1996. Isolation of Chlamydia pneumoniae from the coronary artery of a 
patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study 
Group. Ann Intern Med; 125: 979-982. 
 
Read, T.D., Brunham, R.C., Shen, C., Gill, S.R., Heidleberg, J.F., White, O., Hickey, 
E.K., Peterson, J., Utterback, T., Berry, K., Bass, S., Linher, K., Weidman, J., Khouri, H., 
Craven, B., Bowan, C., Dodson, R., Gwinn, M., Nelson, W., DeBoy, R., Kolonay, J., 
McClarty, G., Salzberg, S., Eisen, J., and Fraser, C.M., 2000. Genome sequences of 
Chlamydia trachomatis MoPn and C. pneumoniae AR39. Nucleic Acids Research, 28 (6): 
1397-1406 
 
Reed, J. C.; Cuddy, M.; Slabiak, T.; Croce, C. M.; Nowell, P. C., 1988. Oncogenic 
potential of bcl-2 demonstrated by gene transfer. Nature 336: 259-261.  
  
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, 
and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 
973–9.  
 
Ross R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 
362: 801-809. 
 
Russell, D. W.; Schneider, W. J.; Yamamoto, T.; Luskey, K. L.; Brown, M. S.; Goldstein, 
J. L. : Domain map of the LDL receptor: sequence homology with the epidermal growth 
factor precursor. Cell 37: 577-585, 1984.  
 
Rutledge R. G. and CoÃ C., 2003. Mathematics of quantitative kinetic PCR and the 
application of standard curves Nucleic Acids Research, , Vol. 31, No. 16 e93 
 
Saikku P., 1999. Epidemiology of Chlamydia pneumoniae in atherosclerosis.American 
Heart Journal, 138, Suppl.: S500-S503.  
 
Shenoy, S. K.; McDonald, P. H.; Kohout, T. A.; Lefkowitz, R. J., 2001. Regulation of 
receptor fate by ubiquitination of activated beta-2-adrenergic receptor and beta-arrestin. 
Science 294: 1307-1313. 
 
Shimomura, I.; Matsuda, M.; Hammer, R. E.; Bashmakov, Y.; Brown, M. S.; Goldstein, J. 
L. , 2000. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and 
sensitivity in livers of lipodystrophic and ob/ob mice. Molec. Cell 6: 77-86 
 
Smith T.F., Gaitatzes C., Saxena K., Neer E.J., 1999. The WD repeat: a common 
architecture for diverse functions. Trends Biochem Sci. May 24(5):181-185. 
 
Shor A., Kuo C.C., Patton D.L., 1992.Detection of Chlamydia pneumoniae in coronary 




Song, Z.-H.; Modi, W.; Bonner, T. I., 1995. Molecular cloning and chromosomal 
localization of human genes encoding three closely related G protein-coupled receptors. 
Genomics28:347-349. 
 
Sudhof, T. C.; Goldstein, J. L.; Brown, M. S.; Russell, D. W., 1985. The LDL receptor 
gene: a mosaic of exons shared with different proteins. Science 228: 815-822.  
 
Sundstrom C. and Nilsson K., 1976. Establishment and characterization of a human 
histiocytic lymphoma cell line (U937). Int. J. Cancer, 17: 565-577. 
 
Sun, X. J.; Wang, L.-M.; Zhang, Y.; Yenush, L.; Myers, M. G., Jr.; Glasheen, E.; Lane, 
W. S.; Pierce, J. H.; White, M. F. , 1995. Role of IRS-2 in insulin and cytokine signalling. 
Nature 377: 173-177.  
 
Thierfelder, L.; Watkins, H.; MacRae, C.; Lamas, R.; McKenna, W.; Vosberg, H.-P.; 
Seidman, J. G.; Seidman, C. E., 1994. Alpha-tropomyosin and cardiac troponin T 
mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 
77:701-712. 
 
Tiso, N.; Rampoldi, L.; Pallavicini, A.; Zimbello, R.; Pandolfo, D.; Valle, G.; Lanfranchi, 
G.; Danieli, G. A., 1997. Fine mapping of five human skeletal muscle genes: alpha-
tropomyosin, beta-tropomyosin, troponin-I slow-twitch, troponin-I fast-twitch, and 
troponin-C fast. Biochem. Biophys. Res. Commun. 230: 347-350.  
  
 
Tobe, K.; Suzuki, R.; Aoyama, M.; Yamauchi, T.; Kamon, J.; Kubota, N.; Terauchi, Y.; 
Matsui, J.; Akanuma, Y.; Kimura, S.; Tanaka, J.; Abe, M.; Ohsumi, J.; Nagai, R.; 
Kadowaki, T., 2001. Increased expression of the sterol regulatory element-binding 
protein-1 gene in insulin receptor substrate-2 -/- mouse liver. J. Biol. Chem. 276: 38337-
38340.  
 
Tompkins L.S., Schachter J., Boman J., Chernesky M.A., Dowell S., Gaydos C.A., 
Levison M.E., Maass M., Madico G., Orfila J, Ouchi K., Peeling R.W., Taylor-Robinson 
D, Stamm W.E., Wang S.P., Blasi F., Relman D., 2000. Collaborative multidisciplinary 
workshop report: detection, culture, serology, and antimicrobial susceptibility testing of 
Chlamydia pneumoniae. J Infect Dis 181 (Suppl 3):460.461 
 
Tondella, M. L. C., Talkington, D. F., Holloway, B. P., Dowell, S. F., Cowley, K., 
Soriano-Gabarro, M., Elkind, M. S., Fields, B. S. (2002). Development and Evaluation of 
Real-Time PCR-Based Fluorescence Assays for Detection of Chlamydiapneumoniae. J. 
Clin. Microbiol. 40: 575-583 
 
Tolleshaug, H.; Goldstein, J. L.; Schneider, W. J.; Brown, M. S., 1982. Posttranslational 
processing of the LDL receptor and its genetic disruption in familial 





Tugendreich S., Boguski M. S., Seldin M. S.,  Hieter P., 1993. Linking yeast genetics to 
mammalian genomes: identification and mapping of the human homolog of CDC27 via 
the expressed sequence tag (EST) data base. Proc. Nat. Acad. Sci. 90: 10031-10035. 
 
Wallace, D. C.; Stugard, C.; Murdock, D.; Schurr, T.; Brown, M. D., 1997. Ancient 
mtDNA sequences in the human nuclear genome: a potential source of errors in 
identifying pathogenic mutations. Proc. Nat. Acad. Sci. 94: 14900-14905.  
 
Wang, X.; Sato, R.; Brown, M. S.; Hua, X.; Goldstein, J. L., 1994. SREBP-1, a 
membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77: 
53-62.  
 
Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, Dong XY, Peng JR, Zhao HT, Rui JA, 
Leng XS, Cebon J, Burgess AW, Chen WF. 2002. Large scale identification of human 
hepatocellular carcinoma-associated antigens by autoantibodies. J 
Immunol. ;169(2):1102-9.  
 
Watkins, H.; McKenna, W. J.; Thierfelder, L.; Suk, H. J.; Anan, R.; O'Donoghue, A.; 
Spirito, P.; Matsumori, A.; Moravec, C. S.; Seidman, J. G.; Seidman, C. E., 1995. 
Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic 
cardiomyopathy. New Eng. J. Med. 332: 1058-1064. 
 
Wiedmann, B.; Sakai, H.; Davis, T. A.; Wiedmann, M., 1994. A protein complex 
required for signal-sequence-specific sorting and translocation. Nature 370: 434-440.  
 
Withers, D. J.; Gutierrez, J. S.; Towery, H.; Burks, D. J.; Ren, J.-M.; Previs, S.; Zhang, 
Y.; Bernal, D.; Pons, S.; Shulman, G. I.; Bonner-Weir, S.; White, M. F., 1998. 
Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391: 900-902.  
 
Whyte, J., Roberts, A. D. G., Morley, K. A., Sharp, R. J. & Marsh, P. D., 2000. 
Phagocytosis of mycobacteria by U937 cells: a rapid method for monitoring uptake and 
separating phagocytosed and free bacteria by magnetic beads. 
Letters in Applied Microbiology  30 (1), 90-94. 
 
Yamamoto, T.; Davis, C. G.; Brown, M. S.; Schneider, W. J.; Casey, M. L.; Goldstein, J. 
L.; Russell, D. W. , 1984. The human LDL receptor: a cysteine-rich protein with multiple 
Alu sequences in its mRNA. Cell 39: 27-38.  
 
Yang, E.; Zha, J.; Jockel, J.; Boise, L. H.; Thompson, C. B.; Korsmeyer, S. J., 1995. Bad, 
a heterodimeric partner for Bcl-X(L) and Bcl-2, displaces Bax and promotes cell death. 
Cell 80: 285-291.  
 
Yen, T. J.; Machlin, P. S.; Cleveland, D. W., 1988. Autoregulated instability of beta-






Yokoyama, C.; Wang, X.; Briggs, M. R.; Admon, A.; Wu, J.; Hua, X.; Goldstein, J. L.; 
Brown, M. S., 1993. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that 
controls transcription of the low density lipoprotein receptor gene. Cell 75: 187-197.  
 
Yotov, W. V.; St-Arnaud, R., 1996. Mapping of the human gene for the alpha-NAC/1.9.2 
(NACA/1.9.2) transcriptional coactivator to chromosome 12q23-24.1. Mammalian 
Genome 7: 163-164.  
 
Yu D., Jing T., Liu B., Yao J., Tan M., McDonnell, T. J.; Hung, M.-C., 1998. 
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, 
which inhibits p34Cdc2 kinase. Molec. Cell 2: 581-591. 
 
Zheng, Y.-H.; Yu, H.-F.; Peterlin, B. M., 2003. Human p32 protein relieves a post-



















A. REAGENTS AND MATERIALS FOR MAINTAINING THE CELL LINES 
(i) Cell Culture Media 
Inactivated Fetal Calf Serum (FCS) 
FCS was inactivated by heating at 56oC for 30 min, aliquoted and stored at -20oC. 
CYCLOHEXIMIDE 
Cycloheximide: 200 ug/ml 




Penicillin G sodium BP (Glaxo)    5 x 106 U 
Streptomycin sulphate BP (Glaxo)   5g 
Media for HEP2 cell line (per 100ml) 
       Maintenance Media Growth Media 
DULBECCO MODIFIED EAGLE’S    92ml  84ml 
MINIMUM ESSENTIAL MEDIA DMEM (1x)  
(Sigma-Aldridge, St. Louis, USA)        
Inactivated FCS (Invitrogen, CA, USA)       3ml (3%) 10ml (10%) 
Sodium bicarbonate (7.5%) (Invitrogen, CA, USA)      2ml (2%) 2ml (2%)  
HEPES buffer (1M) (Invitrogen, CA, USA)       2ml (2%) 2ml (2%) 
Cycloheximide (Calbiochem, CA, USA)    -------  1ml (1%) 
Penicillin/streptomycin (100x) (Invitrogen, CA, USA)  1ml (1%) 1ml (1%) 
One packet of DMEM powder was dissolved in 1L of nanopure water. The solution is 
then stirred till all the DMEM powder has been fully dissolved. The prepared DMEM 
media is then filtered thru the 0.22 µm membrane filter, and aliquoted to 100ml bottles to 





Media for U937 cell line (per 100ml) 
       Maintenance Media Growth Media 
RPMI-1640 (1x) (Sigma-Aldridge, St. Louis, USA)      92ml  85ml  
Inactivated FCS (Invitrogen, CA, USA)       3ml (3%) 10ml (10%) 
Sodium bicarbonate (7.5%) (Invitrogen, CA, USA)      2ml (2%) 2ml (2%)  
HEPES buffer (1M) (Invitrogen, CA, USA)       2ml (2%) 2ml (2%) 
Penicillin/streptomycin (100x) (Invitrogen, CA, USA)  1ml (1%) 1ml (1%) 
One packet of RPMI powder was dissolved in 1L of nanopure water, and 2 g of NaHCO3 was added. The 
solution is then stirred till all the RPMI powder has been fully dissolved. The prepared RPMI media is then 
filtered thru the 0.22 µm membrane filter, and aliquoted to 100ml bottles to be stored at 4˚C. 
 
Chlamydia pneumoniae overlay medium (per 100ml) 
RPMI-1640 (2X) (Sigma-Aldridge, St. Louis, USA)   46ml 
...................... (Calbiochem, CA, USA) in ddH2O   46ml 
Inactivated FCS (Invitrogen, CA, USA)    3ml 
Sodium bicarbonate (7.5%) (Invitrogen, CA, USA)   2ml 
HEPES buffer (1M) (Invitrogen, CA, USA)    2ml 
Penicillin/streptomycin (100x) (Invitrogen, CA, USA)  1ml 
B. Buffers and reagents 
(i) Phosphate Buffered Saline (pH 7.4) 
  (per litre) 
  NaCl   8.000g 
  KCl   0.020g 
  KH2PO4  0.240g (monopotassium phosphate) 




  10mM Tris (Trizma base – Sigma) adjusted to pH 8.3 
 
(iii) Reagents used for PCR 
  a. Taq DNA Polymerase in Storage Buffer A (Promega) 
  b. Advantage 2 Polymerase (CLONTECH) 
  c. 10 mM each of dATP,dCTP,dGTP and dTTP. 
C. Buffers and Reagents Used for Agarose Gel Electrophoresis 
 
(i) 10x  Tris-Borate EDTA (TBE) (pH 8.5 ± 0.15) 
Tris base (Calbiochem, CA, USA)  218g 
Boric Acid (BDH, UK)   111.3g 
EDTA (BDH, UK)    7.31g 
ddH2O      2 litres 
  
Working solution = 1 x for agarose gel elctrophoresis 
(ii) 10x Tris-Acetate EDTA buffer 
  0.40 M  Trizma base (Sigma)   48.44 g/l 
  Glacial acetic acid(Merck)     11.42 ml 






(iii) Ethidium Bromide (EtBr) 
0.20 g of EtBr (Sigma-Aldridge. St. Louis, USA ) was added to 20 ml of 
distilled water and disolved by stirring with a magnetic stirrer at room 
temperature for several hours. The solution was then stored in the dark at 
48 C. Prepared in 10mg/ml stock and then aliquoted out for usage. 
 
 (iv) 10x Gel Loading Buffer (Agarose Gels) (per 20ml) 
Glycerol (Sigma-Aldridge, St. Louis, USA)   10ml 
20mM Tris-HCl pH 7.5 (Sigma-Aldridge, St. Louis, USA) 10ml 
Bromophenol blue (Sigma-Aldridge, St. Louis, USA) 8mg 
 
The reagents were pre-autoclaved prior to mixing after which the buffer 
was aliquoted and stored at -20oC. 
 
(v) DNA markers 
  a. 100bp DNA ladder marker  (Research Biolabs) 
  b. 1 Kb Plus DNA ladder (GIBCOBRL) 
 
D. Buffer for elution of DNA from Agarose Gel 
Tris-EDTA (TE) 1x Buffer, pH 8.0 
Tris-HCL 10mM 
EDTA   1 mM 
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E. Reagents for Sequencing 
ABI PRISMTM BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit 
F. Composition of Gels 
Agarose Gel (per 250ml) 
 a. Agarose (Bio-Rad, CA, USA) 4.00 g (1.6% gel) 
 b. 10x TBE/ 10x TAE    25.0 ml 
 c. 10mg/ml EtBr    12.5 µl 
 d. ddH2O     225 ml 
 
The agarose was weighed out into a conical flask.10x TBE and ddH2O was 
measured out such that the final concentration will be 1x TBE (250ml). The 
mixture was heated in the microwave oven until the agarose was dissolved. This 
gel mix was then allowed to cool on the shaker at 150rpm. Finally, before the 
casting for the gel, 0.8µl of ethidium bromide (EtBr) was added and this cooled 
mix was then poured into the gel casting tray. 
 
G. POLYACRYLAMIDE GEL ELECTROPHORESIS 
6% Acrylamide Solution (per litre) 
Acrylamide (Bio-Rad, CA, USA)    57g 
N,N’-methylenebisacrylamide (Bio-Rad, CA, USA)  3g 
Urea (Bio-Rad, CA, USA)     450g 
10x TBE       100ml 
ddH2O        900ml 
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The dissolved mixture was passed through a 0.45-micron filter and de-gassed before use. 
6% Polyacrylamide gel (per 100ml) 
6% acrylamide solution      99ml 
Ammonium persulfate (10%) (Sigma-Aldridge, St. Louis, USA) 1ml 
TEMED (Sigma-Aldridge, St. Louis, USA)    30µl 
 
Stop solution for PAGE 
95% Formamide 
20mM EDTA 
0.05% Bromophenol blue 
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Many studies have shown that atherosclerosis and coronary heart disease are linked to 
infection with Chlamydia pneumoniae, an obligate intracellular human pathogen. Our 
objective was to analyze the genetic expression profiles arising from the interaction 
between Chlamydia pneumoniae and U937 human macrophages in the presence or 
absence of low density lipoproteins (LDL). The experimental models included untreated 
control macrophages; macrophages exposed to LDL; macrophages infected with 
Chlamydia pneumoniae alone; and macrophages exposed to both LDL and Chlamydia 
pneumoniae. RNA was isolated from the different models, converted to cDNA, and the 




From the series of experiments, a total of 84 bands were successfully sequenced, 
representing transcripts that were closely associated with the interaction between 
macrophages with Chlamydia pneumoniae and/or LDL. The cDNA sequences were 
subjected to analysis using various bioinformatics tools, and compared with the gene 
databases.  
 
Interesting genes which provide an insight into the gene expression responses arising 
between interaction of macrophages with Chlamydia pneumoniae and/or LDL include a 
gene similar to IK cytokine, down-regulator of HLA II; nuc2 homolog; genomic DNA of 
chromosome 8p11.2, senescence gene region; BCL2-related protein A1 (BCL2A1); 
cyclic AMP phosphoprotein, 19 kD (ARPP-19) mRNA; ribosomal protein L27a 
(RPL27A) mRNA; cell division cycle 2, G1 to S and G2 to M (CDC2) gene. Work is 
underway to isolate more genes of interest that mediate the mechanisms of interaction 
between macrophages and Chlamydia pneumoniae using proteomic and microarray 
strategies. 
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Chlamydophila pneumoniae is an obligate intracellular bacterium that has been 
associated with atherosclerosis. Low density lipoprotein (LDL) is another key factor 
since foam cells are formed when macrophages take up oxidized LDLs. To simulate the 
events leading to atherosclerosis, study models were designed for differential display RT-
PCR to analyze mRNAs derived from U937 macrophages following C. pneumoniae 
infection and/or LDL exposure for 24, 72 and 96 hours.  
 
Out of 235 cDNA fragments that were isolated and sequenced, 190 exhibited differential 
expression profiles in the study models compared to the control, whereas 45 displayed 
unaltered expression patterns. Homology searches revealed no similarity hits for 32 
differentially expressed mRNAs, whereas 158 differentially expressed transcripts 
matched known genes encoding components involved in ubiquitination (nuc2, CDC27, 
CTSH, HSPC150), cell proliferation (BCL2A1, CDC2, α-NAC, CDC42), immune 
response (BLAME, C1QBP, PPP2RB, GPR6), protein translation and modification 
(EEF1A1, IF2), and structural proteins (TUBE1, FLOT1, ACTG1, TPM1). The altered 
expression profiles of 29 selected genes of interest were authenticated by real-time and 
semi-quantitative RT-PCR. Our data can provide insights into the contribution of C. 
pneumoniae and LDL towards the development and progression of the atherosclerosis 
mediated by inflammatory processes. 
 
 
 
 
 
